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Abbreviations 
 
Alg/ALG Asparagine linked glycan in yeast/human  
ApoC-III ApolipoproteinC-III 
ARCL Autosomal recessive cutis laxa 
CDG Congenital disorder(s) of glycosylation, formerly  
Carbohydrate deficient glycoprotein syndrome(s) 
CDG-I Congenital disorder(s) of glycosylation type I 
CDG-II Congenital disorder(s) of glycosylation type II 
CDT Carbohydrate deficient transferrin 
CNS Central nervous system 
COG Conserved oligometric Golgi complex 
DPM Dolichol-Phosphate-Mannose 
Dol Dolichol 
DPAGT1 Dolichyl-phosphate N-acetylglucosamine phosphotransferase 1 
ER Endoplasmic Reticulum 
Fuc Fucose 
FUCT Fucose Transporter 
Gal Galactose 
GalNAc N-Acetylgalactosamine  
Glc Glucose 
GlcNAc N-Acetylglucosamine 
GLS1 Glucosidase 1 
GnT N-Acetylglucosaminyltransferase 
IEF Isoelectric Focusing  
LAD  Leukocyte adhesion deficiency 
LLO Lipid-linked oligosaccharide 
Man Mannose 
MEB Muscle-Eye-Brain 
MGAT Mannoside acylglucosaminyltransferase 
MPI Phosphomannose Isomerase 
NeuAc N-Acetylneuraminic acid (sialic acid) 
PMM  Phosphomannomutase 
sLe* Sialyl-Lewis antigen 
TBG Thyroxin-Binding Globulin 
TF Transferrin 
TIEF Transferrin isoelectric focusing 
WWS Walker-Warburg-Syndrome 
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Outline and aim of the study 
Only in the last couple of years, an ever-growing number of human genetic diseases in the synthesis 
of glycoproteins has been identified, even though glycobiologists have been able to delineate the 
glycosylation pathways in yeast and man for some time. Correct glycosylation of glycoproteins is 
essential for their biological function and the sugar chains act as biosignals for cell-cell 
communication, intracellular signalling, protein folding or targeting of proteins within cells 
(Helenius et al, Annu Rev Biochem 2004 73:1019-49, Haltiwanger et al, Rev Biochem 2004 73: 
491-537). Underglycosylation of glycoproteins, functioning as hormones, enzymes or transporters, 
lead to impaired bioability, decreased activity and rapid degradation. Given the overall importance 
of glycosylation, it is not surprising, that a disruption of the glycosylation machinery leads to 
multisystemic and severe diseases in affected patients.    
Up until now, mainly defects in the N-glycosylation pathway have been discovered and are grouped 
as Congenital Disorders of Glycosylation (CDG), formerly known as Carbohydrate-Deficient 
Glycoprotein syndromes. More recently, defects in the less well defined O-glycosylation pathway 
were identified and it is noteworthy, that glycosylation disorders might affect both, the N- and O- 
glycosylation pathway.  
 
The focus of this study was to investigate the clinical, biochemical and molecular genetic aspects of 
different CDG subtypes:  
Chapter 1 gives an introduction and update on the glycosylation defects characterized so far. 
Chapter 2 summarizes molecular and genotype-phenotype correlation studies on CDG-Ia due to 
phosphomannomutase deficiency, the most commonly identified N-glycosylation defect. It also 
highlights the possible pitfall in measurement of enzyme activity in patients´ fibroblasts. Correct 
glycosylation of secreted glycoproteins is essential for their trafficking and in Chapter 3 abnormal 
transfer and storage of misfolded and degraded glycoproteins in liver tissue of patients with 
different CDG subtypes is described. Chapter 4 summarizes the clinical, biochemical and 
molecular delineation of CDG-Ic. In Chapter 5 it is shown, that hypoglycosylation in CDG patients 
is generalized and can be detected in various glycoproteins not only in those present in blood but 
also in a brain derived glycoproteins (ß-trace protein). Chapter 6 bridges N- and O-glycosylation 
defects. We describe a new method, the IEF of Apolipoprotein CIII, which can be used as a 
screening method to search for O-glycosylation defects and which led to the identification of a new 
CDG subtype with defective glycosylation of N- and O-glycoproteins.  
The group of defects in the human glycosylation pathways is a rapidly emerging field. Yet more 
powerful tests are needed not only to identify new patients, but also to characterize additional 
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defects awaiting elucidation. There is still a considerable lack of understanding the underlying 
pathomechanisms of CDG. Intensive research work is ongoing and a broad spectrum of specialists 
including biochemists, glycobiologists, geneticists, clinicians and others need to add on their 
expertise to get a better insight into this fascinating field. With the better understanding, new 
therapeutic options will hopefully be discovered. Chapter 7 gives an outlook on some future 
perspectives. It can be quite a challenge for clinicians to explain CDG to the parents. Chapter 8 
aims to serve as a useful tool for colleagues to try to explain the complex glycosylation pathway to 
affected patients and their families.  
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Chapter 1 
General introduction 
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Chapter 1.1 
Congenital Disorders of Glycosylation: an Introduction  
Glycosylation, the addition of sugar chains (glycans) to proteins, occurs in every human cell. In 
general, secreted, cell surface, and extracellular matrix proteins are glycosylated. Correct 
glycosylation of glycoconjugates, glycoproteins or glycolipids, is essential for their biological role 
(Varki 1993). Carbohydrates aid protein function by ensuring correct folding, providing solubility 
and protease resistance. By facilitating cell adhesion and migration, they help to mediate the 
process of development (McDowell and Gahl 1997). Not surprisingly, disruption of glycosylation 
leads to severe problems in man.  
 
The recently delineated Congenital Disorders of Glycosylation (CDG), formerly known as 
Carbohydrate-Deficient Glycoprotein syndromes, are a group of inherited multisystemic diseases 
primarily due to defective N-glycosylation of proteins (Aebi, Helenius et al. 1999). The 
biosynthesis of N-linked oligosaccharides is elaborate and numerous glycosyltransferases are 
involved, attaching, stepwise, nucleotide-activated or dolichol phosphate-linked sugars to a 
growing lipid-linked oligosaccharide chain. Finally, the completed structure (Gluc3Man9GlcNAc2) 
is transposed en bloc in N-linkage to an asparagine residue of a nascent protein via the 
oligosaccharyltransferase complex. In the Golgi compartment, several glycosidases remodel the 
oligosaccharide chain into a more complex structure by removal of mannose residues and the 
addition of N-acetylglucosamine, galactose, fucose and sialic acid residues (Kornfeld and Kornfeld 
1985).  
 
The synthesis of oligosaccharides, their transfer to the nascent polypeptide chain, and subsequent 
modification requires a complex pathway of at least 40 steps. Considering the ubiquitous presence 
of glycosylation and the multiple functions of the glycans, it is obvious that defects in the 
biosynthesis of glycoproteins will be detrimental and result in a broad spectrum of clinical signs 
and symptoms.   
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In 1980 Professor Jaeken described the first patients with multiple problems including 
developmental delay, dysmorphic features and biochemical abnormalities (Jaeken, 
Vanderschueren-Lodeweyckx et al. 1980). Since then, 18 enzyme defects in the N-glycosylation 
pathway have been identified: chapter 1.2 summarises the clinical and biochemical hallmarks of 
CDG Ia-Ie and CDG IIa-IIc, followed by the description of CDG If-Il and IId-IIf in Chapter 1.3.  
 
Patients suffering from CDG were first identified by studying changes in transferrin. Transferrin 
has two N-glycosylation sides and usually two glycans each bearing two sialic acid residues are 
attached. Any changes in the number of these negatively charged residues can be detected in the 
pattern of isoelectric focusing (IEF). Two main CDG groups are recognised and can be 
distinguished by IEF: the CDG type I pattern is characterised by a decrease of tetra- and an increase 
of di- and asialotransferrin. This pattern is found in disorders of the N-glycan assembly. In CDG 
type II IEF pattern, additionally an increase of trisialo- and monosialotransferrin is seen, indicating 
the presence of structurally abnormal glycans, due to a processing defect of the carbohydrate 
chains. The IEF of transferrin is widely used as a screening test, and needs complementation by 
subsequent analysis of other glycoproteins, enzymatic and molecular genetic studies.  
 
The disorders of glycosylation are remarkable for their clinical diversity. The majority of CDG 
disorders presents with multi organ involvement and literately all organs can be involved. Table 1 
summarises more common clinical signs and symptoms recognised in CDG patients.  
 
There still remain numerous patients with CDG of unknown cause, subtyped as CDG-x. Most of 
them show an abnormal transferrin IEF pattern and they are likely to have different defects in one 
of the numerous steps in the glycosylation pathway. Their clinical presentations are very variable 
and clinical signs and symptoms already observed in other CDG subtypes such as hydrops fetalis or 
oligohydramnios, dysmorphic features, intractable seizures, severe hypotonia, cataracts, failure to 
thrive, absent psychomotor development, progressive microcephaly, severe thrombocytopenia, 
diarrhoea, vomiting, ascites, demineralisation of distal bones and tubulopathy have been described.  
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Table: Clinical features of CDG patients 
 
Neurology 
axial hypotonia; hyporeflexia; developmental delay; seizures; stroke-like 
events; micro- and macrocephaly; myopathy 
Gastroenterology/ 
Hepatology 
failure to thrive; vomiting; protein-losing enteropathy; liver dysfunction; 
hepatomegaly; cholangitis; chronic diarrhoea 
Neonatology hydrops; ascites; multiorgan failure; failure to thrive; floppy baby 
Haematology 
thrombocytosis; thrombocytopenia; coagulopathy; thrombosis;  
anaemia; leukocytosis, thrombocytopenia 
Endocrinology 
hyperinsulinemic hypoglycemia; hypothyroidism; hypergonadotropic 
hypogonadism; growth retardation 
Clinical genetics dysmorphic features 
Orthopaedics 
osteopenia; joint contractures; kyphosis/scoliosis; short limbs; 
arthrogryposis 
Ophthalmology 
abnormal eye movements; squint; cataract; retinitis pigmentosa; 
nystagmus; iris coloboma; cortical blindness 
Radiology 
cerebellar hypoplasia; calcification of white matter; delayed 
myelinisation; micropolygyria;  renal hyperechogenecity 
Histology 
liver fibrosis; liver cirrhosis; lamellar inclusions in hepatocytes; 
intestinal villus atrophy 
Dermatology ichthyosis; abnormal fat distribution 
Nephrology nephrotic syndrome; tubulopathy; cystic kidneys 
Immunology recurrent infections; hypogammaglobulinaemia 
Cardiology cardiomyopathy; pericardial effusions 
Biochemistry 
hypoalbuminaemia; elevated transaminases; low cholesterol, 
triglycerides; decreased antithrombin III; decreased factor VIII and XI; 
decreased protein C and S; elevated FSH, LH and prolactin; elevated 
TSH, low free T4 
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Chapter 1.2 
Congenital Disorders of Glycosylation: A Review 
Stephanie Grünewald*, Gert Matthijs°, Jaak Jaeken# 
*    Children’s University Hospital, Essen, Germany 
° Center for Human Genetics, Katholieke Universiteit Leuven, Belgium 
# 
Center of Metabolic Disease, Katholieke Universiteit Leuven, Belgium 
Pediatric Research 2002 52:618-24 
Abstract  
Congenital Disorders of Glycosylation (CDGs) are a rapidly growing group of inherited 
disorders due to defects in the synthesis and processing of the ASN-linked oligosaccharides of 
glycoproteins. The first CDG patients were described in 1980. Fifteen years later, a 
phosphomannomutase deficiency was found as the basis of the most frequent type, CDG-Ia. In 
recent years several novel types have been identified. The N-glycosylation pathway is highly 
conserved from yeast to human and the rapid progress in this field can largely be attributed to 
the systematic application of the knowledge of yeast mutants. Up to now, eight diseases have 
been characterized, resulting from enzyme or transport defects in the cytosol, the endoplasmatic 
reticulum (ER) or the Golgi compartment. CDGs affect all organs and particularly the central 
nervous system, except for CDG-Ib, which is mainly a hepatic-intestinal disease (Pediatr Res 
52:618-624, 2002). 
Introduction  
The biosynthesis of ASN-linked oligosaccharides of glycoproteins proceeds along an extended 
pathway, spread over the cytosol, the ER and the Golgi compartment. In the cytosol and the ER, 
numerous glycosyltransferases stepwise attach monosaccharides to a  
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growing LLO chain. The sugar donors are either nucleotides or dolichol phosphate-linked 
sugars. The completed basic glycan (Glc3 Man9GlcNAc2) is transferred en bloc within the ER to 
an asparagine residue of a nascent protein, through the oligosaccharyltransferase complex 
(Figure 1). In the ER and the Golgi compartment, several glycosidases and glycosyltransferases 
remodel the oligosaccharide chain into a more complex structure by removal of glucose and 
mannose residues and the addition of GlcNAc, galactose, fucose and sialic acid residues (1). 
 
 
Figure 1: Simplified scheme of the cytosolic and ER part of the N-glycosylation pathway. The pathway begins in the cytoplasm 
with the synthesis from glucose of the activated sugar precursor GDP-Man. Key enzymes in this pathway are: (1) 
phosphoglucose isomerase; (2) MPI; (3) PMM; and (4) GDP-Man synthase. Dolichol phosphate mannose and 
dolichol phosphate glucose are synthesized from GDP-Man and UDP-Glc (reactions 5 and 15, respectively). The two 
dolicholphosphate sugar precursors are then flipped from the cytoplasmic side of the ER membrane to the luminal 
side. On the cytoplasmic side of the ER membrane, one molecule of GlcNAc-1-phosphate is transferred from UDP-
GlcNAc to dolichol phosphate to form dolichol pyrophosphate GlcNAc, followed by addition of GlcNAc to form 
dolichol pyrophosphate (GlcNAc)2 (reaction 6). Five Man residues are then added from GDP-Man to form 
dolicholpyrophosphate (GlcNAc2Man5 (reaction 7), which then flips to the luminal side (reaction 8) and serves as an 
acceptor  for  four Man residues derived from dolichol phosphate mannose (reaction 9). Three Glc residues are then 
added from dolichol phosphate glucose (reactions 10, 11, and 12). TheGlc3Man9GlcNAc2 oligosaccharide is 
transferred from dolichol pyrophosphate to an asparagine residue of the nascent glycoprotein to initiate protein N-
glycosylation by the action of oligosaccharyltransferase (reaction 13). The three Glc residues are removed by 
glycosidases, and the protein proceeds to the Golgi apparatus for further processing. CDG types Ia, Ib, Ic, Id, and Ie 
are caused by defective enzymes at steps 3, 2, 10, 9, and 5, respectively. 
 
 11 
Glycoconjugates play many critical roles in human metabolism (2): e.g. in cell recognition and 
adhesion, cell migration, protease resistance, host defense and antigenicity. Therefore it is obvious 
that hypoglycosylation of proteins will lead to variable and in general severe and ubiquitous 
problems in affected individuals. In human, eight inherited diseases are known to date to be caused 
by defects in the synthesis of N-glycans. Following recent recommendations (3, 4), congenital 
disorders of glycosylation (CDG) are divided into two groups (Table 1). CDG-I comprises defects 
in the assembly of the LLO chain and its transfer to the protein. Known enzyme defects are located 
to the cytosol (CDG-Ia, CDG-Ib) and the ER (CDG-Ic, CDG-Id, and CDG-Ie). CDG-II refers to 
defects in the processing of the protein bound glycans, either late in the ER (CDG-IIb) or in the 
Golgi compartment (CDG-IIa and CDG-IIc). It is convention that untyped cases are labeled CDG-x 
until they are fully characterized.  
 
Table 1: Congenital disorders of glycosylation: classification (as of June 2001) 
 
Group Defect and localization (cytoplasm, endoplasmic 
reticulum, Golgi apparatus) 
 
Defective Gene Synonym 
I Defects in the assembly of the dolichol-
pyrophosphate linked oligosaccharide chain   
 CDG-I 
    
 PMM (C) PMM2 CDG-Ia 
 MPI (C) MPI CDG-Ib 
 ALG6 (ER) ALG6 CDG-Ic 
 ALG3 (ER) ALG3 CDG-Id 
 Dolichol-P-Man Synthase 1 (ER) DPM1 CDG-Ie 
II Defects in the processing of the protein_bound 
oligosaccharide chain 
 CDG-II 
    
 N-Acetylglucosaminyltransferase II (GA) MGAT2 CDG-IIa 
 Glucosidase I (ER) GLS1 CDG-IIb 
 GDP-fucose Transporter (GA) FUCT1 CDG-IIc 
x Defects not yet completely characterized  CDG-x 
    
         C: cytoplasm; GA: Golgi apparatus. 
 
IEF of serum transferrin remains the most powerful screening test for CDG, although not all types 
can be detected in this assay. A type 1 IEF pattern (observed in CDG-I) is characterized by a 
decrease of tetrasialotransferrin and an increase of di- and asialotransferrin bands, whereas a type 2 
pattern (observed in CDG-II) shows in addition an increase of tri- and monosialotransferrin. This 
review presents highlights of the known and newly discovered congenital disorders of N-linked 
glycosylation and summarizes diagnostic and therapeutic approaches. 
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Clinical presentations 
 
CDG-Ia (PMM deficiency) 
An estimated 300 patients are known worldwide with this most frequent type of CDG. Often 
patients can be diagnosed in the neonatal or early infantile period, on the basis of typical clinical 
features (inverted nipples and fat pads) in addition to strabismus, muscular hypotonia, failure to 
thrive and recurrent elevated transaminases (5, 6). As a rule there is osteopenia. A very common 
feature is cerebellar hypoplasia, which can usually be documented at or shortly after birth. There is 
a substantial childhood mortality of approximately 25%, due to severe infections or organ failure 
(7, 8). 
At a later age, the impairment of the neurological system becomes more evident with variable 
degree of mental retardation, cerebellar dysfunction and retinitis pigmentosa.  Some children 
develop seizures or present stroke-like episodes. In adults, non-progressive ataxia, stable mental 
retardation and peripheral neuropathy mainly characterize the disease. The large majority of 
patients are wheelchair bound. Adult female patients present as a rule with hypergonadotropic 
hypogonadism (9, 10). Thanks to the broadened screening for CDG, the number of patients with a 
less typical presentation is increasing, including children with nearly normal psychomotor 
development. 
CDG-Ia is a result of PMM 2 (EC 5.4.2.8) deficiency (11) and the gene is localized on chromosome 
16p13 (12, 13).  
 
CDG-Ib (MPI deficiency) 
Although MPI (EC 5.3.1.8) catalyses the reaction one step upstream of PMM, the clinical 
presentation of this disease is very different from the PMM deficiency and the other CDG types. 
Some 20 patients are known. The classical clinical presentation is protein losing enteropathy, 
congenital hepatic fibrosis and coagulopathy without overt neurological manifestations (14-18). 
Other presentations are persistent vomiting (15) and hyperinsulinemic hypoglycemia (18). Early 
diagnosis is essential, because patients can be successfully treated with oral mannose (see 
“Treatment”).  
 
CDG-Ic (ALG 6 deficiency) 
ALG 6 deficiency (CDG-Ic) causes mainly a neurological disorder that is in general milder than 
CDG-Ia (19, 20). Features of CDG-Ia, such as cerebellar hypoplasia, polyneuropathy, fat pads and 
inverted nipples are missing (21, 22). In two of 20 patients the disease had a fatal outcome because 
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of severe coagulopathy and hormonal disturbances, combined with untreatable seizures 
(unpublished data). This type of CDG is probably under diagnosed because of the absence of 
typical morphological features and of cerebellar hypoplasia. The enzyme, ALG 6, catalyses the 
attachment of the first glucose to the LLO intermediate Man9GlcNAc2-PP-dolichol in the ER.  
 
CDG-Id (ALG 3 deficiency) 
Thus far, only one patient has been described with an ALG 3 deficiency (23). This child was first 
reported in 1995 as CDG “type IV” (24). The boy presented with microcephaly, severe epilepsy 
and nearly absent psychomotor development. The IEF of serum transferring (type 1 pattern) shows 
no increase of asialotransferrin. The defect is in the ALG 3 that transfers mannose from dolichol-
phosphate mannose to the LLO intermediate Man5GlcNAc2-PP-dolichol.  
 
CDG-Ie (dolichol-P-mannose synthase 1 deficiency) 
Two groups have reported on four severely handicapped patients (in three families) with minimal 
psychomotor development, microcephaly, absent visual contact and severe epilepsy. Brain imaging 
revealed delayed myelination in two of them. As in the previous types, IEF of serum transferrin 
showed a type 1 pattern with only little or no increase of asialotransferrin. This clinical picture is 
caused by a dolichol-P-mannose synthase deficiency (EC 2.4.1.83) and mutations in DPM1, the 
catalytic subunit of Dol-P-Man synthase, have been identified (25, 26).  
 
CDG-IIa (N-acetyl-glucosaminyltransferase II deficiency) 
When in the early 1990s an Iranian girl and a Belgian boy were reported with severe psychomotor 
retardation but without peripheral neuropathy or cerebellar hypoplasia, it became clear that CDGs 
are a heterogeneous group of disorders. Up to now, four children in three families have been 
diagnosed as CDG-IIa (27, 28). They showed craniofacial dysmorphy, stereotypic hands movement 
and psychomotor retardation to a variable degree. Glycan structural studies revealed a similar 
monoantennary N-acetyllactosamine type glycan as found in patients with congenital 
dyserythropoietic anemia type II (29, 30). This suggested an N-Acetyl-glucosaminyltransferase II 
(EC 2.4.1.143) deficiency, which was demonstrated in monocytes and fibroblasts (31, 32). 
Mutations have been found in the MGAT2 gene (33).  
 
CDG-IIb (glucosidase I deficiency) 
Very recently, a different type of CDG was identified in a child with severe developmental delay, 
muscular hypotonia, recurrent edema, seizures and peculiar dysmorphy, including retrognathia, 
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high arched palate and overlapping of fingers.  It results from defective glucosidase that, in the ER, 
reacts in the first step of the processing of the glycan structure, after its transfer to the protein. 
Interestingly, IEF of transferrin was normal, whereas the IEF of serum hexosaminidase was slightly 
abnormal. The defect was found after oligosaccharide analysis of urine revealed the presence of a 
tetrasaccharide [Glc(α1-2)Glc(α1-3)Glc (α1-3)Man] (34).  
 
CDG-IIc (GDP-fucose-transporter deficiency) 
Three patients have been reported (35, 36): they presented craniofacial dysmorphism, severe 
psychomotor retardation, hypotonia and growth retardation. A typical feature was recurrent 
infections with marked leukocytosis. Neutrophils of these patients lack sialyl-Lewis x, a fucose 
containing carbohydrate ligand of the selectin family of cell adhesion molecules. Sialyl-Lewis x is 
necessary for the recruitment of neutrophils to the infection focus. Other fucose-containing 
carbohydrate sequences such as A, B, O and Lewis A blood groups, are also absent. Mutations in 
the gene for a specific GDP-fucose transporter were identified as the underlying causes of this so-
called leukocyte adhesion deficiency type II (37,38). 
 
CDG-x 
The number of patients with a CDG not belonging to the known types is steadily increasing. They 
undoubtedly harbor different defects in the numerous other steps of the N- and O-glycosylation 
pathways. Their clinical presentations are very variable: hydrops fetalis,  dysmorphy and early 
death after intractable seizures (39); severe hypotonia, cataracts, failure to thrive, absent 
psychomotor development, progressive microcephaly and death in status epilepticus (40); 
oligohydramnios, dysmorphy, hypotonia, seizures, cerebellar hypoplasia and severe 
thrombocytopenia (41); oligohydramnion, hypotonia, diarrhea, vomiting, ascites, demineralization 
of distal bones and tubulopathy (42); dysmorphy, muscular hypotonia and infantile spasms (43).  
 
Table 2 summarizes either the most common or most characteristic symptoms of the known 
defects. Note that for several of the disorders only very few patients are known, making a 
comprehensive clinical description premature. 
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Table 2: Signs and symptoms in CDG 
 
 
Number of 
patients known 
CDG- 
Ia 
> 300 
CDG- 
Ib 
~ 20 
CDG- 
Ic 
~ 20 
CDG- 
Id 
1 
CDG- 
Ie 
4 
CDG- 
IIa 
4 
CDG-
IIb 
1 
GDP-
IIc 
3 
Psychomotor 
retardation 
+ → +++ - + / ++ +++ +++ - → +++ +++ +++ 
 
Seizures 
 
- → ++ 
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Liver disease 
 
 
+ 
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Coagulopathy 
 
++/+++ 
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+++ 
  
+ 
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LAD, leukocyte adhesion deficiency. 
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Diagnosis 
  
In view of the extremely broad clinical spectrum of known CDG patients, it is recommended to 
consider CDG in any unexplained multisystem disorder. Figure 2 proposes a stepwise diagnostic 
flowchart for the detection and characterization of CDG patients.  
 
 
             isoelectrofocusing (IEF) of serum transferrin 
 
 
    
                abnormal            normal     
           (does not exclude CDG !)   
 
     
 
protein variant     
 artefact * 
 
CDG with sialic acid-deficient glycoproteins 
 
 
 
 
    type 1 pattern                        type 2 pattern 
 
 
secondary         primary   
             (galactosemia,                       glycan structure     
  fructose intolerance,                   analysis 
     alcohol abuse, …..) 
            enzymatic tests 
      (PMM,MPI, ....)   
       
            enzymatic tests 
           mutation analysis 
              
     
deficient                  normal 
                   
    
 
   mutation analysis           lipid-linked oligosaccharides 
            
           enzymatic tests +/- mutation analysis 
 
Figure 2:  Proposed diagnostic flow chart for Congenital Disorders of Glycosylation (CDG). * The use of EDTA plasma can cause 
artefacts due to iron chelation. 
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IEF of serum transferrin 
Transferrin, one of the predominant serum glycoproteins, has two N-glycosylation sites. Hence, 
most transferrin molecules carry two biantennary chains with terminal sialic acid residues, and  
tetrasialotransferrin is the main serum sialotransferrin. Deficient synthesis of N-glycans results in a 
deficient incorporation of sialic acid, the terminal negatively charged sugar. The molecules acquire 
a more positive charge which causes a cathodal shift in the IEF pattern of transferrin. In the so-
called type 1 pattern (the most frequent) there is an increase of di- and asialotransferrin and a 
decrease of tetrasialotransferrin whereas the type 2 pattern is a combination of the type 1 pattern 
and an increase of trisialotransferrin and, but not always, monosialotransferrin. One has to make 
sure that the abnormal pattern is not due to a transferrin protein variant by performing IEF of the 
parents’ transferrin. Pre-incubation of the sample with  
neuraminidase is another means to differentiate between CDG and protein variants. It is worthwhile 
to perform IEF of other glycoproteins (e.g. hexosaminidase, thyroxine-binding globulin or α1- 
antitrypsin) to document that there is a generalized glycosylation defect in the patients (44). 
Because IEF is based on the deficiency of sialic acid, fucose defects cannot be picked up. In 
patients suspected of a fucose defect the blood groups should be determined: they show the 
Bombay blood group (38). Also, the IEF of serum transferrin was normal in the one reported 
patient with CDG-IIb (34) and can be normal in patients with CDG-Ia (45). 
Carbohydrate-deficient transferrins (CDT) can also be observed in uncontrolled fructosemia, 
galactosemia and in chronic alcohol ingestion (46-50). The cathodal shift on IEF disappears with 
efficient treatment.  
                    
Enzymatic measurements 
PMM and MPI activity are most readily measured in fibroblasts or leukocytes (11). Regarding 
PMM activity, leukocytes seem to be more reliable than fibroblasts, because a high residual activity 
has been observed in the fibroblasts of some CDG-Ia patients, whereas the leukocyte values were 
always in the clearly abnormal range (51). Thus, patients with slightly decreased or low normal 
values of PMM in fibroblasts might still harbor mutations in PMM2. Especially in the case of a 
clinical picture that strongly suggests CDG-Ia, it is worthwhile to look for PMM2 mutations.   
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Mutation studies 
The PMM2 gene has been cloned in 1997 (13) and more than 50 different mutations have been 
identified (13; 52-56). There is a clear predominance of missense mutations. The R141H mutation 
is found in approximately 40% of all patients. F119L is frequent in the Northern European 
countries due to a founder effect (54, 57), whereas V231M and P113L are frequent all over Europe 
(Table 3) (13, 58). Most patients are compound heterozygous for 2 different mutations, and 
homozygosity is not observed for R141H or other mutations that severely impair the protein (52, 
53, 59-61).  
Mutations in the MPI gene have been found in most patients with a MPI deficiency. The gene is 
localized on chromosome 15p22 and again, mutations are generally of the missense type. Because a 
very limited number of patients are known, the spectrum of mutations is rather limited for the 
moment (Table 3) (14, 16, 18, 62).  
 
Table 3: mutations in CDG-Ia, CDG-Ib and CDG-Ic 
 
Gene Mutations References 
 
PMM2  
(CDG-Ia) 
 
Frequent mutations: 
R141H, F119L, V231M, P113L. 
Other Mutations: 
C9Y, D65Y, V129M, F157S, F183S, D188G, T237M, T237R, 
C241S 
 
(54) (57) (6) (56) 
(13, 58, 59) 
 
MPI  
(CDG-Ib) 
 
Reported mutations: 
M51T, S102L, D131N, M138T, R152Q, R219Q, G250S, Y255C, 
I398T, R418H, c.166-167insC, IVS5-1G>c. 
 
(18) (16) (83) (62) 
 
ALG6  
(CDG-Ic) 
 
Frequent (Dutch) mutation A333V. 
Other mutations 
IVS3+5G>A, S478P, F304S, ∆ I299. 
 
(21) (63) (22) (64) 
 
 
Genetic studies in CDG-Ic patients revealed a prevalence of the A333V mutation in ALG 6, 
probably due to a founder effect in the Dutch population. Only a handful of other mutations has 
been described to date (table 3) (21, 22, 63, 64). 
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Prenatal diagnosis 
Prenatal diagnosis has become reliable for CDG-Ia (54, 65) since the mapping of the disease locus 
on chromosome 16p13 (12), and the subsequent identification of the enzymatic defect (11) and the 
cloning of the PMM2 gene (13). Early attempts for prenatal diagnosis on the basis of transferrin 
isoforms in fetal blood have failed and thus revealed, that this method is not reliable (66, 67). 
Enzymatic measurements of PMM activities in cultured amniocytes or trophoblasts are useful but 
may give inconclusive data (65). As a result, preference is given to the direct mutation analysis in 
the fetus. 
Prenatal diagnosis is possible in all other types of CDG for which the molecular defect is known, 
on the condition that the diagnosis has been confirmed in the index patient or the mutations have 
been detected in the parents.  
 
LLO analysis 
The N-glycosylation pathway in the ER is highly conserved in eukaryotic cells (19) and yeast 
genetic techniques have been instrumental in the identification of new N-glycosylation disorders in 
human. By comparing LLO structures of patients with those of yeast mutant strains the defects of 
CDG-Ic, Id and Ie have been elucidated (19, 20, 23, 25, 26). The power of the LLO analysis is of 
course limited to defects in the cytosol and ER.  
 
Glycan structure analysis 
Structural studies of the complex Asp-linked glycans have mainly been performed on serum 
transferrin, i.e. IEF, chromatofocusing, Western-blotting, capillary zone electrophoresis and anion 
exchange chromatography (68-74). Electrospray mass spectrometry (ES-MS) of protein bound 
oligosaccharide chains (glycoproteins) can separate the different glycoforms (75) and nuclear 
magnetic resonance spectroscopy analysis determines the glycan structures and molecular mass of 
the glycovariants (76). Such glycan structure analysis will be instrumental for the elucidation of 
CDG-x cases, by pinpointing candidate enzymes and genes responsible for the abnormal N-glycan 
synthesis.  
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Treatment 
 
CDG-Ia 
Unfortunately, an efficient treatment is still not available for the CDG-Ia patients. Although it was 
reported that incubation with mannose resulted in an increased incorporation of mannose in 
patient’s fibroblasts (77), mannose administration to CDG-Ia patients did not improve the clinical 
or biochemical features (78, 79). Also fucose supplementation, with the aim to enhance the GDP-
mannose pool, was not successful (T. Marquardt, personal communication). Studies with a 
ketogenic diet in CDG-Ia are ongoing. The rationale for this treatment is the observation that 
glucose starvation improves N-glycosylation in fibroblasts from CDG-Ia patients (80).  
As to symptomatic treatment, we have obtained efficient prevention of stroke-like events by using 
0.5 mg/kg per day acetylsalicylic acid (Van Geet and Jaeken, in preparation). In patients with 
recurrent fractures, biphosphonates should be considered. 
 
CDG-Ib 
In CDG-Ib patients, treatment with oral mannose (4-6 doses per day x 100-150 mg/kg per day) has 
shown significant improvement (81-83). Serum mannose levels should be greater than 200 µmol/l. 
Since mannose supplementation is probably a life-long therapy for MPI-deficient patients, side 
effects have to be monitored carefully. High mannose intake can cause osmotic diarrhea (81). Also 
a slight increase of the glycosylated hemoglobin (HbA1c) has been observed (82).   
 
CDG-IIc 
In one patient with a GDP- fucose transporter defect, fucose supplementation (25 mg/kg per day in 
3 doses) was reported to improve the fucosylation of glycoproteins and to control the recurring 
infections (36).  
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Conclusion and Outlook 
 
In the last two years, the field of the CDG has been rapidly expanding, thanks to the increasing 
awareness of the clinical variability of CDG and the use of yeast genetic technology. The extremely 
wide clinical spectrum of CDG makes a broad screening for these disorders in children as well as in 
adults mandatory by using serum transferrin IEF. It is quite certain that many new glycosylation 
disorders are awaiting identification as it is estimated that some 500 genes (approximately 0.5 to 
1% of the translated human genome) participate in oligosaccharide synthesis and function (84). The 
development of animal models offers the potential to test therapeutic approaches and will be 
helpful in understanding the pathogenesis of these disorders.  
Addendum 
Very recently two new CDG have been identified: CDG-If (an ER defect) and CDG-IId (a Golgi 
defect). CDG-If has been reported in four patients with a severe encephalopathy and, in three of 
them, a dry, scaling skin with erythroderma. Mutations were found in the Lec35/MPDU1 gene 
involved in the use of dolichylphomannose and dolichylphosphoglucose (85, 86). CDG-IId was 
described in a patient with moderate psychomotor retardation and macrocephaly as well as 
myopathy. A homozygous mutation (insertion of a single nucleotide) was found in the gene for 
UDP-Gal: N-acetyl-glucosamine β-1,4-galactyosyltransferae I (87, 88). 
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Chapter 1.3 
Congenital Disorders of Glycosylation (CDG): 
A Rapidly Expanding Group Of Neurometabolic Disorders 
 
1.3.1 N-Glycosylation defects 
The rapid delineation of additional CDGs – especially for CDG-I defects – have been facilitated by 
using yeast as a model system: the N-glycosylation assembly pathway is highly conserved between 
yeast and man and is notable for the substrate specificity of the transferases involved (Burda and 
Aebi 1999). Saccharomyces cerevesiae mutants with defective asparagine linked glycosylation 
(alg) had already been created in the early eighties (Huffaker and Robbins 1982) and their 
metabolic defects had been characterized by the accumulation of specific lipid-linked 
oligosaccharide (LLO) patterns. Comparing these specific LLO patterns of different yeast mutants 
with those being found in patients’ fibroblasts, helped to identify the candidate genes for several 
human glycosylation defects, primarily of the group of CDG-I defects. Patients’ fibroblasts have 
been labeled either with radioactive mannose (Thiel, Schwarz et al. 2003), or with glucosamine, to 
allow the analysis of the LLOs (Kranz, Denecke et al. 2004) (Schwarz, Thiel et al. 2004). The very 
short LLOs have recently been detected by a non-radioactive labeling study with the fluorescent 
group 2-aminobenzamide (Grubenmann, Frank et al. 2004). 
Following the review on CDG Ia-Ie and CDG IIa-IIc in chapter 1.2, since 2002, additional CDG 
subtypes have been identified and at present we have reached “CDG-Il” of the type I alphabet and 
CDG-IIf of type II defects.  
Table 1 gives an overview of all N-glycosylation defects identified to date and figure 1 illustrates 
the different enzyme defects in the N-glycosylation pathway.  
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Table 1: Update on Congenital Disorders of Glycosylation (September 2006) 
 
 
CDG 
subtype 
 
 
Defective 
Gene 
 
Enzymatic defect  
 
CDG-I 
 
CDG-Ia PMM2 Phosphomannomutase  
CDG-Ib MPI Phosphomannose Isomerase  
CDG-Ic ALG6 Dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase  
CDG-Id ALG3 Dolichyl-P-Man:Man5GlcNAc2-PP-dolichyl mannosyltransferase  
CDG-Ie DPM 1 Dolichyl-P-Man Synthase 1  
CDG-If MPDU1 Mannose-P-dolichol utilization defect 1 
CDG-Ig ALG12 Dolichyl-P-Man:Man7GlcNAc2-PP-dolichyl mannosyltransferase 
CDG-Ih ALG8 Dolichyl-P-Glc:Glc1Man9GlcNAc2-PP-dolichyl glucosyltransferase 
CDG-Ii ALG2 GDP-Man:Man1GlcNAc2-PP-dolichyl mannosyltransferase 
CDG-Ij DPAGT1 UDP-GlcNAc:dolichyl-P-N-Acetylglucosamine-1Phosp transferase 
CDG-Ik ALG1 GDP-Man:GlcNAc2-PP-dolichyl mannosyltransferase 
CDG-Il ALG9 Dolichyl-P-Man: Man6GlcNAc2-PP-dolichyl and  
Man8GlcNAc2-PP-dolichyl mannosyltransferase 
 
CDG-II 
 
CDG-IIa MGAT2 Mannosyl 1,6-glycoprotein 1,2  N- acetylglucosaminyltransferase  
CDG-IIb GLS1 Glucosidase 1 
CDG-IIc FUCT1 GDP-fucose transporter 1 
CDG-IId B4GALT1 UDP-Gal:NAc-ß-1,4-galactosyltransferase 1 
CDG-IIe COG7 Conserved Oligometric Golgi (COG) complex 
CDG-IIf SLC35A1 CMP-NeuAc transporter 
 
CDG-x 
 
 
Still to be established 
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Figure 1: Simplified scheme of the cytosolic, ER and Golgi part of the N-glycosylation pathway. Indicated are the different CDG subtypes identified so far. 
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CDG-If (MPDU1 deficiency) 
CDG-If has been reported in four patients with a severe encephalopathy and, in three of them, a 
dry, scaling skin with erythroderma. Mutations were found in the Lec35/MPDU1 gene involved 
in the use of dolichylphosphomannose and dolichylphosphoglucose (Kranz, Denecke et al. 
2001) (Schenk 2001).  
 
CDG-Ig (ALG12 deficiency) 
Thus far, simultaneously, three groups have reported on patients with ALG12 deficiency (Thiel, 
Schwarz et al. 2002) (Grubenmann, Frank et al. 2002) (Chantret, Dupre et al. 2002). These three 
children presented with microcephaly, severe epilepsy, hypotonia and nearly absent 
psychomotor development. The IEF of patients’ serum transferrin showed partial loss of 
complete N-glycan side chains. In skin fibroblasts, the activity of dolichol-P-
Man:Man7GlcNAc2-PP-dolichyl mannosyltransferase was severely reduced. Interestingly, in one 
patient, undetectable insulin-like growth factor (IGF)-1 and IGF-binding protein 3 was reported 
and low levels of immunoglobulins were repeatedly measured (Grubenmann, Frank et al. 2002).  
 
CDG-Ih (ALG8 deficiency) 
The first clinical description of a CDG-Ih patient was published in 2003 (Chantret, Dancourt et 
al. 2003), and this was followed by the paper of Schollen et al (Schollen, Frank et al. 2004): 
whereas the first patient described showed clinical symptoms similar to those of CDG-Ib 
patients including severe protein losing enteropathy, the three additional CDG-Ih patients had a 
much more severe course and died early in multi-organ failure complicated by a rapidly 
developing massive ascites. The diagnosis of CDG-Ih was based on the accumulation of LLO 
linked dol-PP-GlcNAc2Man9 and dol-PP-GlcNAc2Man9Glc1 due to dolichyl-P-Glc: 
Glc1Man9GlcNAc2-PP-dolichyl glucosyltransferase deficiency.  
 
CDG-Ii (ALG2 deficiency) 
Only one patient so far has been found to have a deficiency of GDP-Man:Man1GlcNAc2-PP-
dolichyl mannosyltransferase. This child, described by Thiel et al in 2003 (Thiel, Schwarz et al. 
2003), is visually impaired, showed bilateral coloboma and cataract and suffered from infantile 
spasms. The MRI showed pronounced dysmyelination, clinically reflected in severe 
developmental delay. The molecular defect in this glycoprotein biosynthesis defect, affects the  
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transfer of mannosyl residues from GDP-Man to Man1GlcNAc2-PP-dolichol on the cytosolic 
side of the endoplasmatic reticulum.  
 
CDG-Ij (DPAGT1 deficiency) 
Dramatically decreased activity of UDP-GlcNAc:dolichol phosphate N-Acetylglucosamine-1 
phosphate transferase was proven in a severely handicapped child, that had shown hardly any 
psychomotor development. Wu et al (Wu, Rush et al. 2003) showed lowered incorporation of 
radio-labeled mannose into full-length dolichol-linked oligosaccharides. The patient inherited a 
paternal point mutation and in the maternal allele abnormal splicing resulted in only about 12% 
of normal DPAGT1 mRNA expression.    
 
CDG-Ik (ALG1 deficiency) 
Three different reports were published in 2004 on four patients with a defect in the first 
mannosylation step of the N- glycosylation pathway, due to GDP-Man:GlcNAc2-PP-dolichyl 
mannosyltransferase deficiency (Grubenmann, Frank et al. 2004) (Kranz, Denecke et al. 2004). 
Glycosylation and growth of alg1 deficient PRY56 yeast cells (Kranz, Denecke et al. 2004) or 
Sacharomyces cerevisia alg1-1 strains (Schwarz, Thiel et al. 2004) could be restored by the 
human wild type allele, whereas only slight restoration was observed after transformation with 
the patients’ alleles.    
 
CDG-Il (ALG9 deficiency) 
A homozygous point-mutation was detected in the ALG9 gene in a patient presenting with 
severe microcephaly, central hypotonia, seizures and developmental delay (Frank, Grubenmann 
et al. 2004). This mannosyltransferase deficiency causes dual accumulation of LLO 
Man6GlcNAc2- and Man8GlcNAc2 structures, as the human homologue of the yeast alg9 
catalyses the transfer of mannose onto these two acceptor substrates. In a second case, published 
by Weinstein et al (Weinstein, Schollen et al. 2005) the female infant’s features showed 
additionally failure to thrive, pericardial effusion and cystic renal disease.   
 
CDG-IId (B4GALT1 ) 
CDG-IId was described in a patient with moderate psychomotor retardation and macrocephaly 
as well as myopathy. A homozygous mutation (insertion of a single nucleotide) was found in  
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the gene for UDP-Gal: N-acetyl-glucosamine β-1,4-galactyosyltransferae I (Hansske, Thiel et al. 
2002) (Peters, Hackler et al. 2002). 
 
CDG-IIe (COG7 deficiency) 
A new area of defects in the glycosylation pathway has been entered with the identification of 
the underlying pathomechanism in CDG-IIe. All the other CDG defects identified so far showed 
mutations in a gene encoding for a single enzyme in the glycosylation pathway. In CDG-IIe, 
however, a defect in the conserved oligometric Golgi (COG) complex, attached to the 
cytoplasmatic surface of the Golgi, leads to mislocation of interacting enzymes and transporters. 
This disruption of the COG complex impairs multiple glycosylation pathways leading to a very 
severe multisystemic disease that caused early death in two siblings (Wu, Steet et al. 2004).  
 
CDG-IIf (SLC35A1 deficiency) 
The second CDG disease caused by a nucleotide transporter defect has been recently identified  
(Martinez-Duncker, Dupre et al. 2004). Whereas CDG IIc is due to a fucose transporter defect, 
in CDG IIf an inactivation of the CMP-sialic acid transporter was found. This led to a mainly 
hematological presentation with massive bleeding due to pronounced thrombocytopenia. 
Ultrastructural studies showed hypogranular giant platelets. There was a complete lack of sialyl-
Lex antigen on the polymorphic nuclear cells. This patient had normal glycosylation of plasma 
glycoproteins and it was suggested, that this might be due to different degrees of altered splicing 
in different cells.  
 
Clinical spectrum of CDG 
The importance of proper glycosylation is dramatically illustrated by the severity of the clinical 
signs and symptoms of patients suffering from different CDG syndromes and by the fact that 
literally all organ systems can be affected. Table 2 summarizes the clinical signs and symptoms 
of the CDG subtypes published so far. It is important to stress that for some of the more recently 
identified CDG family members, only very few patients have been described. Therefore, these 
observations cannot be generalized and their clinical presentation might vary considerably when 
more patients are detected. This has already been well observed and documented for CDG-Ia: 
the first patients identified all belonged to the severe end of the clinical spectrum, whereas with 
time, very mild cases were diagnosed and broadened the  
 
clinical spectrum from very disabled (de Lonlay 2001) to CDG-Ia individuals with normal 
neurological development (Giurgea, Michel et al. 2005), 121-3 and Coman (personal 
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communication at the EUROGLYCANET meeting in Athens 2005: three siblings, living 
independently, professional artist, assistant librarian and secretarial worker).   
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Table 2a:                                      Signs and symptoms in CDG: type I subtypes 
 
Number of patients known CDG-Ia 
700 
CDG-
Ib 
~ 20 
CDG-Ic 
~ 30 
CDG-
Id 
2 
CDG-Ie 
4 
CDG-If 
4 
CDG-Ig 
3 
CDG-Ih 
4 (1 sib) 
CDG-Ii 
1 
CDG-Ij 
1 
CDG-Ik 
4 
CDG-Il 
2 
Psychomotor retardation + → +++ - / (+) + / ++ +++ +++ +++ +++ - +++ +++ +++ + 
Seizures - → ++ +/- - → +++ +++ +++ +++ + - ++ +++ ++++ + 
Axial hypotonia +++ +/- ++ / +++  +++ hypo/hy-
pertonia 
+++   ++ + + 
Cranial MRI 
Cerebellar hypoplasia 
 
 
+++ 
    
 
+/- 
 
 
    delayed 
myelination 
PET 
abnor-
mal 
cerebral 
atrophy 
cerebral 
atrophy 
Dysmorphy 
* (fat pads, inverted nipples) 
- → +++ 
* 
+++ 
- +/- 
 
+ 
+/- ++ 
 
- 
+/- ++ +/-  clino-
dactyly 
+/-  
Failure to thrive +++ ++ +/-   ++       
Liver disease 
Hepatosplenomegaly 
Liver fibrosis 
Coagulopathy 
 
 
++ 
 
+ 
 
++/+++ 
 
 
+++ 
 
++ 
 
+-+++ 
 
 
       +  
 
 
 
     +++ 
  
 
++ 
 
 
 
+ 
 
 
+ 
 
 
 
+/- 
 
 
 
 
 
 
+ 
 
 
++ 
 
 
 
+ 
 
 
+ 
 
 
 
++ 
  
 
+ 
 
+ 
 
++ 
 
 
+ 
 
+ 
Protein-losing enteropathy +/++ +++ + - -   +++     
Other multiorgan 
involvement, 
retinitis 
pigmentosa, 
hypergonadotropic 
hypogonadism 
renal 
cysts 
retinal 
degeneration 
intracranial 
hypertension 
micro- 
cephaly 
micro- 
cephaly 
blindness 
optic 
atrophy, 
ichthiosis, 
short 
stature, 
retinopathy 
micro-
cephaly, 
undetec 
IGF, 
IGFBP3 
early death, 
thrombocy-
topenia, 
renal cysts, 
tubulopathy 
coloboma, 
seizures, 
hypomyelina-
tion 
micro-
cephaly 
blindness, 
microcephaly, 
nephritic 
syndrome, 
absent IgG, 
hydrops 
micro-
cephaly, 
pericard 
effusion, 
cystic renal 
disease 
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Table 2b:                                         Signs and symptoms in CDG: type II  
 
Number of patients known CDG-IIa 
4 
CDG-IIb 
1 
CDG-IIc 
5 
CDG-IId 
1 
CDG-IIe 
2 siblings 
CDG-IIf 
1 
Psychomotor retardation - → +++ +++ +++ +++   
Seizures +++ +++ -  +++  
Axial hypotonia ++ ++ +++ ++ +++  
Cerebellar hypoplasia - - -    
Dysmorphy* (fat pads, 
inverted nipples) 
++ +++ +++  +++  
Liver disease + +++   ++ 
HSM 
 
Coagulopathy +++ ++  +++  Massive 
haemorrhages 
Protein-losing enteropathy - - - - -  
Other stereotypic 
behaviour 
early death LAD II* 
phenotype 
macrocephaly, Dandy Walker,  
myopathy, hydrocephaly 
thrombocyto-
penia, early fatal 
megathrombo-
cytopenia 
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1.3.2 O-Glycosylation defects 
 
There are two main types of protein glycosylation: N – and O- glycosylation. Whereas N-
glycosylation takes place in the cytoplasm, endoplasmatic reticulum and Golgi and includes 
assembly and processing steps, O-glycosylation lacks a processing pathway but is otherwise 
more complex. There is much more diversity in O-glycan structures, as there are many more 
core structures underlying the synthesis of O-glycoproteins. The most commonly observed O-
glycans are the so called mucin-type O-glycans with GalNAc as the initiating sugar, comprising 
six core structures (Van den Steen, Rudd et al. 1998). O-glycosylation defects in man have so 
far only been described for O-glycans with mannose or xylose as first sugar attached in 
threonine or serine binding to its protein (table 3).   
 
 
Table 3: Update on O-glycosylation defects (August 2006) 
 
 
1.3.2.1 Defects in the biosynthesis of O-mannosylated glycans 
Two distinct disorders from the genetically heterogeneous group of congenital muscular 
dystrophies were recently included in the CDG family. Defective post-translational modification 
 
 
 
 
Defective 
Gene 
 
 
Enzymatic defect  
 
Defects in the biosynthesis of O-mannosylated glycans 
 
 Muscle-eye-brain disease (MEB) POMTGnt1 O-linked mannose ß1,2-N-acetylglucosaminyl-
transferase  
Walker-Warburg syndrome (WWS) POMT1 Protein-O-mannosyltransferase 1 
 
Defects in the biosynthesis of O-xylolylated glycans 
 
Hereditary multiple exostoses 
syndrome 
EXT1/ EXT2 Glucuronyltransferase / N-acetyl-D-hexosaminyl-
transferase  
Ehlers-Danlos syndrome – Progeria 
variant 
XGALT7/ 
XGAL-T1 
Xylosylprotein ß 1,4 galactosyltransferase  
 40 
seems to be confined to a small number of proteins, of which only one has been identified so 
far, dystroglycan which is heavily N- and O-glycosylated. Whereas N-glycosylation plays a 
minor role in alpha-dystroglycan, the sialylated O-glycans seem to play a crucial role in the 
binding of alpha-dystroglycan to the extracellular matrix protein laminin (Chiba, Matsumura et 
al. 1997). The underglycosylation of the dystroglycan, the key component of the dystroglycan 
complex, leads to a disruption of the integrity of the basal membrane in skeletal muscle and 
brain. Walker-Warburg Syndrome (WWS) and muscle-eye-brain-disease (MEB) are caused by 
mutation in two genes involved in O-mannosylation, POMT1 and POMGnT1, respectively 
(Beltran-Valero de Bernabe, Currier et al. 2002) (Yoshida, Kobayashi et al. 2001).  
 
 
 
  
 
 
 
 
 
 
 
Walker-Warburg Syndrome (WWS) and Muscle-eye-brain-disease (MEB) 
The clinical presentations of WWS and MEB show a considerable overlap and might be 
undistinguishable on clinical grounds. Muscular dystrophy, ocular abnormalities, type II 
lissencephaly and cortical dysplasia has been described in both diseases. Skeletal muscle from 
affected patients, show hardly any α-dystroglycan by Western blotting or immuno-histochemical 
analysis. The finding, that one of its ligands in skeletal muscle, the laminin α chain, is 
simultaneously reduced, supports the hypothesis, that aberrant α-dystroglycan glycosylation 
underlies the pathogenesis of these disorders (Michele, Barresi et al. 2002) (Moore, Saito et al. 
2002). In parallel, basal lamina defects affecting the lamina propria of the central nervous 
system, is thought to be the underlying cause for uncontrolled neuronal growth resulting in a 
migration disorder (Muntoni, Brockington et al. 2002).  
 
 
 
 
  Man  GlcNAc  Sia  Gal Ser/Thr 
POMT1 POMGnT1 
αD
G 
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1.3.2.2 Defects in the biosynthesis of O-xylolylated glycans 
 
Hereditary multiple exostoses syndrome 
Of all glycosylation defects, this is the most prevalent CDG and the only one to be inherited as 
an autosomal dominant trait. Osteochondromas, often already present postnatally, start growing 
with time with hazardous effects on the local tissue and vessels and a tendency for developing 
malignancy. The defective genes encoding for glycosyltransferases EXT1/EXT2 are thought to 
affect the expression of Indian hedgehog, a tumour suppressing gene(Wuyts and Van Hul 2000).  
 
Ehlers-Danlos syndrome – Progeria variant 
Premature ageing and hyperelastic skin in a patient with macrocephaly and joint hyperlaxicity 
should lead to further investigation of members of the ß-1,4-galactosyltransferase family. 
Hypoglycosylation of a small proteoglycan resulting in a core protein carrying only one xylose 
O-linked to serine is the biochemical characteristic. Molecular studies and biochemical analysis 
showed markedly reduced activity of galactosyltarnsferase 1 activity and mutations were found 
in the ß-GalT7 and XGal-T1 gene (Okajima, Fukumoto et al. 1999) (Furukawa and Okajima 
2002).  
 
1.3.3 Combined N- and O-Glycosylation defects 
Part of the already well identified and known CDG defects involves actually not only the N- 
glycosylation but as well the O-glycosylation pathway as nucleotide sugars and transporters are 
shared in both pathways. Defects such as CDG-Ia,-Ib, -Ie and -If for example reduce the pool of 
luminal dol-P-Man and therefore affect N- and O-glycosylation.  
 
More combined defects are waiting to be discovered, however, screening methods for O-
glycosylation still need to be established. A first successful attempt in detecting patients with an 
O-glycosylation defect is discussed in chapter 6, giving in parallel the details of the discovery of 
a new clinical identity.  
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Chapter 2 
The classical CDG: CDG-Ia   
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Chapter 2.1 
Phosphomannomutase Deficiency: The Molecular Basis of the 
Classical Jaeken Syndrome (CDGS Type Ia) 
Gert Matthijs, Els Schollen, Leen Heykants, Stephanie Grünewald 
Center for Human Genetics, University of Leuven, Leuven, Belgium 
Molecular Genetics and Metabolism 1999 68:220–26  
CDGS is a group of autosomal recessive, metabolic diseases, described for the first time by 
Jaeken et al. (1). The observation of unusual serum glycoprotein abnormalities led to the 
inference that a defect in the glycosylation of these proteins was involved in the etiology of the 
disease (2). The descriptive name “carbohydrate-deficient glycoprotein syndrome” is derived 
from this feature. This mouthful definitely needed an acronym or synonym: CDGS or Jaeken 
syndrome (see Ref. 3 for most recent review).   
The classical clinical picture of CDGS type I (or CDGS1) includes three main features: a 
moderate to severe neurological disease, more or less typical dysmorphic signs, and variable 
involvement of different organ systems (3, 4). The neonatal period is characterized by a severe 
failure to thrive and acute, life threatening problems caused by liver failure, cardiac 
insufficiency, and/or nephrotic syndrome in some infants. Later in infancy, the involvement of 
the central nervous system becomes more obvious. All patients are moderately to severely 
mentally retarded, and most suffer from epilepsy and some from stroke-like episodes. The 
disease is largely non-progressive, be it that skeletal deformities present at later age and an overt 
premature aging is apparent in some adults (5). Actually, very few adult cases have been 
described, and the disease is definitely under recognized despite the availability of an easy 
screening test, the isoelectric focusing (IEF) of serum transferrin.   
The multiorgan involvement pointed to a defect in a very fundamental pathway. Biochemical 
and genetic investigations have elucidated the basis of the aberrant protein glycosylation: the 
defect is located in the early steps of the synthesis of N-linked glycans (1, 2, 6, 7). More 
precisely, a deficiency of phosphomannomutase (PMM) limits the supply of GDP mannose, 
required for the assembly of the dolichol-oligosaccharide in the endoplasmic reticulum (8). The 
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observation that the parents of children with a PMM deficiency showed intermediate values lent 
major support to the idea that this was the primary defect. The localization of the PMM2 gene, 
encoding an active phosphomannomutase, on chromosome 16 and the identification of 
mutations in this gene that segregate with the disease (9) gave conclusive support to the 
biochemical evidence that PMM deficiency is a cause of CDGS1 (8, 10). The knowledge that 
PMM2 has the key role in this disease now leads the way to the unraveling of the pathogenesis.   
Because other enzyme deficiencies, leading to an identical IEF pattern of serum transferrin, have 
recently been described (11–15), the PMM deficiency is referred to as CDGS1a. It is thus far the 
most frequent subtype. This review describes briefly the quest for the gene involved in CDGS1a 
and some particular observations that were made during the molecular exploration of the defect, 
and presents the most straightforward approach for the molecular confirmation of the disease in 
patients with a clinical diagnosis of CDGS.   
A Yeasty Cloning Strategy   
The identification of the gene has taken advantage of the availability of expressed sequence 
tagged (EST) sequences in the database, and the success is a tribute to the efforts of the IMAGE 
consortium to systematically sequence cDNAs. Both the human PMM1 gene (16–18) and the 
human PMM2 gene (9) were identified on the basis of the similarity of EST sequences in the 
public database with the sequence of yeast PMM or Sec53 (19). The cDNA of PMM2 has an 
open reading frame of 738 bp and encodes a protein of 246 amino acids. For PMM1, these 
numbers are 786 bp and 262 amino acids. Both proteins have been expressed in vitro and shown 
to have phosphomannomutase activity (16, 20, 21). With yeast SEC53 (19), the identity is 54 
and 58% at the amino acid level for, respectively, PMM1 and PMM2. At the DNA level (coding 
sequence only), the identity is, respectively, 32 and 52%. The degree of identity with yeast 
SEC53 is thus higher for PMM2 than for PMM1 (9, 16). Remarkably, the conservation is not 
sufficient to result in cross-hybridization in Southern or Northern experiments. Both genes were 
isolated independently using the distinct IMAGE clones. An alignment of PMM1 and PMM2 
was published in Matthijs et al. (9). There are 78 differences at the amino acid level between 
PMM1 and PMM2, not including the 4 mutational events that have led to difference in length of 
the proteins (the identity is 65% at the nucleotide and 66% at the amino acid level). PMM2 is 
shorter than PMM1 and yeast and Candida albicans PMM, and the difference is mainly due to a 
deletion of 7 amino acids in the N-terminal part of the protein. An insertion of 2 amino acids, 
after position 63 and between two conserved domains, is unique to PMM1. The bacterial 
phosphomannomutase genes show no sequence similarity at all.   
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The CDGS1 locus has been assigned to chromosome 16p13 by linkage analysis (22, 23). The 
evidence that the PMM2 gene mapped to the CDGS1 minimal candidate region on the short arm 
of chromosome 16 was obtained by fluorescence in situ hybridization analysis and by 
hybridizing a PMM2 probe to DNA from YACs in a contig that spanned this region (24, 25). 
PMM1 is located on the long arm of chromosome 22 (16, 17) and is therefore excluded as a 
candidate for the disease. Also, the kinetic and enzymatic characteristics of PMM1 point to an 
entirely different role for this enzyme in normal physiology (20, 21). Further investigations and 
a mouse model will reveal whether there is any link between PMM1 and a human disorder. On 
the other hand, PMM2 neatly fulfills the role of the phosphomannomutase implicated in the 
synthesis of GDP-mannose (21).   
 
 
 
 
 
 
 
 
Figure 1: Comparison of the genomic structure of the PMM2 (top) and PMM1 (middle) genes and structure of the PMM2p 
gene (bottom). An EcoRI (E) and HindIII (H) restriction map has been established for PMM1 and PMM2. Both 
genes are composed of eight exons, represented by black boxes. The corresponding exon junctions in PMM2p are 
indicated as well as an EcoRI site in exon 5 of PMM2 (conserved between PMM2 and PMM2p).   
 
Comparison of the genomic structure of PMM1 and PMM2 indicates that these genes have 
arisen by gene duplication (Figure 1) (24). At the DNA level, the silent sites vary in over 50% 
of the positions, suggesting that the ancestral gene was duplicated before the mammalian 
radiation that occurred 75 to 110 million years ago. We have cloned Pmm1 and Pmm2, the 
orthologues of PMM1 and PMM2 in the mouse, and these genes are indeed located on syntenic 
chromosomal regions in the human and the mouse genome (24, 26).   
In the course of the mapping experiments, a processed pseudogene was identified on 
chromosome 18. It is more closely related to PMM2 then to PMM1. When compared to PMM2, 
several base substitutions and single base insertions or deletions are present, suggesting that this 
processed pseudogene (PMM2p) has been inactivated by mutations. Remarkably, several base 
substitutions in PMM2 that are associated with disease (see below) are also present at the 
corresponding positions in PMM2p. Thus, mutations that occur at a slow rate in the active gene 
in the population have also accumulated in the processed pseudogene (24). The mutations in 
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PMM2p and in PMM2 preferentially occurred at CpG dinucleotides, due to deamination of a 
methylated cytosine. An illustration is given in Figure 2.  
   
  Codon 113   Codon 119 
                                          Pro                                                          Phe  
 …ctcCCGaag…                    …actTTCatt… 
 …gagGGCttg…                   …tgaAAGtaa… 
         
 …ctcCTGaag…   …actTTAatt… 
 …gagGACttg…   …tgaAATtaa 
          Leu               Leu 
 
   
             Codon 129   Codon 141 
                                          Val                                                          Arg 
 …aacGTGtcc…                    …gaaCGCatt… 
 …ttgCACagg…                   …cttGCGtaa… 
         
 …aacATGtcc…   …gaaTGCatt… 
 …ttgTACagg…   …cttACGtaa… 
          Met               Cys 
…gaaCACatt… 
                     …cttGTGtaa… 
                         His 
   
Figure 2 Mutations in PMM2 and the processed pseudogene PMM2p. The P113L and V129M mutations are caused by the 
common transition of the (methyl)cytosine to a thymine in a CpG island on the coding and noncoding strand, 
respectively: CCG to CTG and cGTG to cATG. F119L is caused by a transversion of TTC to TTA. These three 
mutations are also found in the processed pseudogene PMM2p. On the other hand, codon 141 (CGC, coding for 
Arg) is mutated to CAC (coding for His) in PMM2 while in PMM2p TGC (predicting a Cys) is found.    
 
 
A Very Limited Genotype–Phenotype Correlation and a Variable 
Residual Activity of the Mutant Proteins   
 
In the first large survey of PMM2 mutations in patients with CDGS1a, 56 patients from 13 
countries were included, and all except 2 were of Caucasian origin (27). The 
phosphomannomutase deficiency was documented biochemically in 47 patients from whom 
fibroblasts, lymphoblasts, or fresh leukocytes were available. In total, mutations were found on 
111 of 112 disease chromosomes (99%). The mutations, which have been identified in this and 
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other studies, are almost exclusively of the missense type (27–29). Probably only the types of 
mutations, which retain residual enzymatic activity (30), are compatible with life. This is 
supported by the observation that the few nonsense and splice site mutations are always 
combined with a mild mutation on the second allele. We have detected so far more than 30 
different mutations (Table 1). The mutation analysis has revealed extensive allelic 
heterogeneity, and very limited inferences can be made from the genotype–phenotype 
comparison. The D188G mutation must be among the most severe missense mutations because 
4 of 5 patients with this mutation died at an early age (27). On the other hand, some mutations, 
especially in the C-terminal part of the protein, are associated with a particularly mild 
phenotype. Examples are H218L, T237M, and C241S (Table 1). Apart from these extreme 
cases, there is a great variability in the phenotype in patients with the same genotype: there is no 
clear correlation between the residual phosphomannomutase activities and the genotype in 6 and 
14 patients with the R141H/P113L and R141H/F119L combinations, respectively (27). This 
presents a difficult situation for counseling and prognosis.   
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Table 1 Mutations in the PMM2 Gene in 84 Patients of Different Populations  
 
Exon Mutation AA No. Conser- 
vation 
Geographical origin 
2 131T>C V44A 3 conserved  EC,ES 
3 193G>T D65Y 3 conserved F,P 
3  P69S 1 semiconserved AUS 
3 Int3(+2)T>C splice mut 1  D 
4 303C>G N101K 1 not conserved D 
4 317A>G Y106C 1 conserved E 
4 324 del G frame shift 1  D 
4 323C>T A108V 1 semiconserved F 
4 338C>T P113L 14 conserved E,D,ES,F,NL,P 
5 357C>T F119L 23 conserved E,D,F,NL,UK,CH,US 
5 368C>A R123Q 7 conserved B,ES,F,NL,JP 
5 385G>A V129M 3 semiconserved F,I,US 
5 389delC frame shift 1  US 
5 391C>G P131A 1 conserved F 
5 395T>C I132T 1 conserved I 
5 422G>A R141H 67 conserved AUS,B,CH,D,EC,ES,F,I,IRE,P,PE,NL,UK,US 
6 452A>G E151G 1 semiconserved NL 
6 470T>C F157S 1 semiconserved ES 
6 484C>T R162W 2 conserved NL,UK 
6 523G>C G175R 1 conserved B 
7 563A>G D188G 5 conserved B,NL 
7 584A>G H195R 1 semiconserved D 
7 623G>C G208A 1 conserved US 
8 647A>T N216I 1 conserved I 
8 653A>T H218L 1 semiconserved D 
8 682G>T G228W 1 conserved NL 
8 686A>C Y229S 1 conserved JP 
8 691G>A V231M 9 conserved E,F,L,NL,PE,US 
8 697G>A A233T 2 conserved D,F 
8 710C>T T237M 5 conserved ES,F,I,IRE,US 
8 710C>T T237R 2 conserved F,D 
8 713G>C R238P 1 semiconserved JP 
8 722G>C C241S 4 non cons E,ES 
 52 
The most intriguing observation is the total lack of patients homozygous for the most frequent 
mutation (27, 29). The R141H mutation is present in more than 75% of the patients in 
Caucasians. Surprisingly, it has never been observed in the homozygous state in patients, 
although it should be present on a mathematical basis. The residual activity of the in vitro 
expressed R141H recombinant protein is almost zero and thus supports the inference that 
homozygosity for this mutation is lethal early in development (30). We have determined the 
frequency of the R141H mutation in the general population: the carrier frequency is 
approximately 1/80 in the Western European population (31). Thus, R141H is far more frequent 
than estimated on the basis of the disease frequency. It is tempting to suggest that a 
heterozygous advantage of R141H is at the basis of this relatively high frequency. On the other 
hand, patients homozygous for the relatively frequent F119L mutation were found (27, 32, 33) 
as well as one patient homozygous for the D65Y mutation (27). In these patients, the residual 
activity of the deficient enzyme is relatively pronounced. This has now been confirmed by in 
vitro activities of the mutant protein (30).   
Geographic Distribution of the Different Mutations   
CDGS1a is panethnic, but the different populations have their own set of mutations. The R141H 
mutation is by far the most frequent mutation, but it was not detected in the Japanese patients 
(27, 28).  There is a clear founder effect in Scandinavian families with CDGS1 (25). Of 25 
CDGS1 chromosomes, originating from the southwestern part of Sweden, southern part of 
Norway, and eastern part of Denmark, 15 had a common haplotype (A-haplotype). It has now 
been shown that the underlying Scandinavian mutation is the F119L mutation (32, 29). The 
same mutation has been observed in Dutch, Flemish, German, and French patients, but it seems 
that the incidence of this mutation decreases from north to south.   
P113L has a frequency of 8% in our series. The D188G mutation seems to be restricted to 
Belgian (Flemish) and Dutch patients. The V44A mutation is probably of Spanish origin, while 
the D65Y mutation, homozygous in a Portuguese patient, is also found in a French patient (with 
Portuguese ancestors). The V129M mutation might well be of Italian origin. In Japanese 
patients, a few, specific mutations have been found (27, 28).   
It seems that some mutations are old mutations that have been present in the different 
populations for centuries. Thus, the common R141H mutation may be a very old mutation, like 
the frequent ∆F508 in cystic fibrosis (33). This hypothesis is supported by the following 
observation at the molecular level. The R141H mutation is caused by a CGC to CAC transition 
in the CpG dinucleotide in codon 141. However, the equally likely CGC to TGC transition, 
 53  
resulting from deamination of methylcytosine in the CpG dinucleotide on the other strand 
(predicting R141C at the protein level), was observed in the processed pseudogene (Figure 2), 
but has not yet been observed in patients. The hypothesis was recently confirmed by haplotype 
analysis of patients heterozygous for R141H in different populations: 52 of 56 patients carry the 
same ancestral haplotype for marker D16S3020 (31). On the other hand, some mutations must 
have occurred independently in the different populations. For instance, the R123Q mutation 
shared by Spanish and Dutch patients (which is not in contradiction with the political history of 
The Netherlands) is syntenic with a polymorphism at nucleotide 324 in the coding region. The 
same mutation was also identified in a Japanese patient, but without the polymorphism (27).   
The frequency of the disease has been estimated at 1/80,000 in Sweden (35). Available data 
suggest that the disease is a little less frequent in Denmark (1/35,000, M. Schwartz, personal 
communication).   
Gene Structure and Expression Pattern   
The PMM2 gene is a relatively small gene, consisting of eight exons spanning approximately 20 
kb of genomic DNA (9, 24). An analysis of the sequence of the 59 region of the gene suggests 
that PMM2 has a housekeeping promoter: the region upstream of the first ATG is characterized 
by a high GC content and contains several potential binding sites for the transcription factor 
Sp1. This is expected for an enzyme with a very fundamental role in posttranslational 
processing. However, the variable expression (see below) suggests that the basal expression can 
be modulated in a tissue-specific manner. Thus, specific elements must be present in the 
promoter or in enhancers to regulate more precisely the expression in tissues with an important 
production of glycosylated (secreted) proteins and a correspondingly high expression of the 
gene.   
Northern analysis showed the highest expression of the PMM2 gene in pancreas and liver, two 
organs with an important production of secreted glycoproteins. The gene is also expressed in 
kidney and placenta, to a lesser extent in skeletal muscle and heart, and weakly in brain. On 
Northern blots, no expression is detected in the lung. The expression pattern of PMM1 is 
slightly different from the pattern obtained for PMM2:PMM1 is expressed in brain (9). It is not 
clear at present how these levels of expression of PMM2 would correlate to the clinical picture, 
in which the brain is one of the most severely affected organs. Immunohistological studies are 
ongoing and we are also looking at expression in fetal or infant brain.   
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Diagnosis   
 
The identification of the genetic basis of the disease allows confirmation of the diagnosis at the 
molecular level. However, the diagnostic decision tree should be respected. In the case of 
CDGS, the most efficient screening test identifies the aberrant glycosylation of (serum) proteins 
by means of isoelectric focusing of, for instance, serum transferrin. If the typical type I pattern is 
observed, the enzymatic measurements are necessary to identify the PMM deficient cases. 
Preferably, the enzyme assay should be performed on freshly isolated leukocytes because it was 
observed that the activity found in cultured fibroblasts or in lymphoblasts of patients may 
represent up to 30% of the control value. In the leukocytes, a profound deficiency has always 
been observed. A possible explanation is that the mutant forms of PMM2 become overexpressed 
after several passages in culture. Moreover, we have recently identified three patients with an 
apparently partial deficiency (30–50% activity) and detected mild mutations. Thus, when 
intermediate PMM activities are found, mutation analysis is a requisite. It remains to be 
investigated to what extent a restoration of normal PMM activities and glycosylation patterns 
occurs as a function of age.   
The identification of mutations in the PMM2 gene will definitively confirm the diagnosis of 
CDGS1a. The methods and primers for the mutation analysis of the eight exons of the PMM2 
gene by SSCP analysis have been described (27). Given the frequency of the R141H, F119L, 
and P113L mutations, the obvious approach is to search for these mutations first. The PMM 
measurements are also useful for the identification of carriers. If cells from an affected child are 
not available, indirect evidence can be obtained from the PMM activities in leukocytes from the 
parents. This has proven worthwhile in two cases with an urgent request for prenatal diagnosis, 
in which we derived information on the PMM defi- ciency from the parents before initiating 
molecular analysis. In view of genetic heterogeneity, prenatal testing should only be offered in 
families with a documented PMM deficiency and mutations in PMM2 (36, 37). Mutation 
analysis is the most dependable method for prenatal testing.   
 
Conclusion   
 
The search for the basis of CDGS1a has pinpointed the defect to the reduced production of 
mannose 1-phosphate in a pre-endoplasmic reticulum compartment. The disease is caused by a 
deficiency of PMM2 and leads to an underglycosylation of glycoproteins. The fact that mainly 
missense mutations are observed suggests that a residual activity of the enzyme is required to 
support life. The unraveling of the pathogenesis of CDGS1 and related syndromes will greatly 
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benefit from the availability of an animal model, which can now be established because the gene 
defect is known. The simple cloning strategy, which has taken advantage of the knowledge on 
mutants in yeast and the availability of human EST sequences in the public database, has been 
used again in the cloning of the gene for CDGS1c (38). The systematic approach warrants the 
swift identification and isolation of most other genes with a role in the synthesis and tailoring of 
N-glycans.   
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Abstract 
Congenital disorders of glycosylation (CDGs) are a rapidly enlarging group of inherited 
diseases with abnormal N-glycosylation of glycoconjugates. Most patients have CDG-Ia, which 
is due to a phosphomannomutase (PMM) deficiency.  
In this article, we report that a significant portion (9 of 54) of patients with CDG-Ia had a rather 
high residual PMM activity in fibroblasts included in the normal range (means of the controls ± 
2 SD) and amounting to 35%-70% of the mean control value. The clinical diagnosis of CDG-Ia 
was made difficult by the fact that most (6 of 9) of these patients belong to a subgroup 
characterized by a phenotype that is milder than classical CDG-Ia. These patients lack some of 
the symptoms that are suggestive for the diagnosis, such as inverted nipples and abnormal fat 
deposition, and, as a mean, had higher residual PMM activities in fibroblasts (2.05 ±0.61 
mU/mg protein, n = 9; vs. controls  5.34 ± 1.74 mU/mg protein, n = 22), compared with patients 
with moderate (1.32 ± 0.86 mU/mg protein, n = 18) or severe (0.63 ±0.56 mU/mg protein, n = 
27, P < .001) cases. Yet they all showed mild mental retardation, hypotonia, cerebellar 
hypoplasia, and strabismus. All of them had an abnormal serum transferrin pattern and a 
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significantly reduced PMM activity in leukocytes. Six of the nine patients with mild 
presentations were compound heterozygotes for the C241S mutation, which is known to reduce 
PMM activity by only ~2-fold. Our results indicate that intermediate PMM values in fibroblasts 
may mask the diagnosis of CDG-Ia, which is better accomplished by measurement of PMM 
activity in leukocytes and mutation search in the PMM2 gene. They also indicate that there is 
some degree of correlation between the residual activity in fibroblasts and the clinical 
phenotype.  
Introduction 
An estimated 300 patients worldwide are known to have congenital disorders of glycosylation 
type Ia (CDG-Ia [PMM deficiency, MIM 601785]), the most frequent type among the CDGs 
(Van Schaftingen and Jaeken 1995; Jaeken et al. 1997a; Matthijs et al. 1997, 1999, 2000). Often 
patients can be diagnosed in the neonatal or early infantile period on the basis of a typical 
morphology (inverted nipples and fat pads), strabismus, axial hypotonia, and hyporeflexia. 
Recurrent elevated transaminases and failure to thrive often complicate the clinical course 
(Hagberg et al. 1993; Petersen et al. 1993; Jaeken et al. 1997b). A very common feature is 
cerebellar hypoplasia, which can be documented at or shortly after birth (Jaeken and Carchon 
1993; Akaboshi et al. 1995; Jensen et al. 1995). There is a substantial childhood mortality of 
~20%, due to severe infections or organ failure (Hagberg et al. 1993; Petersen et al. 1993; 
Hutchesson et al. 1995; Garcia Silva et al. 1996; van der Knaap et al. 1996; Kristiansson et al. 
1998; Matthijs et al. 2000). At a later age, the impairment of the neurological system becomes 
more evident, with a variable degree of mental retardation, cerebellar dysfunction, and retinitis 
pigmentosa (Andreasson et al. 1991; Fiumara et al. 1994; Di Rocco et al. 2000). Some children 
develop seizures and/or strokelike episodes, probably because of the particular coagulopathy 
with marked decrease of factor XI, antithrombin, and proteins C and S (Okamoto et al. 1993; 
Van Geet and Jaeken 1993; Stibler et al. 1996). In adulthood, nonprogressive ataxia, stable 
mental retardation, and peripheral neuropathy are the main characteristics of the disease (Stibler 
et al. 1994; Barone et al. 1999). Most patients are wheelchair bound (Stibler et al. 1994). 
Electrophysiological investigations document decreased sensory and motor nerve–conduction 
velocities and abnormal somatosensory, auditory, and visual evoked potentials (Itoh et al. 1993; 
Barone et al. 1999). Adult female patients typically present with hypergonadotropic 
hypogonadism (Ohzeki et al. 1993; de Zegher and Jaeken 1995; Kristiansson et al. 1995). The 
clinical suspicion of CDG can be substantiated by isoelectric focusing (IEF) of serum transferrin 
(Jaeken et al. 1984; Stibler and Jaeken 1990). Initially, IEF of serum transferrin and PMM 
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measurements in fibroblasts were performed mainly in patients presenting with a “classical” and 
typically severe clinical picture of CDG-Ia (Van Schaftingen and Jaeken 1995), and often a 
profound PMM deficiency was documented (Kjaergaard et al. 1998; Imtiaz et al. 2000). Thanks 
to increasing awareness of CDGs and broader screening for N-glycosylation defects, the number 
of patients with a less typical presentation is growing, including children with a much milder 
clinical presentation and nearly normal psychomotor development (Di Rocco et al. 2000; van 
Ommen et al. 2000). Because we identified among these cases patients with high residual PMM 
activity, we decided to look for mutations in the PMM2 gene in all patients who had a type 1 
pattern in IEF and clinical symptoms suggestive of CDG-Ia. The aims of the study were to 
determine the percentage of patients with high to normal residual PMM2 activity in fibroblasts 
and to determine whether some cases could not be better diagnosed by PMM assays in 
leukocytes rather than in fibroblasts. After careful analysis of the clinical data, a correlation 
between the severity of clinical expression and residual PMM activity became apparent, to the 
extent that we have been able to identify the key symptoms that best allow the identification of 
CDG-Ia (very mild to severe cases) in patients. A comparison of the genotype was made, to find 
out whether the high PMM residual activities are typically associated with particular mutations. 
Subjects and Methods 
Subjects 
Among 150 patients with a clinically suspected CDG and a CDG type 1 pattern in serum 
transferrin IEF, the diagnosis of CDG-Ia was confirmed in 50 patients by identification of PMM 
deficiency in fibroblasts and by mutation analysis. In the remaining patients, the clinical data 
were reviewed and 14 patients with a clinical picture compatible with CDG-Ia were identified. 
In spite of PMM activities in fibroblasts within the normal range in four of these patients, the 
diagnosis was confirmed by the identification of PMM2 mutations. Thus, a total of 54 patients 
were included in this study. Clinical data were collected via a questionnaire (including family 
and patient history, biochemical data, and clinical symptoms), literature review, and through 
personal communication. In addition, PMM values were measured in patients’ and parents’ 
leukocytes, if available. 
 
Isoelectrofocusing of Serum Transferrin 
Analysis of transferrin isoforms was performed in serum and dried blood spots by IEF as 
described elsewhere (Stibler and Cederberg 1993; de Jong et al. 1994). 
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PMM Measurement in Fibroblasts and Leukocytes 
PMM was measured in fibroblasts and leukocytes as described elsewhere (Jaeken et al. 1997a). 
The means of the three groups were compared by ANOVA analysis, followed by a post hoc test 
for pair wise comparison, using the Bonferroni correction for multiple testing. 
 
Mutation Studies 
Genomic DNA was isolated from fibroblasts or white blood cells by means of standard 
laboratory procedures. Mutations were identified by a combination of SSCP analysis and direct 
sequencing, as described elsewhere (Matthijs et al. 1998b). 
Results 
Figure 1 shows the PMM values in fibroblasts from 54 patients with CDG-Ia and from 22 
control subjects. There is obviously a wide scatter of values in both groups, with overlap. If the 
mean control value (5.34 mU/mg protein) ± 2 SD (2 x 1.74 mU/mg protein) is taken to define 
the normal range, CDG-Ia would not have been diagnosed in as many as 9 of 54 patients. In four 
cases the PMM values were 35%, 41%, 62%, and 70% of the mean control value, clearly within 
the normal range. These patients received diagnoses only when we decided to search for 
mutations in patients with high PMM values. 
Figure 2 shows the values of the PMM activities in leukocytes. There is no overlap between the 
values for the control subjects and for patients with CDG-Ia. In particular, the patients with high 
residual activities in fibroblasts displayed activities in leukocytes that were in the range of 0.01–
0.32 mU/mg protein (13 SD below the mean control value) (see table 1). Figure 2 also shows 
the distribution of the values of the obligate heterozygotes (parents of CDG-Ia patients). 
Although there is an overlap with the controls, 72% of the values are 12 SD below the mean 
control value. 
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Figure1: Phosphomannomutase values measured in fibroblasts of CDG-Ia patients (n = 54 ) and control subjects (n = 22). 
The mean  value and SD (5.34 ± 1.74 mU/mg protein) in the control group is indicated. The scattered line gives 
the mean -2 SD (1.86 mU/mg protein).                                                                                                                                                                                               
 
  
Figure 2: Phosphomannomutase values measured in leukocytes of patients with CDG-Ia (n = 37), heterozygotes (n = 38), 
and control subjects (n = 19). The mean value and standard deviation (SD) (2.19 ± 0.57 mU/mg protein) in the 
control group is indicated. The scattered line reflects the mean -2 SD (1.05 mU/mg protein). 
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Table 1 lists the residual PMM activities in fibroblasts from the CDG-Ia patients included in this 
study (in mU/mg protein; the corresponding leukocyte values are given when available). In an 
attempt to characterize the variable phenotype of the CDG-Ia patients, the clinical outcome was 
graded as mild, moderate, or severe on the basis of the predominant clinical symptoms. Patients 
with the classical CDG-Ia phenotype, including failure to thrive, recurrent infections, 
multiorgan involvement, convulsions, retinitis pigmentosa, severe developmental delay and 
inability to walk, peripheral neuropathy, or scoliosis were classified as having “severe” clinical 
expression. This group includes the patients who died early in childhood. Patients with mild 
developmental delay but who learned to sit and walk and had no failure to thrive, no feeding 
difficulties, no visceral organ problems, or no disturbance of clotting factors and transaminases 
were classified as having “mild” clinical expression. Between these extremes were the patients 
with “moderate” clinical expression. In all patients, psychomotor retardation (to a very variable 
degree), strabismus, hypotonia, and cerebellar hypoplasia were documented. There is a clear 
overrepresentation of (very) mild cases in the group with residual PMM activities >25% of 
normal, measured in fibroblasts. Overall, there is a correlation between the severity of clinical 
presentation and the decrease of PMM activity in fibroblasts: in the 9 patients with mild 
expression, 2.05 ± 0.61 mU/mg protein PMM activity was measured; in the 18 patients with 
moderate expression, mU/mg 1.32 ± 0.86 protein; and in the 27 severely affected patients, 0.63 
± 0.56 mU/mg protein (P < .001 for a comparison of the means of the three groups; P values for 
comparisons of mild vs. moderate, moderate vs. severe, and mild vs. severe are .034, .004, and < 
.001, respectively) (control subjects 5.34 ± 1.74 mU/mg protein; n = 22).  
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Table 1: Characteristics of 54 Patients with CDG-Ia 
 
 
 66 
Table 2 summarizes the frequency of typical symptoms in the general CDG-Ia population and 
compares it with the occurrence of these symptoms in the group of patients with mild cases of 
CDG (as available to the authors). Remarkably, inverted nipples, fat pads, failure to thrive, and 
convulsions are absent in the latter group. On the other hand, all patients present with 
strabismus, hypotonia, cerebellar hypoplasia, and mental retardation, although to a very variable 
degree. 
 
Table 2: Frequency of reported clinical symptoms in all CDG-Ia cases in this series and in  
the cases considered “Mild”. 
 
Clinical and biochemical features All CDG-Ia patients (%) Mild cases (%) 
Inverted nipples 10/26 38% 0/9 0% 
Fat pads 10/26 38% 0/9 0% 
Failure to thrive 13/30 43% 0/9 0% 
Elevated transaminases 13/25 52% 0/9 0% 
Clotting factor deficiency 17/23 75% 2/9 22% 
Convulsions or strokes 10/27 37% 0/9 0% 
Strabism 33/33 100% 9/9 100% 
Hypotonia 33/33 100% 9/9 100% 
Cerebellar hypoplasia 33/33 100% 9/9 100% 
Mental retardation 33/33 100% 9/9 100% 
 
Note. – Data are no. of cases with characteristic: TOTAL no. of cases for which data are available. 
 
Table 1 also lists the mutation data for the CDG-Ia patients included in this study, which allows 
for a comparison between the phenotype, the PMM activity, and the genotype. Among the 
plethora of missense mutations observed in this group, several mutations are more frequent. 
First, the common R141H mutation is observed in 33 of 54 cases. Second, two mutations are 
frequently associated with the milder phenotype. Mutation C241S in combination with R141H 
or with F157S was found only in patients with relatively high residual PMM activity and a 
(very) mild clinical picture. Mutation T237M, again in combination with R141H, is also more 
frequently found among the patients with higher residual activity, whereas, in the patients with 
low residual activity, it is found in combination with P113L and T237R. On the other hand, the 
phenotype in six of seven patients who are compound heterozygous for V231M and R141H was 
severe. One child died in early childhood because of liver failure. Finally, patients who are 
compound heterozygous for F119L and R141H are found only in the CDG-Ia patient group with 
a low residual activity of PMM in fibroblasts, and all patients were severely affected. One 
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patient homozygous for F119L had a more favorable clinical outcome. The clinical presentation 
in five pairs of siblings was only slightly different. The PMM activities were in the same range 
but not necessarily in direct relation to the severity of the disease (e.g. in patients 18 and 7). 
 
Discussion 
 
CDG-Ia occurs worldwide, and patients can present with a wide range of symptoms. By using 
IEF of serum transferrin as a screening test for N-glycosylation defects, we have found several 
patients with an abnormal pattern that did not present the full diagnostic criteria for CDG-Ia. 
Enzyme analysis showed, in many of these patients, a PMM deficiency, establishing the 
diagnosis of CDG-Ia. Since high PMM activities (up to 25% of the normal activity) had been 
reported in fibroblasts or lymphoblasts from some patients (Matthijs et al. 1998b), mutation 
search in the PMM2 gene was also performed in patients with fibroblast PMM values in the 
normal range, leading to the diagnosis of additional CDG-Ia cases. Thus, the data presented in 
this study show that the residual PMM activities in fibroblasts from patients with two allelic 
mutations in the PMM2 gene could be quite high, reaching 70% of the normal value in one 
patient. The problem with partial deficiencies has not been encountered in assays performed in 
leukocytes. Thus, in patients with high residual PMM activity in fibroblasts, analysis of PMM 
activity in leukocytes can substantiate the diagnosis of CDG-Ia. 
The difference between the residual activity in fibroblasts and in leukocytes points to a cell-
specific effect. Analysis of the mutant proteins in vitro has shown that they have altered kinetic 
properties, with Vmax values ranging from 0.4% to ~50% of the wild-type enzyme, and that they 
are less stable than the latter (Kjaergaard et al. 1999; Pirard et al. 1999; Vuillaumier-Barrot et al. 
2000). This difference in stability is most likely responsible for the fact that the residual 
activities are, as a rule, higher in fibroblasts, which are rapidly dividing cells with active protein 
synthesis, than in leukocytes, most of which are terminally differentiated cells with little or no 
protein synthesis. This problem may be compounded by the fact that a higher PMM2 residual 
activity may lead to a selective advantage in culture condition and to overgrowth. In this way, 
the passage number of the cells may affect the PMM values. However, there is no apparent 
influence of passage number on the PMM values (see Table 1), although it was not possible to 
retrieve the passage number for all fibroblast cultures. Alternatively, the growth phase of the 
cells might affect the measurement, although this is unlikely for the fibroblasts, because they 
were all grown to confluency. 
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Measurement of PMM activity in leukocytes of obligate carriers showed that this enzyme 
activity was below the mean value -2 SD in 70% of the cases. Thus, PMM assays in leukocytes 
were also useful for the identification of carriers. In practice, when no material is left from the 
proband, indirect evidence can be obtained from the PMM activities in leukocytes of the parents 
(Matthijs et al. 1998a). 
It is obvious that hypotonia, strabismus, cerebellar hypoplasia, and mental retardation are 
consistent features in CDG-Ia and are therefore reliable diagnostic criteria, whereas convulsions 
and/or stroke-like events and visceral complications are less common in the milder cases. 
Importantly, typical symptoms such as inverted nipples, abnormal fat pad distribution, and 
failure to thrive are missing in these patients. 
The PMM2 protein is encoded by the PMM2 gene, located on chromosome 16p13 (Matthijs et 
al. 1997). The open reading frame of 738 nucleotides predicts a protein of 246 amino acids, 
whose three-dimensional structure is not yet known. PMM2 belongs to the haloacid 
dehalogenase superfamily of proteins, which are characterized by the conservation of three 
different motifs that are most likely involved in the catalytic activity (figure 3) (Aravind et al. 
1998). The reaction mechanism of the enzyme involves the phosphorylation of the first aspartate 
in an extremely conserved DXDXT/V sequence that is close to the amino-terminus of the 
enzyme (Asp-12; see Figure 3) and is also found in a series of other phosphatases and 
phosphomutases (Collet et al. 1998). 
Mutation analysis in CDG-Ia patients reveals a plethora of mutations, mainly missense (Matthijs 
et al. 1997, 1998b, 2000; Kjaergaard et al. 1998; Bjursell et al. 2000; Imtiaz et al. 2000; de 
Lonlay et al. 2001). R141H, the most frequent mutation among whites, is present in 33 of 54 
cases in this series, and this frequency does not differ from the overall frequency of this 
mutation among patients described elsewhere (Congenital Disorders of Glycosylation Web site). 
However, R141H is a severe mutation with virtually no residual activity, as shown by 
overexpression of the mutant protein (Kjaergaard et al. 1999; Pirard et al. 1999), which might 
explain why homozygosity for this mutation has not been observed (Kjaergaard et al. 1998; 
Matthijs et al. 1998b; Schollen et al. 2000). Thus, whenever the R141H mutation is found in 
patients, differences in the clinical presentation and in the residual activity in fibroblasts are 
likely to correlate with the mutations in the second allele. 
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Figure 3:  Nucleotide and amino acid sequence of PMM2. Amino acid residues that are phylogenetically strictly conserved 
are indicated in boldface type. The mutations that are discussed in the context of this study are indicated. Amino 
acid 241 is not conserved at all, whereas amino acid 237 is conserved between human and yeast but not between 
human/yeast and Babesia bovis (see also Matthijs et al. 2000). On the basis of structural data obtained with P-type 
ATPases, Aravind et al. (1998) have delineated three motifs, in the phosphomannomutases, that may be directly 
involved in the catalytic activity. They are underlined. 
 
In this series, one mutation—C241S—is particularly frequent in the milder phenotypes (see 
table 1). The C241S mutation is in the C-terminal part of the protein, in a nonconserved region, 
and seems to impair the protein activity to a minor extent, since it decreases the activity by only 
50% (Vuillaumier-Barrot et al. 2000). The combination of R141H/T237M is also observed 
more frequently in the patients with higher residual activity in fibroblasts, but the phenotype 
ranges from mild to severe. T237M affects a conserved amino acid of the protein, and one can 
assume that the mutated protein has only limited residual activity. When T237M is combined 
with either P113L, T237R or F157S, the clinical outcome is severe. Because the enzyme acts as 
a (homo)dimer, the differences between the effects of these combinations of mutations might be 
due to molecular “interactions” between the mutated proteins.  
V231M is also frequent in the group of patients described here. The V231M mutation has a 
residual activity of 38.5%, but the mutated protein is extremely unstable (Pirard et al. 1999), 
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which might explain why the compound heterozygous patients with R141H/ V231M have, in 
general, a less favorable clinical outcome than patients with the R141H/C241S mutation. F119L 
is the second most common PMM2 mutation in CDG-Ia, because of a founder effect in the 
Scandinavian population (Bjursell et al. 1997; Kjaergaard et al. 1998). Its presence among the 
CDG-Ia patients in this series who are heterozygous for F119L/R141H was limited to severe 
cases. In expression studies of F119L in Escherichia coli, a residual activity of 25% was 
measured and the mutated protein showed a marked decrease of substrate affinity (Kjaergaard et 
al. 1999; Pirard et al. 1999). The other mutations are too rare for conclusions about their 
phenotypic impact to be drawn. 
 
In conclusion, patients with high to normal residual activity of PMM in fibroblasts may harbor 
mutations in PMM2. Most of these patients have mild to moderate clinical expression, 
significantly broadening the spectrum of CDG-Ia. 
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Abstract  
 
We report on a retrospective electron microscopical  study of liver biopsies and fibroblast 
cultures of 19 CDG patients with different subtypes. A constant finding in liver biopsies of all 
CDG-I cases were abnormal lysosomal lamellar inclusions in the hepatocytes which were not 
found in CDG-II. None of the patients showed significant abnormalities in their fibroblasts. 
Introduction 
The congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic 
diseases. N-Glycosylation defects are due to defective assembly (CDG-I) or processing (CDG-
II) of the carbohydrate moieties (glycans) of glycoconjugates (McKusick 212065). 
Isoelectrofocusing (IEF) of serum transferrin (TF) is a powerful screening test for CDG (Keir et 
al 1999).  The latter pattern is also characterized by an increase of trisialotransferrin and/or 
monosialotransferrin. So far, 12 enzyme defects have been identified (Jaeken and Matthijs 2001, 
Hansske et al 2002). In a number of patients classified as CDG-x, the basic defect remains to be 
identified (Aebi et al 1999).  
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Although the clinical presentation of CDG is broad, commonly the central nervous system and 
liver are involved. In 1991 we reported electron microscopic (EM) findings in liver biopsies 
showing abnormal lysosomal inclusions in the hepatocytes in CDG-Ia patients (Conradi et al 
1991). EM of a liver biopsy of a CDG-IIa patient was normal (Jaeken et al 1994). We 
wondered, whether these observations could be extended to CDG subtypes with other enzymatic 
defects either in the glycoprotein assembly or processing pathway and whether these lysosomal 
changes are present in other cell types. Here we report a retrospective EM study of liver tissue 
and/or EM study on fibroblast cultures of 19 CDG patients of different CDG subtypes (CDG -
Ia,-Ib,-Ic,-Ie,-If, CDG IIa and CDG-x).  
Patients and Methods 
Patients 
Liver biopsies and/or fibroblast cultures of 19 paediatric CDG patients taken for diagnostic and 
clinical investigations were examined by electron microscopy (Table 1). All patients except 
those numbered17-19 showed an IEF type 1 pattern of serum transferrin, with a decrease of 
tetrasialotransferrin and an increase of asialo- and disialotransferrin (data not shown). 
Enzymatic and genetic studies confirmed in each of patients 1-14 one of  CDG-Ia, -Ib, -Ic, -Ie or 
-If. Three CDG-x cases were included in the study: patients 15 and 16 had an IEF type 1 pattern, 
whereas patient 17 presented with an increase of asialo-, monosialo-, disialo- and 
trisialotransferrin and a major decrease of tetrasialotransferrin, representing a so-called type 2 
pattern. These CDG-x patients presented with a variable clinical picture (patient 15: moderate 
developmental delay and ataxia; patient 16: severe developmental delay, no visual contact and 
epilepsy; patient 17: dysmorphy, failure to thrive, developmental delay). Patients 18 and 19 
have been diagnosed as CDG-IIa (Jaeken et al 1993).  
 
Methods 
Liver needle biopsies from 13 children with CDG and fibroblasts from skin biopsies of 13 
children with CDG were obtained (Table 1) after the informed consent of their parents. 
Immediately after the liver biopsy sampling, the specimen was divided into several fragments. 
One of these fragments was cut into small blocs and immediately fixed in 2.5% glutaraldehyde 
in 0.1 mol/L phosphate buffer. After postfixation in 1% OsO4, 0.1 mol/L phosphate buffer, the 
specimens were further prepared for routine electron microscopy. Other liver fragments were 
processed for light-microscopic histopathologic examination and for biochemical and molecular 
 78 
investigation. Isolated fibroblasts, obtained from skin biopsies of 13 patients were grown in 
DMEM-F12 medium (Gibco) containing Hepes and supplemented with 10% fetal calf serum. 
Confluent cultures from passages 5 to 7 were fixed in situ with glutaraldehyde 3% in 0.1 mol/L 
sodium cacodylate buffer, pH 7.4 and prepared according to routine procedures for electron 
microscopy.  
Ultrathin sections from liver biopsies and from fibroblast cultures were cut, stained with uranyl 
acetate and lead citrate and examined using a Zeiss EM 10 electron microscope. 
 
Table 1: CDG patients included in the study: listed by their diagnosis, serum TF IEF pattern,     
              material studied (liver and/or fibroblast culture), age at liver biopsy 
 
Patient  Diagnosis TF  IEF pattern Liver Biopsy at Fibroblast Study 
1  CDG-Ia 1 1 y 6 m NA (*) 
2  CDG-Ia 1 2 y 11 m NA 
3  CDG-Ia 1 1 y 1 m NA 
4  CDG-Ia 1 12 y 1 m Yes 
5  CDG-Ia 1 12 y 1 m Yes 
6 CDG-Ia 1 NA Yes 
7  CDG-Ia 1 1 yr NA 
8  CDG-Ia 1 2 y 11 m NA 
9  CDG-Ib 1 NA Yes 
10  CDG-Ic 1 5 m Yes 
11 CDG-Ic 1 NA Yes 
12  CDG-Ic 1 NA Yes 
13  CDG-Ie 1 NA Yes 
14  CDG-If 1 17 y 1 m Yes 
15  CDG-x 1 7 y 11 m NA 
16  CDG-x 1 5 y 1 m Yes 
17  CDG-x 2 2 y 3 m Yes 
18  CDG-IIa 2 4 y Yes 
19  CDG-IIa 2 NA Yes 
 
(*) NA: no material available 
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Results 
 
The hepatocytes of the liver parenchyma presented normal bile canaliculi provided with 
numerous fine regular microvilli. Most hepatocytes had normal sinusoidal poles, other had 
flattened sinusoidal membranes. In the cytoplasm of nearly all hepatocytes in biopsies of CDG-
Ia patients, numerous abnormal lysosomal inclusions of variable size were found. They were 
composed of concentrically arranged lamellar electron-dense membranes alternating with lucent 
content (Figure 1). Liver biopsies of CDG-Ic, and -If patients and those CDG-x patients with a 
IEF TF type 1 pattern, also showed these inclusions but only in a moderate number of 
hepatocytes. No other significant alterations were observed in the cytoplasmic organelles 
including the Golgi apparatus. In the CDG-IIa patient and the CDG-x patient with an IEF 
transferrin type 2 pattern, the hepatocytic lysosomes were normal. Only some mild aspecific 
changes such as small and larger fat droplets and some lipofuscin inclusions were observed.  
In all 13 liver biopsies included in the study, the sinusoidal cells had a generally normal 
appearance. Kupffer cells did not show the abnormal lysosomal inclusions described above. 
Prominent collagen bundles were occasionally seen in the Disse spaces. The ultrastructural 
morphology in fibroblasts of 13 CDG patients did not show lysosomal inclusions or other 
significant abnormalities.  
 
 
Figure 1 : Electron micrograph of part of the cytoplasm of a hepatocyte of the liver of a CDG-Ia patient. Numerous 
lysosomal inclusions of variable size composed of concentrically lamellar membranes (arrow) are evident. 
Magnification: x 14375 
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Discussion 
 
CDGs are caused by enzymatic or transport defects in the assembly (CDG-I) and processing 
(CDG-II) of glycan moieties of glycoproteins in the cytosol, the ER and the Golgi apparatus  
(Patterson 1999). As a result of a defect in the assembly of glycans in CDG-I, whole glycans are 
missing, which explains that the targeting to the secretory pathway and its sorting of 
glycoproteins is disturbed, leading to accumulation and storage of misfolded heterogeneous 
material. Hypoglycosylation e.g. of mainly high-mannose type lysosomal enzymes causes a 
missorting or deficiency of their uptake in the lysosomes (Beccari et al 2000), explaining 
elevated levels of lysosomal enzymes in plasma (Barone et al 1998). Hepatocytic lysosomal 
inclusions with concentric lamellar electron-dense material have been reported in CDG-Ia 
(Conradi et al 1991). In our study we observed these lysosomal changes as well in other CDG-I 
subtypes, although in a lower number. In contrast, these abnormalities are absent in CDG-II. In 
CDG-II, defects are localized in the Golgi compartment, which is not involved in the 
glycosylation of glycoproteins of the high-mannose type.  
Lysosomes containing membranous myelin-like inclusions have been reported  in Niemann Pick 
disease type C. In the liver these storage lysosomes were seen in Kupffer cells as well as in 
hepatocytes (Ishak et al 2002). In our CDG-I patients, however, the Kupffer cells were normal. 
In cholestatic conditions, hepatocytes and Kupffer cells can show membranous lysosomal 
inclusions representing mainly biliary constituents (Phillips et al 1987). In these liver biopsies, 
cholestatic bile canaliculi are always obvious, while in our study bile canaliculi are normal.  
In the present study, we could see abnormal lysosomal storage material only in the hepatocytes 
of the CDG-I patients, whereas the fibroblast culture from different CDG subtypes (Table 1) did 
not show any significant abnormality. This tissue-specific difference might be due to the 
residual activity of the deficient enzymes, which may be just sufficient for cells with a slower 
metabolism, such as fibroblasts. Tissue-specific differences in CDG patients have also been 
shown in other studies: some membrane-bound and secreted N-glycoproteins of extrahepatic 
origin were fully glycosylated in fibroblasts, lymphoblastoid cells, enterocytes, etc., whereas 
glycoproteins of hepatic origin showed hypoglycosylation (Bergmann et al 1998, Dupre et al 
2000, Ichisaka et al 1998).  
An EM study on fibroblasts has been reported in three patients with CDG; in agreement with 
our findings, ultrastructural studies revealed a normal Golgi apparatus (Marquardt et al 1995). 
However, the authors described a dilatation of the rough ER as a constant feature. To exclude 
secondary aging effects, we have investigated the fibroblast cultures in early passages and we 
did not observe significant and constant changes. 
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In conclusion, the present study shows tissue-specific differences in EM lysosomal findings in 
N-glycosylations disorders. On the other hand, the hepatocytic lysosomal abnormalities are only 
present in N-glycan assembly, not in N-glycan processing defects. 
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Abstract  
 
We report on eight patients with a recently described novel subtype of the congenital disorders 
of glycosylation type C (CDG-Ic). Their clinical presentation was mainly neurological with 
developmental retardation, muscular hypotonia and epilepsy. Several symptoms, commonly 
seen in CDG-Ia, such as inverted nipples, abnormal fat distribution and cerebellar hypoplasia, 
are not observed. The clinical course is milder overall with a better neurological outcome, than 
in CDG-Ia. The isoelectric focusing pattern of serum transferrin in CDG-Ia and CDG-Ic is 
indistinguishable.  
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Interestingly, ß-trace protein in cerebrospinal fluid derived from immunoblot analysis of the 
brain showed a less pronounced hypoglycosylation pattern in CDG-Ic than in CDG-Ia patients. 
Analysis of lipid-linked oligosaccharides revealed an accumulation of Man9GlcNAc2 
intermediates due to dolichol pyrophosphate-Man9GlcNAc2 α−1,3 glucosyltransferase 
deficiency.  All patients were homozygous for an A333V mutation.  
Introduction 
In 1980, Jaeken and co-workers (1) described monozygotic twins with developmental 
retardation and several glycoprotein abnormalities. This observation initiated the delineation of 
a rapidly growing group of genetic disorders caused by defects in the synthesis or processing of 
N-glycans (2). These congenital disorders of glycosylation (CDGs), formerly known as 
carbohydrate deficient glycoprotein syndrome, present with variable clinical symptoms. 
Isoelectric focusing (IEF) of serum transferrin is the commonly used diagnostic test. The most 
frequently observed IEF pattern is characterized by an increase in the a- and disialotransferrin 
bands (type I) (3). Most CDG-I cases result from phosphomannomutase (PMM) 2 deficiency 
(CDG-Ia) (4, 5, 6). The common features of CDG-Ia patients are moderate to severe impairment 
of neurological function and variable dysmorphology (7, 8). More recently, patients with a 
mainly hepato-intestinal presentation caused by a deficiency of phosphomannose isomerase 
(PMI) have been described (CDG-Ib) (9, 10-12). To date, 5 cases have been reported with a 
typical CDG-I transferrin IEF pattern due to a deficiency of the endoplasmatic reticulum 
localized α−1,3 glucosyltransferase (Figure 1) (13, 14). The molecular genetic basis of CDG-Ic 
has been described by Imbach et colleagues (15). In this report, we review its clinical and 
biochemical characteristics in 8 children and compare the clinical features with those of CDG-
Ia. 
Patients and Methods 
Clinical evaluation 
Eight children were studied (5 boys and 3 girls), ranging in age from 1.6 to 10.10 years (mean 
5.2 years).  Four Dutch children, a pair of monozygous twins and two other siblings, are from 
related families. All other patients originated from unrelated Dutch and Belgian families. The 
diagnostic evaluation included interictal electroencephalography, visual-evoked and brainstem 
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auditory-evoked responses, motor and sensory conduction velocities and funduscopic 
examination. Computed tomography of the brain was available in two children. Magnetic 
resonance imaging was performed in 6 patients. Body fluid samples and skin fibroblasts were 
obtained after obtaining parental informed consent. 
 
Biochemical data 
Isoelectric focusing of serum transferrin was performed as described by van Eijk and van Noort 
(16). Separation of thyroxin-binding globulin (TBG) in serum was performed on a Phast-System 
(Pharmacia Biotch, Uppsala, Sweden) and after immunodetection by a rabbit-anti-human TBG 
antibody (DAKO, Glostrup, Denmark) visualized by silver staining. PMM and PMI activities 
were measured in leukocytes or fibroblasts as described (17). The ß-trace protein (ßTP) 
isoforms in cerebrospinal fluid (CSF) were analyzed by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) as described (18).  
 
 
Figure 1: N-glycosylation pathway in mammals, indicating deficiencies of phospho-mannomutase (PMM; CDG-Ia), 
phosphomannose isomerase and α-1,3 glucosyltransferase (CDG-Ic). PMI= phosphormannose isomerase; GDP = 
guanosine diphosphate. 
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Results 
 
Clinical study 
All children had been referred for neurological examination in the first 2 years of life because of 
developmental delay and/or epilepsy. The diagnosis of CDG was established between the age of 
4 months and 8 years by serum transferrin IEF.  
All children were born after an uneventful pregnancy, with only slight facial dysmorphic 
features (e.g., broad nasal bridge, prominent forehead, large ears). In early childhood, internal 
strabismus, floppiness and feeding problems were reported in all patients. Four children 
required nasogastric feeding. Tendon reflexes were normal. Pronounced axial hypotonia and 
retarded motor development were documented in all patients. All children could sit without 
support in the second or third year of life. Five children started to walk independently at the age 
of 3 to 4 years. Speech development was delayed. The older patients were attending special 
education classes. A striking feature was their extrovert and friendly character. 
Motor and sensory nerve conduction velocities and visual-evoked and brainstem auditory-
evoked potentials were normal. All children had recurrent seizures, ranging from febrile 
convulsions to a frank epilepsy (febrile convulsions in 3, atonic seizures in 2, myoclonic 
seizures in 2, generalized tonic seizures in 1). Interictal and long-term EEG monitoring in 6 
children was normal.  Brain imaging ruled out cerebellar hypoplasia (Figure 2). In 5 patients, 
slight cortical atrophy was detected. 
 
        
 
Figure 2: T1-weighted brain MRIs of midline structures form a patient with congential disorder of glycosylation (CDG) type 
Ia (cerebellar atrophy ; A) and a patient with CDG-Ic (normal; B) included in this study. 
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Biochemical investigations 
Laboratory parameters In 3 children, serum transaminases were episodically increased (eg, 
during infections; aspartate aminotransferase levels up to 2000 U/l and alanine aminotransferase 
levels up to 500 U/L). Serum glycoprotein levels such as alpha1-antitrypsin, haptoglobin, and 
thyroxin-binding globulin were reduced in 4 patients. Hypoalbuminaemia was not detected. In 
all cases, coagulation factor XI, antithrombin III and protein C, and protein S levels were 
markedly decreased (Table 1). In 5 of 8 children tested, extremely low to low normal low-
density lipoprotein-cholesterol values were detected (range, 0.1-0.8mmol/L, reference, >1.55 
mmol/l) and in 3 patients low apolipoprotein B levels were detected (range, 0.35-0.6g/L; 
reference range 0.8-1.3 g/L). 
 
Table 1: Biochemical Observations in 8 Glycosylation Type Ic Cases 
Patient 1 2 3 4 5 6 7 8 
Sex:  F= female; M=male F F F M M M M M 
Age at clinical evaluation (year/months) 5/5 5/5 10/10 8/4 4/2 1/9 3/7 1/6 
Factor XI (70-130%) 6.5 4.5 5.5 3.0 8.0 4.0 12.0 3.3 
Antithrombin III (70-130%) 39 32 37 33 15 26 25 13 
Protein C (70-130%) 39 32 28 23 16 28 30 17 
Protein S total (70-130%) 38 36 85 45 46 23 23 39 
 
Serum glycoproteins and enzyme activity: 
 Isoelectric focusing of serum transferrin showed the typical type I pattern, characterized by 
markedly reduced amounts of tetrasialotransferrin and an increase in di- and asialotransferrin 
(Figure 3A). Densitometric analysis showed that the range was comparable to CDG-Ia cases 
(Table 2). Isoelectric focusing of serum TBG also showed a cathodal shift, documenting the 
generalized abnormalities of glycoproteins in these patients (data not shown). In all patients, 
PMM and PMI activity was normal in leukocytes and/or fibroblasts. 
 
CSF ßTP: 
On SDS-PAGE, ßTP of CSF samples from control subjects migrated as a single 27 kd band 
corresponding to the diglycosylated isoform. In all CDG-Ic patients, another additional 24kd 
band of the monoglycosylated isoform constituted 15 to 30% of ßTP. In CSF of 4 CDG-Ia 
patients, an additional band was obtained with a molecular mass of 21kd, representing the 
aglycosylated ßTP-isoform. The relative distribution ranged from 60:30:10 to 60:35:5 (Figure 
3B). 
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Figure 3:  A. Isoelectric focusing of serum transferring. Isoelectric focusing of serum transferrin from CDG patients and a 
healthy subject.  Lane 1: control, lane 2 CDG-Ic patient, lane 3 CDG-Ia patient. The numbers given at the left 
indicate the number of sialic acid residues present on each sialotransferrin fraction.  
 B. Western blot analysis of ß-trace protein (ßTP) in cerebrospinal fluid (CSF) after separation on a sodium 
dodecyl sulfate polyacrylamide gel electrophoresis system: purified ß-trace protein (lane 1), CSF from a CDG-Ic 
(lane 2), CSF from a CDG Ia patient (lane 3) and CSF from a healthy subject (lane 4).  
   Standard molecular mass marker proteins indicated at the right in kilodaltons. 
 
 
 
Table 2: Percentage of Serum Sialotransferrin Fractions from CDG-Ia and -Ic Patients and Controls 
Determined by Isoelectric Focusing 
 
Sialotransferrin 
Fraction 
Controls 
(n=30) 
CDG-Ia Patients 
(n=12) 
CDG-Ic Patients 
(n=7) 
0 0.0 – 2.6 5.4 – 29.5 4.4 – 16.8 
1 0.0 – 2.6 0.1 – 7.1 1.1 – 3.3 
2 1.6 – 6.1 17.0 – 37.7 28.5 – 42.7 
3 2.5 – 15.6 5.0 – 12.5 6.1 – 9.8 
4 51.2 – 72.2 20.6 – 49.5 22.5 – 41.5 
5 12.1 – 30.8 3.9 – 19.3 6.7 – 16.4 
6 0.0 – 9.0 0.0 – 5.9 0.0 – 2.0 
 
CDG-Ia = congenital disorder of glycosylation type Ia, CDG-Ic = congenital disorder of glycosylation type Ic 
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Discussion 
 
So far, three defects in the early steps of the N-glycosylation pathway characterized by a CDG-I 
transferrin IEF pattern have been elucidated. The two defects in the synthesis of guanosine 
diphosphate (GDP)-mannose (CDG-Ia, PMM deficiency and CDG -Ib, PMI deficiency) are due 
to mutations in the genes encoding these cytosolic enzymes. Recently, the first deficiency of an 
endoplasmic reticulum-localized enzyme of the N-glycan synthesis pathway was discovered, 
namely the α−1,3 glucosyltransferase deficiency (Figure 1). Analysis of lipid-linked 
oligosaccharides in patients’ fibroblasts showed an accumulation of dolichyl pyrophosphate-
Man9GlcNAc2 (13). A homozygous A333V mutation in the human homologue of the yeast alg6 
gene has recently been identified (15).  
This is the first report summarizing the clinical symptomatology of a series of CDG-Ic patients. 
Apart from the 8 cases presented, Körner et co-workers (14) described an additional patient with 
a similar clinical picture. Clinically CDG-Ic resembles the “neuro(visceral)” phenotype of CDG-
Ia, but differs from the “hepatointestinal” presentation of CDG-Ib (Table 3). 
 
Table 3: Clinical features in CDG Type Ia, Ib, and Ic patients 
 CDG-Ia CDG-Ib CDG-Ic 
Enzyme defect PMM PMI 1,3 glucosyltransferase 
Failure to thrive +++ +++ ++ 
Strabismus +++ - ++ 
Axial hypotonia +++ - +++ 
Psychomotor retardation +++ +/- +/++ 
Seizures +++ - +++ 
Cerebellar hypoplasia +++ - - 
Retinitis pigmentosa ++ - - 
Abnormal fat distribution +++ - - 
Inverted nipples +++ - - 
Hepatomegaly ++ ++ - 
Hypoalbuminaemia +++ +++ - 
Hypoglycaemia +/- +++ - 
Coagulopathy ++/+++ + +++ 
Transaminaemia +++ +/++ + 
Liver fibrosis + +++ - 
Tubular proteinuria +++ - - 
Protein-losing enteropathy +/- +++ - 
PMM = phosphomannomutase; PMI = phosphomannose isomerase. 
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CDG-Ia patients usually have characteristic dysmorphic features, including inverted nipples, 
thoracic deformities, abnormal fat distribution and joint restrictions. The CDG-Ic patients did 
not show any of these physical signs. Feeding problems and internal strabismus were present in 
both groups. During the first years of life, CDG-Ia children often suffer from life-threatening 
episodes such as severe infections, hepatic failure, or cardiac effusions with tamponad, with a 
high mortality. (15-20%) (7,19,20). Stroke-like episodes due to partial cerebrovascular 
thrombosis occur in half of the CDG-Ia patients after the age of 4 to 5 years.  None of these life-
threatening acute episodes were observed in the CDG-Ic patients, although the pronounced 
disturbance of the coagulation factors could trigger hemorrhagic or thrombotic complications. 
One CDG-Ic child suffered meningococcal sepsis at the age of 4 years, without major 
complications. Hepatomegaly and hepatic fibrosis, enlarged kidneys and proteinuria, common in 
CDG-Ia, were not observed. 
In general, the neurological outcome in CDG-Ic patients is better than that in CDG-Ia patients. 
CDG-Ia and CDG-Ic patients show developmental delay and pronounced axial hypotonia. CDG-
Ia patients generally have a peripheral neuropathy associated with muscular atrophy and are 
wheel chair dependent.  Retinal degeneration has been described (21-23). Cerebellar ataxia due 
to cerebellar hypoplasia, which is commonly present already at birth (24-26) should initiate the 
search for an N-glycosylation defect (27). In contrast, the peripheral nervous system appears 
unaffected in CDG-Ic, and 5 of the CDG-Ic patients learned to walk, the earliest onset at the age 
of 3 years. Retinal degeneration was not noticed, and cerebellar hypoplasia was not observed 
(Figure 2). Ataxia, however, was present in 2 CDG-Ic patients.  
Hypoglycosylation of brain glycoproteins is probably a contributing factor in the neurological 
involvement in CDG patients. The hypoglycosylation of intrathecally synthesized ßTP is clearly 
less pronounced in CDG-Ic than in CDG-Ia. It remains to be established whether glycosylation 
of other brain proteins in CDG-Ic is also less severely disturbed than in CDG-Ia. This might 
explain the better neurological outcome in CDG-Ic patients. 
Alternatively, the more severe course of CDG-Ia might be due to the fact that impaired 
biosynthesis of GDP-mannose and dolicholphosphate-mannose also affects the availability of 
GDP-fucose and the biosynthesis of the glycosyl phosphatidylinositol anchor (28). These 
pathways are not affected in CDG-Ic. 
Strikingly, all presented cases are homozygous for the A333V mutation in the α−1,3 
glucosyltransferase gene (15). Accordingly, the clinical presentation is rather homogeneous. 
Nevertheless, it is possible that different genotypes might lead to a different clinical 
presentation. In conclusion, patients with CDG-Ic have a significantly milder phenotype than 
the case in classic CDG-Ia.  
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The field of N-glycosylation defects is rapidly developing. Recently, CDG Id (1,3 
mannosyltransferase) and CDG Ie (dolichol phosphate mannose synthase 1 ) have been 
elucidated as further defects in the early steps of N-glycosylation (29). Because the N-
glycosylation pathway involves more than 30 enzymatic steps many more defects may be 
anticipated. Given the already marked variability in the clinical symptomatology of the known 
CDG types, this may encourage clinicians to request IEF of serum transferrin in children with a 
still broader range of clinical presentation. 
In cases where a CDG-I pattern is obtained in the serum transferrin IEF, secondary causes for 
transferrin hypoglycosylation (e.g. galactosaemia, hereditary fructose intolerance, alcohol 
abuse) should be excluded, and PMM and PMI enzyme activity should be measured. If these 
enzymes are normal, but very low factor XI and low-density lipoprotein-cholesterol levels are 
measured, this is suggestive of CDG-Ic. Analysis of lipid-linked oligosaccharides and mutation 
analysis of the dolichol pyrophosphate-Man9GlcNAc2 α-1,3 glucosyltransferase gene should 
then be performed. 
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Abstract  
 
Congenital disorders of glycosylation (CDG), formerly known as carbohydrate-deficient 
glycoprotein syndrome represent a family of genetic diseases with variable clinical 
presentations. Common to all types of CDG characterized to date is a defective Asn-linked 
glycosylation caused by enzymatic defects of N-glycan synthesis. Previously, we have identified 
a mutation in the ALG6 α1,3 glucosyltransferase gene as the cause of CDG-Ic in 4 related 
patients. Here, we present the identification of 7 additional cases of CDG-Ic among a group of 
35 untyped CDG patients. Analysis of lipid-linked oligosaccharides in fibroblasts confirmed the 
accumulation of dolichyl pyrophosphate-Man9GlcNAc2 in the CDG-Ic patients. The genomic 
organization of the human ALG6 gene was determined, revealing 14 exons spread over 55 kbp. 
By PCR amplification and sequencing of ALG6 exons, three additional mutations besides the 
previously described A333V substitution were detected in CDG-Ic patients. The detrimental 
effect of these mutations onto ALG6 activity was confirmed by complementation of alg6 yeast 
mutants. Haplotype analysis of CDG-Ic patients revealed a founder effect for the ALG6 allele 
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bearing the A333V mutation. Although more than 80% of CDG are type Ia, CDG-Ic may be the 
second most common form of the disease. 
 
Introduction  
 
Congenital disorders of glycosylation (CDG), previously known as carbohydrate-deficient 
glycoprotein syndrome are a family of genetic diseases related to defective Asn-linked 
glycosylation (Jaeken et al., 1993; Krasnewich and Gahl, 1997). To date, six defects causing 
CDG have been identified at the molecular level. Mutations in the cytosolic enzymes 
phosphomannomutase-2 (PMM2, CDG-Ia; Matthijs et al., 1997) and phosphomannose 
isomerase (PMI, CDG-Ib; Jaeken et al., 1998; Niehues et al., 1998) lead to hypoglycosylation 
by lowering the intracellular mannose-1-phosphate pool; this is paralleled by low levels of the 
donor molecules GDP-mannose and dolichyl phosphate-mannose. Deficiency in the 
endoplasmic-reticulum-located α1,3 glucosyltransferase (ALG6, CDG-Ic; Imbach et al., 1999; 
Körner et al., 1998) and α1,3 mannosyltransferase (ALG3, CDG-Id; Körner et al., 1999) impair 
the assembly of the lipid-linked oligosaccharide (LLO) core. Mutations in the dolichyl 
phosphate-mannose synthase-1 gene (DPM1, CDG-Ie; Imbach et al., 2000; Kim et al., 2000) 
lead to a shortage of the donor molecule dolichyl phosphate-mannose, which is required in 
several glycosylation pathways (Doucey et al., 1998; Sugiyama et al., 1991). Whereas the 
disorders affecting the assembly of the N-glycan core are referred to as CDG-I, defects along the 
N-glycan processing pathways are grouped as subtypes of CDG-II. Therefore, the deficiency of 
β1-2 N-acetylglucosaminyltransferase-II, which decreases the structural complexity of N-
glycans by impairing the formation of bi- and multi-antennary chains, represents CDG-IIa (Tan 
et al., 1996). 
Although all of the different types of CDG-I affect the formation of the LLO core, the 
corresponding patients display distinctive symptoms and pathologies. For example, CDG-Ia 
patients show dysmorphic features, psychomotor retardation, and ataxia, in addition to non-
neurological dysfunctions with potential lethal outcome (Jaeken et al., 1993). By contrast, 
CDG-Ib is a hepatic-intestinal disease without or with only minor neurological involvement 
(Jaeken et al., 1998; Niehues et al., 1998). This diversity of clinical features renders the 
diagnosis of CDG difficult, especially in the less severe forms, such as CDG-Ic. Moreover, 
many patients, including the CDG-Ic cases, do not present the cardinal symptoms of CDG-Ia, 
such as inverted nipples, lipodystrophy, and cerebellar hypoplasia. 
CDG-Ic has recently been characterized in four related Dutch patients (Burda et al., 1998; 
Imbach et al., 1999) and one German girl (Körner et al., 1998). CDG-Ic is associated with a 
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mutation in the dolichyl-P-Glc:Man9GlcNAc2-pyrophosphate-dolichyl (PP-Dol) α1-3 
glucosyltransferase gene (ALG6). The resulting enzyme defect leads to accumulation of the non-
glucosylated Man9GlcNAc2-PP-Dol structure in the endoplasmic reticulum. This incomplete 
oligosaccharide is poorly transferred to nascent proteins by the oligosaccharyltransferase 
complex (Figure 1; Burda and Aebi, 1998; Murphy and Spiro, 1981). CDG-Ic patients show a 
mild to moderate neurological involvement with hypotonia and epilepsy (Grünewald et al., 
2000). 
To evaluate the incidence of CDG-Ic, we have screened a pool of 35 untyped CDG patients. 
Among these, we identified 7 additional CDG-Ic cases, featuring novel mutations in the ALG6 
locus. Our data suggest that CDG-Ic may be one of the most frequent types of CDG after CDG-
Ia caused by PMM2 deficiency. 
 
 
 
 
 
 
Figure 1: Oligosaccharide core glucosylation in the endoplasmic reticulum. Mannose (∆) and glucose () are both added to 
GlcNAc2 ()-PP-Dol () to form the nascent oligosaccharide core. The terminal glucose residues are required 
for optimal recognition by the oligosaccharyltransferase (OTase) complex, which catalyzes the transfer of the 
oligosaccharide core to N-glycosylation sites of glycoproteins 
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Material and Methods 
 
Cell culture 
Primary fibroblasts obtained from upper-arm punch biopsies were cultured in DMEM/F12 high 
glucose medium supplemented with 10% fetal calf serum (FCS; Life Technologies). 
 
LLO analysis 
Culture plates (530 cm2) of 90% subconfluent fibroblasts were rinsed once with phosphate 
buffered saline (PBS) and incubated at 37° C for 90 min in 80 ml minimal Eagle medium (Life 
Technologies) supplemented with 5 % dialysed FCS for 1 h. Cells were labeled by the addition 
of 175 µCi [3H]-mannose (Amersham Pharmacia Biotech) at 37 °C for 1 h. After labeling, cells 
were washed twice with ice-cold PBS, and scraped off in 10 ml methanol, 0.1 mM TRIS, pH 7.4 
(8:3, vol/vol) and transferred into 50 ml conical tubes. Chloroform (10.9 ml) was added, the 
cells were vortexed and centrifuged at 5300 g for 5 min. The upper and lower phases were 
removed, and the LLO were extracted as described previously (Burda et al., 1998) and analyzed 
by high pressure liquid chromatography (HPLC; Zufferey et al., 1995). 
 
Complementation of yeast mutant strains 
Saccharomyces cerevisiae strains YG592 (Matα, ade2-101, his3∆200, ura3-52, lys2-801, 
∆alg6::HIS3) and YG36 (Matα, ade2-101, his3∆200, ura3-52, lys2-801, alg6, wbp1-2) were 
used. Standard yeast media and genetic techniques were applied (Berlin et al., 1991). Human 
ALG6 cDNA from healthy individuals and from CDG-Ic patients were subcloned into the 
YEp352 plasmid (Hill et al., 1986) including the GAL1-10 promoter (Fagan and Scott, 1985). 
Yeast strains transformed with either plasmids were grown to mid logarithmic phase in 5 ml 
yeast minimal medium supplemented with appropriate amino acids. Series of 1:10 dilutions 
starting with 5 x 107 cells were prepared in yeast minimal medium and 5 µl of each dilution 
were spotted on YP-galactose plates to induce the GAL1-10 promoter. Plates were incubated at 
27.5 ºC. Western blot analysis was performed as described previously (Imbach et al., 1999). 
 
Haplotype analysis 
Seven microsatellite markers, spaced around marker D1S203 were analyzed by polymerase 
chain reaction (PCR), utilizing the corresponding primers listed in the Genethon human linkage 
database (Cohen et al., 1993). The position on the map of chromosome 1 is given in 
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centiMorgans (Tables 1 and 2). The alleles were sized on an ALF DNA sequencer (Amersham 
Pharmacia Biotech) using the AlleleLinks program. 
 
Table 1 Genetic haplotype of CDG-Ic patients (ND not done, marker not analyzed) 
 
Haplotype Map 
position 
(cM) 
P1/P2 
A333V/ 
A333V 
P3/P4 
A333V/ 
A333V 
P5  
A333V/ 
A333V 
P6  
A333V/ 
A333V 
P7 
A333V/ 
A333V 
P8 
A333V/  
IVS3+5G→A 
P9  
A333V/ 
A333V 
P10/P11 
F304S/F304S 
S478P/S478P 
D1S2733 73.8 115:109 115:109 121:121 121:115 115:121 115:109 109:115 115:115 
D1S2652 ~83.2 100:98 100:98 100:100 100:94 100:98 100:98 100:98 100:100 
D1S2770 90.3 281:285 281:285 281:281 297:293 283:289 293:279 281:281 295:295 
D1S203 92.5 123:123 123:123 123:123 123:123 123:127 123:123 127:127 127:127 
D1S2788 ~95.9 201:201 201:201 201:201 201:201 201:201 213:191 209:209 215:215 
D1S438 ~99.2 162:162 162:162 162:162 162:162 162:162 162:164 172:172 164:164 
D1S2897 102.0 247:247 247:241 247:247 247:239 247:247 237:243 241:249 ND:ND 
D1S2855 106.7 232:228 252:228 232:232 232:232 232:248 232:232 232:232 246:228 
D1S226 115.4 90:104 90:104 98:98 92:92 98:102 92:102 98:104 102:90 
 
Table 2 Genetic haplotype of the normal parental chromosomes (ND . idem) 
 
Haplotype P1/P2 P3/P4 P5 P6 P7 P8a P9 P10/P11 
D1S2733 107 109 109 109 115 117 115 115 109 109 – 119 113 109 115 
D1S2652 100 94 94 98 98 98 100 100 98 100 – 98 94 98 98 
D1S2770 279 289 289 289 279 289 295 283 293 279 – 293 281 279 277 
D1S203 123 123 123 123 127 123 123 127 123 127 – 123 127 123 123 
D1S2788 215 211 211 211 207 211 209 213 213 209 – 217 215 211 213 
D1S438 170 162 162 170 162 156 164 170 156 166 – 156 169 174 160 
D1S2897 245 241 241 239 249 245 239 245 239 239 – 245 241 ND ND 
D1S2855 252 242 242 230 226 252 228 250 234 246 – 230 230 230 246 
D1S226 104 104 104 106 98 104 104 90 92 90 – 104 102 102 90 
a  DNA from the parents of patient P8 was not available for analysis 
 
Genomic mapping of human ALG6 
A P1 DNA containing the genomic ALG6 sequence was purchased at GenomeSystems Inc (St. 
Louis, Missouri). Randomly selected PCR primer pairs according to the cDNA sequence of 
ALG6 were used to amplify genomic fragments by long-range PCR. PCR was performed by 
using 4 units KlenTaq LA Polymerase Mix (Sigma), 1 pmol primers and 100 ng P1 DNA 
template in a total volume of 50µl. Identical conditions were used for all PCRs carried out: 35 
cycles of denaturation for 45 s at 95°C, annealing for 30 s at 55°C and elongation for 12 min at 
68°C. The PCR fragments obtained were purified by GeneClean (BIO 101) and directly 
sequenced. The genomic sequences were aligned to the cDNA sequence to determine the exon-
intron boundaries. 
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ALG6 genomic PCR 
Genomic DNA from fibroblasts (2×107) was extracted following standard protocols (Sambrook 
et al. 1989). PCR was performed by using 100 ng genomic DNA as template, 2.5 U Taq 
Polymerase (Sigma), 1 pmol primers (Table 3) in a total volume of 50 µl. All PCRs were given 
a “hot” start, and 35 amplification cycles were carried out for 45 s at 95°C, 30 s of annealing at 
specific temperatures (Table 3), and elongation at 72°C for 1 min. The reverse primer for exon 
12 is located on exon 13; consequently, intron 12 and a part of exon 13 were also amplified. 
ALG6 cDNA was prepared from CDG fibroblasts as described previously (Imbach et al. 1999). 
The portion of the cDNA comprising the region encoded by exon 3 was amplified by using 5 µl 
reverse transcription product as a template with the primers 
5’-GAACTATGGAGAAATGGTACTTGATGACAG-3’ and 
5’-TGAGATTTCTTTTAAGCAACAACAGTACAA-3’ binding to regions encoded by exon 1 and exon 
5, respectively. The cycling conditions were 35 cycles at 94°C for 45 s, 58°C for 30 s, and 72°C 
for 45 s.  
 
Table 3 PCR primers for exon amplification 
 
Exon Forward primer Reverse primer Fragment 
size (bp) 
Annea- 
ling T (°C) 
1 5’-TTACTGGGTTCATTGTTGTAGGTACTG-3’ 5’-CCCCAAACAAACACCTATTCAAAG-3’ 400 53 
2 5’-GATATGCTAAAGTACATTGTTGTTTTG-3’ 5’-CCCTTTAATATTTTCAAACAATCTG-3’ 200 53 
3 5’-TTGAATATTGATTAACGGAATGGTG-3’ 5’-TCCCCCTGCTTCTTACTAAATCTGC-3’ 200 53 
4 5’-TGCTAAAAGGGATCAGGAATGAAG-3’ 5’-CAATAATAGTACCTTTACCAGTTTGTCCAA-3’ 220 51 
5 5’-TGGAGGAAGGGAGGCAGTTAATG-3’ 5’-ATACATTTCAGAGAGACGAACTGTCAGGC-3’ 200 53 
6 5’-AAAAGAAAGTGTGACACCTCTGGAAAAG-3’ 5-AAGCAAGCACTCTATCAAATAAGACATTAC-3’ 300 56 
7 5’-AAATCACATAAGAGATATGCTATGAGCTTGC-3’ 5’-ATTTATAAGAAATCACCAAAAGGCAAAGTG-3’ 400 56 
8 5’-GTGAG*-TCTCAGGTTGATTTTGCAG-3’ 5’-TGATTACAGGAGGAAAGTAGCTGAAG-3’ 320 56 
9 5’-AGAGATTATGGGCTGTACTTCATGG-3’ 5’-TTCCCTAATGATGCCAAATAAATG-3’ 250 56 
10 5’-AAACTTAAGTTGATAAATAATATGATCCTT-3’ 5’-GTCTAACACAGAAGCTAAGTATGGG-3’ 340 56 
11 5’-GCTTTAATAAACTTTCAACTTTCATTTG-3’ 5’-CATTTGTGTAGTTTTGTTTTGCATTC-3’ 250 56 
12 5’-ATTTATATTTTTTACAATTAGGAGTTGAAG-3’ 5’-AAGTTACACAAGCTATAAAAAATGCCATTG-3’ 300 56 
13 5’-TATGAAGTGGTTATGGTTTGAATTG-3’ 5’-AAAGGCGTAAAAGAAAATCACTACC-3’ 350 49 
14 5’-GCTACAAGTCAATGTTTCCAGC-3’ 5’-CTTTCAGCACTGTTCACATTTTC-3’ 330 53 
Results 
A group of 35 untyped CDG patients was investigated. The diagnosis of CDG was based on the 
detection of hypoglycosylated serum transferrin by isoelectric focusing (data not shown). These 
patients represented different clinical entities, but also showed common features such as 
psychomotor retardation. It should be noted that a group of four untyped patients presented 
symptoms similar to those encountered in the 4 first cases of CDG-Ic (Grünewald et al., 2000),  
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suggesting that they represent additional cases of ALG6 deficiency. In two siblings, CDG-Ia had 
previously been excluded on the basis of linkage analysis (Matthijs et al., 1996). 
In a first step, the N-glycan assembly pathway was analyzed in fibroblasts isolated from the 
CDG patients. ALG6 deficiency has been found to be accompanied by an accumulation of the 
N-glycan Man9GlcNAc2-PP-Dol precursor structure (Imbach et al., 1999). A similar LLO 
analysis revealed a peak corresponding to the mature Glc3Man9GlcNAc2-PP-Dol core in all 
healthy controls and in most CDG cells investigated (data not shown). However, accumulation 
of the precursor Man9GlcNAc2-PP-Dol structure was observed in seven untyped CDG cell 
samples (Fig. 2), thus suggesting additional cases of CDG-Ic. 
We investigated the status of the ALG6 gene in the CDG cells that showed an accumulation of 
Man9GlcNAc2-PP-Dol. To allow the detection of mutations that possibly affect mRNA splicing, 
we first determined the genomic organization of the ALG6 gene. Exon-intron boundaries were 
identified by PCR on a P1 genomic DNA template using randomly selected primer pairs based 
on the known ALG6 cDNA sequence followed by direct sequencing of the PCR fragments. 
Based on this approach, 12 exons were defined. The remaining two 5’-exons were not accessible 
by PCR, because the P1 clone did not include the proximal portion of the ALG6 gene. The 5’-
half of the gene was retrieved from a bacterial artificial chromosome contig on chromosome 
1p22 (accession AL049636) found in GenBank by screening for genomic fragments including 
the ALG6 sequence. The entire coding region of the gene was found to be divided into 14 exons 
and spanning over 55kb (Figure 3).  
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Figure 2.a–c  LLO analysis in CDG-Ic patients.  
 
a  The HPLC profile obtained from a healthy control subject with a peak at retention time 72 min corresponding 
toGlc3Man9GlcNAc2- PP-Dol (G3M9N2).  
b  The LLO profile of a CDG-Ic patient with a Man9GlcNAc2-PPDol (M9N2) peak at retention time 50 min. 
c  The amount of each fraction is given in percent of total oligosaccharide content for each CDG-Ic patient. The numbers 
represent values obtained from single determinations. M5N2 Man5GlcNAc2-PP-Dol, M8N2 Man8GlcNAc2-PP-Dol, G1M9N2 
Glc1Man9GlcNAc2- PP-Dol, G2M9N2 Glc2Man9GlcNAc2-PP-Dol 
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The determination of the genomic organization allowed the design of a series of intron specific 
primers, thus enabling PCR amplification and sequencing of all ALG6 exons (Table 3). The use 
of intronic primers for exon amplification was necessary, because PCR performed exclusively 
with exon specific primers often lead to amplification of fragments derived from a pseudogene 
(data not shown). 
 
 
 
Figure 3.  Genomic structure of ALG6. The coding region of the ALG6 gene is split in 14 exons and spans about 55 kbp. The 
size and distribution of the exons and introns are shown proportionally (top). The exact splicing sites for each exon 
and the corresponding introns are shown below. The first two bases of the splicing donors and acceptors are printed 
in bold 
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ALG6 sequence analysis in the patients that accumulated the Man9GlcNAc2-PP-Dol 
oligosaccharide revealed 4 additional cases (P5, P6, P7, P9) of homozygosity for the 998C→T 
mutation in exon 11, causing the same A333 V substitution in the ALG6 protein as found in the 
first CDG-Ic patients (P1-P4; Imbach et al., 1999). It was noteworthy, these four patients P5, 
P6, P7 and P9 were compiled as a group based on clinical examination (Grünewald et al., 2000). 
These new CDG-Ic patients were not related to the family previously identified. Another CDG-
Ic patient (P8) carried the 998C→T mutation on one ALG6 allele, together with a G to A 
transition in the 5’-splice site of intron 3 in the second allele. This IVS3+5G→A mutation 
caused an alternatively spliced form of the ALG6 mRNA, by skipping exon 3, which encodes a 
domain conserved in S. cerevisiae, Caenorhabiditis elegans, and human ALG6 protein (Figure 
4). Finally, two siblings (P10, P11) with CDG-Ic were found to be homozygous for two novel 
ALG6 mutations, namely 911T→C and 1432T→C in exon 10 and 14, respectively. These two 
base transitions cause substitutions of Phe by Ser and of Ser by Pro at positions 304 and 478 of 
the ALG6 protein, respectively. 
 
  
 
 
Figure 4.a,b Altered ALG6 splicing in CDG-Ic.  
 
a  Comparison between the boundaries of exon 3 found in the wildtype and IVS3+5G→A ALG6 alleles. The consensual 
sequences for splicing junctions are indicated in gray. 
 b  The ALG6 fragments amplified from control (C) and patient P8 cDNAs with primers specific to exon 1 and exon 5. The 
wildtype allele yields a fragment of 392 bp and the IVS3+5G→A allele gives a fragment of 302 bp indicating the loss of 
exon 3 (90 bp); this was confirmed by sequencing the PCR fragment (not shown) 
 
To investigate the impact of amino acid substitutions analysis the ALG6 function, we performed 
a complementation analysis in S. cerevisiae ∆alg6 and alg6wbp1-2 mutant strains (Reiss et al., 
1996; Runge et al., 1984). The effect of the IVS3+5G→A mutation was not investigated here, 
because it lead to a large deletion in the ALG6 protein caused by the loss of exon 3. These two 
strains were transformed with yeast expression plasmids harboring the human wildtype and 
mutant ALG6 cDNA. Two phenotypes were assessed: the glycosylation of the vacuolar protein 
carboxypeptidase Y (CPY) in ∆alg6 mutants and the growth capacity of alg6wbp1-2 double-
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mutant yeasts. The wbp1-2 mutation affects a subunit of the oligosaccharyltransferase enzyme 
complex (te Heesen et al., 1992). When associated to alg6, wbp1-2 causes a growth defect 
phenotype (Burda et al., 1996). As previously shown (Imbach et al., 1999), the human ALG6 
gene was able partially to complement the hypoglycosylation of CPY observed in ∆alg6 yeasts 
(Figure 5). By contrast, the cDNAs with the A333V and S478P substitutions failed to restore the 
glycosylation defect, thereby confirming their deleterious effects on ALG6 protein function. The 
F304S substitution appeared to be a milder mutation, as CPY glycosylation was restored to 
levels similar to those achieved by expressing the normal human ALG6 protein. The suppression 
of the growth phenotype by different ALG6 cDNAs in alg6wbp1-2 yeasts matched the results 
obtained in the analysis of CPY glycosylation. The A333V and S478P mutations severely 
impaired the ALG6 protein function as deduced from the weak growth of yeast colonies (Fig. 5). 
The analysis of growth of alg6wbp1-2 yeasts clearly demonstrated the negative effect of the 
F304S mutation onto ALG6 integrity, as alg6wbp1-2 yeasts expressing this mutant ALG6 cDNA 
did not grow as well as those transformed with the wildtype human ALG6 cDNA (Figure 5). 
 
  
 
Figure 5 a, b Complementation of S. cerevisiae alg6 mutant strains with different human ALG6 cDNAs.  
 
a  Western blot analysis of CPY carrying 4, 3 or 2 glycan chains. Transformation was performed with the vector (YEp352) 
expressing the S. cerevisiae ortholog (ScALG6), the human wildtype (HsALG6) or the mutant HsALG6 cDNAs, as 
indicated. A wildtype yeast strain (SS328) transformed with the YEp352 plasmid was used as a control.  
b  The same vector constructs were used for transformation of alg6wbp1–2 mutant yeasts. Starting from the top, ten-fold 
dilutions of the same cell number were plated on YP-galactose plates and incubated at 27.5 °C for 4 days 
 
 
 
 
 
 
Given the frequency of the A333V mutation among CDG-Ic patients, we performed a haplotype 
analysis at the ALG6 locus. The chromosomal localization of human ALG6 was determined by 
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screening the expressed sequence tag division of GenBank for fragments identical to ALG6. The 
retrieved fragment AI479334 was part of the cluster Hs.80042 of the Unigene collection. This 
cluster has been mapped to chromosome 1 at position 1p22.3 close to the polymorphic marker 
D1S203. Eight other polymorphic markers localized around D1S203 were analyzed by PCR 
utilizing the corresponding primers listed in the Genethon human linkage database (Cohen et al., 
1993). The microsatellite analysis revealed a founder effect for the allele bearing the A333V 
mutation, as related haplotypes were detected for the markers D1S203, D1S2788 and D1S438 in 
7 CDG-Ic patients (Tables 1, 2). In these patients, the A333V mutation was associated to a rare 
allele (“201”) for marker D1S2788. The informativity of markers D1S203 and marker D1S438 
was limited in this respect. Several historic recombinants were visible. It is not clear whether the 
haplotype in patient P8 was historically related to the haplotype in patients P1-P7; the allele 
“201” for marker D1S2788, which was most closely associated with the mutation in the 
common haplotype, was not present. We did not have material from the parents of P8 to 
reconstruct the phase (Table 2). On the other hand, the haplotype background for A333V in P9 
was different from the haplotype on the common A333V allele. As expected, the patients 
P10/P11 were homozygous for the ancestral haplotype associated with a different mutation. 
Discussion 
Despite the increasing awareness of CDG among clinicians, the early and accurate diagnosis of 
CDG remains a difficult task, mainly because of the heterogeneous clinical pictures associated 
with the disease. In particular, patients with milder forms of CDG may remain undetected. In 
any case, a correct typing of CDG is crucial for diagnosis, to enable reliable prenatal 
examination in affected families, and to provide the basis for possible therapeutic approaches. 
Thorough clinical examination may reveal patterns of similarity, as found for a group of CDG-
Ic patients (Grünewald et al., 2000). However, the availability of specific diagnostic tests to 
type CDG is a key issue. Here, we show that LLO analysis, applied subsequently to the 
isoelectric focusing of serum transferrin (de Jong and van Eijk, 1988), has permitted the 
delineation of seven new CDG-Ic cases among a pool of 35 patients. Including the patient 
described by Körner et al. (1998), we now have 12 cases of CDG-Ic. About the same number of 
CDGI-b cases have been reported. However, taking into account that it is more difficult to 
identify CDG-Ic cases on clinical grounds, it is plausible that the ALG6 deficiency is the second 
most frequent type of CDG after CDG-Ia. 
Three mutations detected in the ALG6 gene of CDG-Ic patients caused single amino acid 
substitutions resulting in altered activity. However, none of these mutations completely 
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abolished the activity, indicating the importance of the ALG6 glucosyltransferase for N-linked 
glycosylation of proteins. Furthermore, complementation in yeast proved to be a sensitive test to 
ascertain the biological significance of mutations in glycosylation enzymes, such as successfully 
documented for the ALG6 glucosyltransferase, the ALG5 dolichyl phosphate-glucose synthase 
(Imbach et al., 1999) and ALG3 mannosyltransferase (Körner et al., 1999). In addition, the 
detection of a mutation in a splicing donor site underlines the importance of analyzing the gene 
sequence at the genomic level. 
The founder effect of the A333V mutation suggests an increased prevalence of this allele in 
Western European patients and further cases of CDG-Ic with this genotype are to be expected. 
In addition, the existence of multiple mutant ALG6 alleles causing CDG-Ic increases the 
probability of the disease. The availability of an ALG6 genomic map now permits a genetic 
screening of ALG6 integrity. This approach requires minimal amounts of biological material and 
can be applied to patient, parental and prenatal diagnosis in a reasonable time. 
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Abstract  
As carbohydrate-deficient glycoprotein syndromes (CDGS) are multisystemic disorders with 
impaired central nervous function in nearly all cases, we tested isoforms of ß-trace protein 
(ßTP), a „brain-type„ glycosylated protein in cerebrospinal fluid (CSF) of nine patients with the 
characteristic CDGS type I pattern of serum transferrin. Whereas the serum transferrin pattern 
did not discriminate between the various subtypes of CDGS type I  (CDGS type Ia, type Ic and 
patients with unknown defect), ßTP isoforms of CDGS type Ia patients differed from that of the 
other CDGS type I patients. The percentage of abnormal ßTP isoforms correlated with the 
severity of the neurological symptoms. Furthermore two patients are described, who illustrate 
that abnormal protein N-glycosylation can occur restricted to either the “peripheral” serum or 
the CNS compartment. This is the first report presenting evidence of a N-glycosylation defect 
restricted to  
the brain. Testing ßTP isoforms is a useful tool to detect protein N-glycosylation disorders in the 
CNS.  
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Introduction  
 
The carbohydrate-deficient glycoprotein syndromes (CDGS) are a new group of inherited 
disorders affecting the synthesis of the asparagine-linked (N-linked) glycans first described by 
Jaeken in 1980 (1). Based on a different banding pattern in the isoelectric focusing (IEF) of 
serum transferrin due to the abnormal glycosylation of the oligosaccharide chains four types of 
CDGS (type I-IV) have been classified (2-6). CDGS type I syndromes are defined by a type I 
sialotransferrin pattern delineated by increased di- and asialotransferrin and decreased 
tetrasialotransferrin bands. Among CDGS type I three different diseases have been identified: 
CDGS type Ia is caused by phosphomannomutase 2 (PMM 2) deficiency (7) and CDGS type Ib 
by phosphomannose isomerase (PMI) deficiency (8, 9).  Both cytosolic enzymes catalyse steps 
in the early glycosylation pathway. In a group of four patients (children of an inbred family) and 
another unrelated child, a defective glycosyltransferase of the endoplasmatic reticulum (ER) 
causes the accumulation of dolichol-linked Man9GlcNAc2. As for historical reasons the 
classification of CDGS is based on the glycoform pattern observed for transferrin, the disorder 
is called CDGS type Ic in this publication and in two earlier papers (11, 12), whereas Körner at 
al. published their single case as CDGS type V (13). In addition, a number of patients with a 
CDGS type I transferrin pattern on IEF but so far unknown N-glycosylation defect have been 
identified. They are labelled as the CDGS type Ix.  
Beta-trace protein (ßTP) is one of the most prominent polypeptide constituents in human 
cerebrospinal fluid (CSF), detectable in a concentration of about 8µg/ml (14). This glycoprotein 
is predominantly intrathecally synthesised and secreted by glia-rich fractions of the brain. It is 
also detectable in trace amounts in kidney, epidydimis and other organs (15, 16). The structure 
of the carbohydrate units of ßTP was elucidated only recently. There is evidence, that ßTP is 
„brain type„ glycosylated. This means that all biantennary N-linked oligosaccharides are of the 
complex type and have a high degree of peripheral fucosylation, high amounts of bisecting N-
acetylglucosamine (GlcNAc) and N-acetylneuraminic acid (NeuNAc) in α2,3 or α2,6 linkage 
(17). In contrast to these characteristics of ßTP in CSF, peripheral fucosylation and bisecting 
GlcNAc are nearly absent in serum-type glycoproteins and NeuNAc is found predominantly in 
α 2,6 linkage (18, 19).  
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CDGS are multisystemic diseases and the common clinical presentation in the most frequently 
occurring CDGS type Ia, but also in CDGS type Ic and Ix, is moderate to severe cerebral 
symptoms. Under the assumption that abnormal glycosylation in brain may play a role in the 
pathogenesis of brain dysfunction in CDGS, the question was whether in certain CDG 
syndromes the abnormal glycosylation pattern of serum glycoproteins can be recovered also in 
“brain-type” glycosylated glycoproteins such as ßTP. Furthermore, based on the idea that 
deficient glycosylation as a cause of brain damage might be confined to the CNS (20), we tested 
ßTP for abnormal glycosylation in 500 CSF samples of children with impaired cerebral function 
of unknown cause.   
Materials and methods 
Materials 
 
Controls 
In 25 age-matched controls CSF was obtained as part of routine diagnostic procedure.  
Retrospectively, the controls were classified as suitable reference subjects because of lack of 
evidence for immunological or renal diseases. Appropriate tests ruled out acute or chronic 
infectious diseases. Serum and CSF samples were kept at -80°C until analysis.  
 
CDGS type Ia, Ic and Ix  
Samples of CSF and serum were obtained from children with CDGS after their parents’ 
informed consent. In nine CDGS type I patients (4 type Ia, 1 type Ic and 4 type Ix cases), aged 
between 3 months and 7 years, the serum transferrin pattern on IEF showed the characteristic 
increase of a- and disialotransferrin and decrease of tetrasialotransferrin (Table1). The 
characteristic abnormalities on IEF were also demonstrated in the IEF pattern of TBG 
(thyroxine binding globulin) confirming a generalised glycoprotein abnormality (data not 
shown). A variant in the protein moiety of transferrin was excluded by IEF of serum transferrin 
after neuraminidase treatment (21). Four CDGS type Ia patients showed reduced PMM activity 
in leukocytes and fibroblasts (leukocytes 0.0-0.1 mU/mg protein, fibroblasts 0.09-0.57 mU/mg 
protein, normal ranges: leukocytes 0.41-1.81 mU/mg protein, fibroblasts 1.27-4.53 mU/mg 
protein). By SSCP analysis and sequencing the frequent missense mutation F119L/R141H was 
identified in two patients and R123Q/R162W was found in another child (22). In the fourth 
subject a new missense mutation H218L was described in combination with a splice mutation in 
intron 3.  In CDGS type Ic and CDGS type Ix cases, PMM and PMI deficiency was excluded by 
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measuring the enzyme activities in leukocytes and fibroblasts. Biochemical characterization of 
the defect in the glycosylation of dolichol-linked oligosaccharides in the CDGS type Ic family 
has been described (10, 11). The basic defect(s) in the CDGS type Ix cases remain(s) unclear 
and may turn out to be heterogeneous.  
In all patients with CDGS type I the CNS was involved. The neurological abnormalities were 
highly variable ranging from only minor neurological symptoms to full-blown neuropathology 
of CDGS type Ia. Muscular hypotonia, psychomotor retardation and speech delay were constant 
features. Overall, CDGS type Ia patients presented with more severe neurological symptoms 
compared to patients with CDGS type Ic and Ix.  
 
CSF from a patient with other hypoglycosylation of serum glycoproteins 
During the workup of a 21-year-old female (H.K.) with severe mental retardation and 
neurological impairment an abnormal pattern of the serum transferrin and TBG was obtained on 
IEF. Also in this patient a polymorphism in the transferrin could be ruled out as an explanation 
for the abnormal isoforms distribution after neuraminidase incubation. The sialotransferrin 
pattern showed elevated mono-, di- and trisialo- and decreased tetrasialotransferrin bands, by 
definition a CDGS type II pattern (Table 1). This patient presented with an Angelman-like 
appearance, severe developmental and speech delay and mild epilepsy. Magnetic resonance 
imaging of the brain showed no abnormalities. 
 
Table 1: Relative distribution (%) of serumsialotransferrin fractions on isoelectric focusing 
of different CDGS type I patients, patient H.K. and CV and healthy controls.  
 
Sialo-transferrin fraction Controls 
(n=30) 
CDGS type Ia 
(n=4) 
CDGS type Ic 
(n=1) 
CDGS type Ix 
(n=4) 
H.K. C.V. 
0 0.0 – 2.6 6.6 – 29.5 10.7 2.2 – 16.8 2.2 3.6 
1 0.0 – 2.6 1.1 – 5.4 2.0 1.4 – 3.3 4.8 2.3 
2 1.6 – 6.1 23.1 – 37.7 34.9 20.7 – 42.7 19.2 8.3 
3 2.5 – 15.6 5.9 – 9.6 6.1 8.0 – 13.3 28.4 18.2 
4 51.2 – 72.2 20.6 – 42.3 33.9 22.5 – 49.0 35.6 48.1 
5 12.1 – 30.8 6.0 – 14.8 11.0 6.7 – 14.7 9.8 16.5 
6 0.0 – 9.0 0.0 – 2.8 1.6 0.0 0.0 2.8 
 
CSF from children with various neurological disorders 
 
A total of 500 CSF samples were collected from children (age 4 months - 18 years) with various 
neurological symptoms. This material was obtained in the context of diagnostic investigations 
and was stored until analysis at -80°C. The leading neurological signs and symptoms included 
mental and motor retardation, epilepsy and muscular hypotonia. 
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Methods 
 
Isoelectric focusing (IEF) of serum transferrin 
IEF of serum transferrin was carried out essentially as described by van Eijk and van Noort  
(23). Iron-saturated serum was separated on a hydrated immobiline gel (pH 4-7) on a Ultrophore 
system (Pharmacia, Uppsala, Sweden). After IEF the transferrin isoforms were visualised by 
adding rabbit anti human transferrin (Dako, Glostrup, Denmark) and the gels were stained with 
Coomassie blue. The relative amounts of transferrin isoforms were quantified with the Ultrascan 
XL laser densitometer.  
 
IEF of thyroxine-binding globulin in serum 
Pure serum was added on a PhastGel (pH 4-6.5, Pharmacia Biotech) and separated on a 
PhastSystem. After addition of rabbit anti human TBG antibody (Dako) the TBG pattern was 
determined by silver staining.  
 
Phosphomannomutase (PMM)- and phosphomannose isomerase (PMI)-assay 
PMM and PMI activities were measured in leukocytes and/or fibroblasts, according to the 
procedure described by Van Schaftingen and Jaeken (7).  
 
SDS-PAGE and immunoblotting of ß-trace protein 
After ethanol precipitation of protein from 100 µl CSF and centrifugation, the pellets were 
dissolved in 20µl SDS-buffer, containing 10.0 mM Tris-HCl, 1.0 mM EDTA, 2.5% SDS, 5% ß-
mercaptoethanol and 0.01% Bromophenol blue, pH 8.0. After heating (5 min, 95°C), 4µl of the 
resolved protein were applied to the sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) 
on a PhastSystem (Pharmacia Biotech), using 20% homogeneous polyacrylamide gels 
(PhastGel, Pharmacia Biotech). Focusing was carried out for 170 Vh at 15°C. Following 
transfer to nitrocellulose 0.2 µm membranes (Schleicher & Shuell, Düren), immunodetection of 
ßTP was performed using a monoclonal mouse antibody against ßTP (Prof. Conradt). The 
different fractions were detected by chemiluminescence with a horseradish peroxidase-labelled 
second goat anti mouse antibody (Pierce, Hyperfilm-ECL). 
 
Enzymatic release of N-glycans by peptide-N-glycosidase F (PNGase F) 
Five µg of purified human ßTP was incubated with 0.2 U of peptide-N-glycosidase F (PNGase 
F, Boehringer Mannheim, Germany) at 37°C (14). The enzymatic reaction was stopped after 30 
min, 60 min, 2 h, 4 h and 8 h by freezing at -20°C. Separation and immunoblotting of the 
protein was performed as described.  
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Results 
Glycosylation of ß-trace protein  
The ßTP of CSF samples from control individuals migrated on SDS-PAGE as a single band of 
about 27 kDa representing the diglycosylated isoform (Figure 1). The a- and monoglycosylated 
isoforms of ßTP were not present or below 1% of the amount of the diglycosylated isoform.  
Glycosylation of ß-trace protein in CDGS type I patients  
As shown in Figure 1 ßTP in CSF of all CDGS type I patients showed the di- (27 kDa) and 
mono- (24 kDa) glycosylated isoforms of ßTP.  
In all CDGS type Ia patients an additional band was present, representing the aglycosylated (21 
kDa) isoform. The estimated ratio for the di-, mono- and aglycosylated fraction was 60-65%:30-
35%:5-10%. This aglycosylated band could not be detected in any of the CDGS type Ic and Ix 
patients. In these cases the relative distribution of the di- and monoglycosylated isoforms was 
70-85%:15-30%.  
Glycosylation of ßTP  in subject H.K. 
In CSF of the mentally impaired patient H.K. with clearly abnormal glycosylation of several 
serum glycoproteins (for transferrin fractions see table 1) a normal ßTP pattern was observed 
with only diglycosylated  ßTP (Figure1). 
 
 
Figure 1:  Western blot analysis of L-trace protein in cerebrospinal fluid from CDGS patients of different subtypes: A, 
puriifed human βTP; B, control; C, CDG Ia; D, CDG Ic; E, CDG Ix; F, case H.K.; G, control; H, case C.V. 
Molecular mass of the isoforms is indicated in kDa. 
 
 
Glycosylation of ß-trace protein in subjects with neurologic disorders 
Investigating the glycosylation of ßTP in CSF from 500 children with unexplained disorders of 
the CNS, a 7 months old child (C.V.) was identified with an abnormal pattern. In this patient the 
diglycosylated (27 kDa) isoform of ßTP was reduced whereas the monoglycosylated (24 kDa) 
isoform was increased. The relative distribution amounted to 60:40 (Figure 1) and was different 
from the distribution in patients with CDGS type Ia, Ic and Ix. Careful reinvestigations on 
serum glycoproteins (transferrin, TBG) revealed only marginal abnormalities as compared to 
normal controls (see Table 1). The clinical phenotype presented as follows. She was a 
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dysmature newborn with neonatal seizures. Other major symptoms were severe muscular 
hypotonia, severe feeding problems, failure to thrive and hypoglycaemic episodes. Detailed 
differential diagnostic procedures, including comprehensive screening for metabolic disorders 
did not lead to a diagnosis. Since the child died at 8 months of age before this ßTP observation 
was carried out, no further investigations could be performed. Post-mortem examination 
revealed liver fibrosis with transition to cirrhosis and spleen infarctions. Examinations of the 
CNS showed no structural abnormalities and routine light microscopic examinations were also 
unremarkable.  
Discussion 
The carbohydrate-deficient glycoprotein syndromes present as genetic multisystemic disorders 
characterised by defective glycosylation of the N-linked glycan units of a variety of 
glycoproteins). The most frequent CDGS type Ia (PMM deficiency) primarily affects the CNS 
and to a variable degree also the peripheral nervous system and other organs, e.g. liver. 
Neuropathology findings characteristically include cerebellar hypoplasia already in new-borns 
and it is assumed that the regularly occurring arrest of locomotor ability in early childhood is 
related to a postnatal degeneration of infratentorial structures (24). Neurological involvement 
appears less severe in CDGS type Ic and CDGS type Ix patients.  Abnormal ßTP isoforms in 
CSF showed disturbed glycosylation in the CNS in CDGS type Ia but also in CDGS type Ic and 
Ix cases. We conclude that protein N-glycosylation is disturbed in the central nervous system 
and in peripheral organs in all CDGS type I subtypes investigated. Our data are in accordance 
with that Pohl et al. (25) who demonstrated hypoglycosylation of ßTP in CSF in CDGS type Ia 
and CDGS type II (N-acetylglucosaminyl-transferase II deficiency. Our study extends these 
findings to CDGS type Ic and Ix subtypes.  
 
On the basis of the glycosylation pattern of ßTP, we could distinguish between CDGS type Ia 
and other CDGS type I syndromes. The fact that among all CDGS type I syndromes the 
aglycosylated (21 kDa) isoform of ßTP is only present in CSF of patients with CDGS type Ia 
may indicate that brain type glycosylation is more severely impaired in these cases than in 
CDGS type Ic or Ix. The biochemical defect in the brain apparently is more deleterious in 
CDGS type Ia than in the other type I CDGS. This is in line with the clinical observation of 
more severe neurological disturbances in patients with CDGS type Ia. In the CDGS type Ia cases 
there seems to be less residual flux through the “brain-type” glycosylation pathway than in the 
CDGS Ic and Ix cases. This may be explained by a higher local residual activity of the 
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enzyme(s) involved in the CDGS type Ic and Ix cases. Of course it cannot be excluded that 
patients with more severe mutations in the gene underlying the CDGS type Ic or Ix defect may 
be found that will turn out to have a similar degree of impairment of the pathway as our CDGS 
type Ia cases. It would be of interest to study the glycosylation pattern of brain-type glycans in 
patients with CDGS type Ib, because they mainly present with hepato-intestinal symptoms, 
without any or only minor neurological involvement (9).  
As a result of investigations of N-glycosylation defects in brain of patients with impairment of 
the CNS of unknown etiology, we identified one subject (H.K.) with an abnormal glycosylation 
pattern of different serum glycoproteins (transferrin and TBG) but with a completely normal N-
glycosylation of ßTP in CSF. Vice versa, we found one subject (C.V.) with only very mild 
abnormalities of serum glycoproteins and a highly abnormal ßTP glycosylation pattern. In the 
first mentioned subject known causes for secondarily impaired glycosylation of serum 
glycoproteins such as alcohol abuse, liver disease, hereditary fructose intolerance and 
galactosemia were excluded (26-28). In patient C.V. one may assume a glycosylation defect 
mainly confined to the CNS which to our knowledge has not been described so far. These 
patients demonstrate that abnormal N-glycosylation of proteins can occur restricted to either 
the”peripheral” tissues or brain.  
Although the physiological role of ß-trace in CSF and its complete biosynthetic pathway still 
remain obscure, different studies on the biological function, especially in brain, indicate that it 
may play a critical role in regulating the development of neurones and may participate in myelin 
metabolism and maintenance (29). ßTP has been discussed as a diagnostic tool in various 
disorders. It is a specific marker for CSF fistulae and abnormal concentrations in CSF have been 
reported in cerebral infarction, multiple sclerosis, schizophrenia, paraproteinaemia and other 
malignancies (30-34). Whereas previous studies on ßTP so far refer only to quantitative aspects, 
we here propose to extend its diagnostic relevance by studying ßTP isoforms to light up 
impaired N-glycosylation of proteins in the CNS. Several defects in glycan synthesis have been 
described recently, and the number of newly discovered defects will rise as attention to these 
disorders increases and new methods are used. The method for the detection of abnormally 
glycosylated ßTP in CSF is an easy and reliable test and can be used in a screening setting. It is 
well documented that the isoelectric focusing of serum transferrin is the ideal approach to screen 
for CDGS (35). ßTP detection in CSF will not replace this approach, but this study suggests its 
diagnostic value for the screening for N-glycosylation defects in the CNS. As we have shown, 
these may even be exclusively brain tissue specific and would therefore be missed in the serum 
transferrin IEF analysis. Furthermore, the degree of ßTP hypoglycosylation seems to reflect the 
severity of the CNS involvement.  
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ßTP isoform analysis in CSF should be considered in the diagnostic workup of patients with 
unexplained disorders of the CNS. 
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Abstract  
Background: Defects in the biosynthesis of N-glycans may be found by iso-electric focusing of 
plasma transferrin. No test is available to demonstrate O-glycan biosynthesis defects.  
Methods: We used isoforms of apolipoprotein C-III (apoC-III) as a marker for the biosynthesis 
of core 1 Mucin type O-glycans. Plasma samples from patients with primary defects and 
secondary alterations in N-glycan biosynthesis were studied by apoC-III isofocusing.  
Results:  Age-related reference values of apoC-III were determined. Plasma samples from 
patients with the primary congenital disorders of glycosylation (CDG) types Ia-Ic, Ie, If, IIa and 
IId all showed a normal apoC-III isofocusing profile. Plasma from two patients with CDG type 
IIx were tested: one showed a normal apoC-III distribution, whereas the other showed a 
hypoglycosylation profile. In plasma from patients with hemolytic uremic syndrome (HUS) a 
hypoglycosylated profile was obtained.  
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Conclusions: IEF of apoC-III is a rapid and simple technique that may be used as a screening 
assay for abnormalities in core 1 mucin type O-glycans. Evidence that a patient in this study has 
a primary genetic defect affecting both N- and O-glycosylation provides the first example of an 
inborn error of metabolism affecting the biosynthesis of core 1 mucin type O-glycans. Our data 
narrow the options for the position of the primary defect in this patient down to a step in the 
biosynthesis, activation, or transfer of galactose or N-acetylneuraminic acid to both N- and O-
glycans. Circulating neuraminidase excreted by Streptococcus pneumoniae caused the high 
percentage of asialo apoC-III in two HUS patients. 
Introduction  
In 1987, Jaeken et al. (1) were the first to describe an inborn error of metabolism in the 
biosynthetic pathways of protein N-glycosylation. During the last decade, several defects were 
found in the biosynthesis of N-glycans. The diseases in this pathway have been collectively 
referred to as congenital disorders of glycosylation (CDG), formerly called carbohydrate-
deficient glycoprotein syndrome (2, 3). The use of transferrin isofocusing on plasma and serum 
has been pivotal in detecting patients suffering from the various forms of the syndrome. At 
present, 13 different diseases in N-glycan biosynthesis are known: CDG-Ia through -Ih and 
CDG-IIa through -IId (4–6). A few inherited diseases have been found in the biosynthesis of O-
linked glycans, mainly by genetic approaches. Examples are muscle-eye-brain disease and 
Walker-Warburg syndrome, in which the defect is situated in the biosynthesis of O-mannose-
based glycans (7, 8). The biochemical hallmark in CDG-IIc patients is hypofucosylation of both 
N- and O-glycosylated proteins. This disease is the first identified in which both N- and O-
glycosylation is affected (9, 10).  
The biosynthesis of N-glycans as well as O-glycans can be divided into three stages (see Figure 
1). In the first stage, biosynthesis and activation of monosaccharides occurs. In the second stage, 
nucleotide sugars enter the endoplasmic reticulum (ER) bound to dolichol phosphate. 
Nucleotide sugars enter the lumen of the Golgi via specific antiporters. In the third stage, 
specific transferases attach the glycan in the ER and the Golgi. In mammals, six different types 
of O-glycans are known, classified on the basis of the first sugar attached to the serine or 
threonine residue of the protein (11). The mucin type O-glycan, starting with N-
acetylgalactosamine (GalNAc), is most common in humans. In total eight core structures can be 
distinguished depending on the second sugar(s) and/or sugar binding (11–13). Further 
biosynthetic steps finally give rise to at least 50 different O-glycan structures, of which core 1 
and 2 are most abundant (14, 15). In brain and neural tissue, core 1 is most common (16 ). The 
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synthesis of core 2 mucin type O-glycans requires the conversion of unsubstituted core 1 mucin 
type O-glycans by a N-acetylglucosamine (GlcNAc) transferase (17, 18).  
In this study, we developed a test that may be used to demonstrate defects in the biosynthetic 
pathway of core 1 mucin type O-glycans. The test uses the isoforms of apolipoprotein C-III 
(apoC-III). This protein carries a single O-glycan at Thr-94 and is not N-glycosylated (19). The 
protein is rather stable and is readily detectable in human plasma. Human apoC-III antibodies 
are commercially available. This study is a step in the development of a biochemical approach 
to find defects in the biosynthesis of O-glycans. To our knowledge it is the first report 
describing a patient with an inborn error of metabolism affecting core 1 mucin type O-glycan 
biosynthesis.  
 
 
 
 
 
 
Figure 1: Glycan biosynthesis can be divided into three stages. Stage 1, monosaccharides are synthesized in the cytoplasm 
and activated as nucleotide sugars. Stage 2, nucleotide sugars enter the ER bound to dolichol phosphate (Dol-P). 
They are carried to the lumen of the Golgi by specific antiporters. Stage 3, the sugars are attached to the glycan 
by specific glycosyltransferases. 
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Patients and Methods 
 
Patients 
We analyzed 15 different plasma samples of patients with secondary N-glycosylation alterations 
were studied [hemolytic uremic syndrome (HUS), n=2, galactosaemia, n=1, alcohol abuse, 
n=12]. In addition, we studied 21 different plasma samples from patients with primary CDG 
[CDG-Ia, n= 8; CDG-Ib, n= 1; CDG-Ic, n= 8; CDG-Ie, n=1; CDG-If, n=1; CDG-IIa, n= 1; 
CDG-IId, n= 1]. CDG-I includes all defects starting from the assembly of dolichol to the 
transferrin of the oligosaccharide to the protein. CDG-II includes all defects that are localized in 
the processing of glycans on the protein. 
We also analyzed plasma samples from two patients with an as yet unidentified primary defect 
in N-glycan biosynthesis. The patients had been classified as CDG-II on the basis of their 
repeatedly abnormal transferrin isofocusing profile.  
Patient A is a child of healthy non-related German parents. He first presented at the age of 13 
years. Until that time, he had been healthy and well and had reached his age-related milestones 
appropriately. Probably as a result of a thromboembolic complication or aspiration, he suffered 
from a sudden respiratory arrest, was resuscitated and needed long-term ventilation. The 
intensive care period was complicated by a severe derangement of coagulation attributable to 
very low antithrombin III (< 10%, reference interval, 70-130), protein C (25%, reference 
interval, 70-130%) and factor XI (11%, reference interval, 70-130%). Recurrent arrhythmia was 
documented by electrocardiogram. Brain imaging showed slightly dilated ventricles. In the later 
course, the patient developed seizures with moderate neurological sequelae and showed 
recurrently increased transaminases and abnormalities of the clotting factors. 
Patient B was born to consanguineous parents with several mentally retarded relatives. The 
neonatal period and early infancy were normal. In the course of an infection at 6 months of age 
she presented with neurological regression mimicking Leigh disease. The child had infection-
triggered episodes with encephalopathy on two other occasions. At 6 years of age she had 
microcephaly, mental retardation, strabismus, pseudoptosis, and a cerebellar syndrome. She 
could not walk without support, but she was able to make psychomotor progress. Brain 
magnetic resonance imaging showed brainstem and cerebellar atrophy. The other clinical data 
are as follows: failure to thrive, epicanthus, and small hands and feet with hypoplasia of the first 
phalanx of some fingers and toes. She also has frequent stomatitis, although immunologic 
studies did not show abnormalities. Increased creatine kinase and transaminase concentrations 
were observed during the acute phases in the disease. In such periods the coagulation pattern 
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was abnormal, with protein C and protein S deficiency and decreased prothrombin time and 
coagulation factors. A detailed clinical description has been published (case 4 (20)).  
Both children had an abnormal isoelectric focusing (IEF) pattern with an increase of 
hypoglycosylated transferrin isoforms.  
 
Samples and sample preparation 
The VLDL pool was isolated by ultracentrifugation, and lipids were extracted by ethanol–
acetone (1:1 by volume) and stored in the freezer to sediment the VLDL apoproteins. 
Identification of the apoC-III isoprotein bands was as published in the literature (21). 
After centrifugation for cell separation, plasma samples were stored without delay at –80°C 
until analysis. Samples used for the apolipoproteinC-III isoform reference interval for the age 
group 0-1 year were from healthy babies at an age of 6 months (further use of leftover plasma 
volumes from a study on calcium homeostasis for which written informed consent was 
obtained). Samples used for the apoC-III isoform reference interval for the age group 1-18 year 
were from healthy volunteers (further use of left over plasma from relatives of patients for 
routine microsatellite studies after informed consent). Samples used for the apolipoproteinC-III 
isoform reference range for >18 years were obtained from healthy volunteers (Dutch blood bank 
donors after written informed consent). Their plasma samples showed no abnormalities when 
tested for N-glycosylation (transferrin IEF). Plasma samples were diluted 10-fold in saline for 
IEF of apoC-III. 
 
ApoC-III isofocusing 
Dry IEF gels for the PhastSystem (cat. no. 17-0677-01; Amersham Pharmacia Biotech) were 
rehydrated for at least 1.5 h at room temperature in a solution of 8 mol/L urea and 60 mL/L 
Pharmalyte, which contained Pharmalyte 4.2–4.9 and Pharmalyte 3.5–5.0 (Amersham 
Pharmacia Biotech) in a ratio of 2:1. The gel was prefocused for 75V  h at 2000 V. After 0.5 
µL of the 10-fold diluted plasma was applied to the gel, IEF was continued for 495 V  h (22). 
 
Western blot procedure 
Proteins were blotted onto a nitrocellulose membrane (cat. no. 12806-200-200BLF; Sartorius) 
by diffusion for 1 h at 60 °C. Nonspecific sites on the nitrocellulose membrane were blocked 
with 50 g/L nonfat dried milk dissolved in phosphate-buffered saline (PBS) containing 5 mL/L 
Tween 20.  
The membrane was washed in PBS containing 0.5 mL/L Tween 20. The primary rabbit anti-
human apoC-III antibody (cat. no. 0650-1707; ANAWA Biomedical Services & Products) was 
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diluted 1000-fold in 15 g/L bovine serum albumin dissolved in PBS containing 5 mL/L Tween 
20. The secondary goat anti-rabbit horseradish peroxidase-conjugated antibody (cat. no. 
1858415; Pierce Perbio Biotechnology) was diluted 5000-fold in the same solution. We then 
added 0.125mL of Western blotting detection reagents [electrochemiluminescence (ECL) 
reagent; cat. no. RPN 2134; Amersham Pharmacia Biotech] per cm² of membrane. A 
chemiluminescent reaction occurs between horseradish peroxidase and the luminol in the ECL 
reagents, producing light emission. The blot was placed against an autoradiography film 
(Hyperfilm ECL; cat. no. RPN 1681 H; Amersham Pharmacia Biotech) and exposed for 
different time intervals. The film was developed on a Kodak RP X-Omat Processor (Model 
M6B) and scanned with the Image master Labscan, Ver. 3.00 (Amersham Pharmacia Biotech). 
Isoforms of apoC-III were quantified by Image master 1D gel analysis, Ver. 4.10, software 
(Amersham Pharmacia Biotech).  
 
Neuraminidase treatment 
Neuraminidase can remove the negatively charged terminal sialic acid residues from N- and O-
linked glycans. After incubation with neuraminidase all apoC-III isoforms migrate to the 
position of apoC-III0. Polymorphisms in the apoC-III protein part can be illustrated by an 
abnormal mobility of the protein on IEF after neuraminidase treatment. For that purpose 
neuraminidase (1 mg/ml 0.1M Tris pH 7.0, Boehringer Mannheim, Germany, nr. 107590) and 
human plasma are incubated in a ratio of 3:2 overnight at room temperature.  
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Results  
 
Human plasma apoC-III isofocusing  
Isofocusing of human plasma apolipoproteinC-III shows the three isoforms apoC-III0, apoC-III1, 
and apoC-III2 (see Figure 2).  
 
 
 
Figure 2: apoC-III isoforms in human plasma and their structures 
 
Theoretically, nonglycosylated apoC-III, apoC-III with only GalNAc, or apoC-III with GalNAc-
Gal could contribute to the apoC-III0 fraction. It was not possible to distinguish the 
nonglycosylated apoC-III or apoC-III with only GalNAc from the asialo form by IEF (Figure 
2). The isoelectric points of the three isoforms were in the pI range 4.5–5.1, which is in 
accordance with data in the literature (23, 24). The apoC-III isoform profile of the VLDL pool is 
shown in lane 10 of Fig. 4. apoC-III1 and apoC-III2 are the major isoforms occurring in plasma 
(~55% and 40%, respectively), whereas only trace amounts of apoC-III0 are present. apoC-III is 
a stable protein; identical apoC-III isoform distribution patterns were found for a fresh plasma 
sample and the same sample stored frozen at -80 °C for 1 week. No other protein bands were 
visible in the pI range 4–5.3, illustrating the specificity of the antibody used.  
The linearity of the assay was assessed by dilution experiments. Samples had to be diluted to 
determine the full range at which the assay was linear (Figure 3A). Exposure time of the blot for 
a 10-fold diluted plasma sample on the radiography film showed a linear response until at least 
60 s of exposure (Figure 3B).  
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Figure 3: Linearity of the area under the curve for apoC-III1, the most prominent isoform in human plasma, as a function 
of exposure time. (A), undiluted plasma; (B), 10-fold diluted plasma. Sample volume for A and B was 0.5 µL. 
 
 
Reproducibility 
The between-run reproducibility was assessed by running the test on the same plasma sample on 
6 different days. Results for the three isoforms, expressed as mean (SD) as percentage of total 
apoC-III, were 4.5 (0.4)%, 59.1 (1.9)%, 36.4 (1.9)% for apoC-III0, apoC-III1, and apoC-III2 
respectively. 
 
Reference intervals 
The reference values for each age group are shown in Table 1. We found no statistically 
significant influence of gender (data not shown). Apoc-III0 was significantly lower in the age 
group 0–1 year than at older ages. Apoc-III1 and apoC-III2 are equally represented in this 
youngest age group, whereas at older ages, apoC-III1 becomes the most predominant isoform in 
most individuals. 
 
Table 1. Reference intervals for plasma apoC-III isoforms in healthy volunteers, expressed  
as percentages of total apoC-III. 
 
Age,   apoC-III0, % apoC-III1, % apoC-III2, % 
years n Mean (SD) Range Mean (SD) Range Mean (SD) Range 
0–1 17 3.7(1.9) 0.0–8.1 47.2(6.4) 34.0–58.5 49.1(5.9) 39.9–61.8 
1–18 17 5.1(2.7) 0.0–11.6 53.2(9.1) 33.1–66.9 41.6(8.3) 27.4–60.0 
>18 29 8.5(4.1) 2.6–18.9 55.5(6.5) 42.9–69.2 36.0(7.2) 23.2–50.0 
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Figure 4: Isofocusing profile of plasma apoC-III isoforms.  
lane 1, patient A (CDGIIx);    lane 2, patient B (CDGIIx);  
lane 3, control;     lane 4, galactosemic patient;  
lane 5, alcohol abuser;    lane 6, HUS patient;  
lane 7, plasma blood donor 1 after neuraminidase treatment;  
   lane 8, plasma blood donor 2 (with apoC-III protein polymorphism) after neuraminidase treatment;  
      lane 9, plasma blood donor 2 (with apoC-III protein polymorphism) before neuraminidase treatment;  
     lane 10, VLDL pool. 
 
ApoC-III polymorphism 
Isofocusing of a plasma sample from a blood donor showed 4 apoC-III isoforms (lane 9 figure 
4). After treatment with neuraminidase, plasma from other blood showed one band in the 
position of apoC-III0 (lane 7 figure 4). The plasma sample of this specific blood donor showed 
bands of equal intensity in the position of apoC-III0 and apoC-III1 (lane 8 figure 4). This is 
evidence for a polymorphism in the apoC-III protein that makes the net charge of the protein 
more negative.  
 
Patient groups 
Patients with primary CDG:  Plasma samples of patients with CDG-Ia, Ib, Ic, Ie, If, IIa and IId 
showed a normal apolipoproteinC-III isoform distribution (data not shown). 
Patients with secondary N-glycosylation alteration:s  Plasma samples from two patients in the 
acute phase of HUS attributable to Streptococcus  pneumoniae showed increased apoC-III0 (18 
% and 23%, respectively; reference interval: 0.0 - 11.6%).  
Plasma samples of patients who abused alcohol (n=12) or had classic galactosemia before 
dietary treatment (n=1) showed a normal apoC-III isoform distribution (Figure 4). 
Patients with unidentified CDG:  Figure 4 shows the apoC-III IEF analysis of two patients with 
unidentified CDG. Patient A has been classified as CDG-Iix on the basis of his transferrin 
isofocusing profile, which showed increased asialo, monosialo and disialotransferrin and 
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decreased tetrasialotransferrin. Thyroxine-binding globulin (TBG), another N-glycosylated 
plasma protein, also showed an abnormal isofocusing profile, confirming the generalized 
character of the defect in N-glycan biosynthesis in this patient. Plasma of this patient showed a 
normal apoC-III isoform distribution (lane 1 figure 4). Patient B has also been classified as 
CDG-IIx. Transferrin isofocusing showed that monosialo (8.6%; reference interval, 0.0-2.6%), 
disialo (22.7%; reference interval, 1.6–6.1%) and trisialotransferrin (28.8%; reference interval, 
2.5–15.6%) and decreased tetrasialotransferrin (32.6%; reference interval, 51.2–72.2%). TBG 
isoforms were also abnormal in this patient. Plasma of this patient showed increased apoC-III0 
(36.9%; reference interval, 0.0-11.6%) and decreased apoC-III2 (5.6%; reference interval, 27.4-
60.0%) (lane 2 figure 4). Apparently the genetic defect in this patient affects both N-glycan 
biosynthesis as well as mucin core 1 type O-glycan biosynthesis. 
 
Discussion 
 
Isofocusing of apoC-III is a simple and rapid technique that allows quantitative determination of 
the three apoC-III isoforms. Apoc-III isoforms from plasma may be used as markers for the 
biosynthesis of core 1 of mucin type O-glycans. This glycan type is widely expressed 
throughout the human body and is abundant in the nervous system; it is considered the most 
common type of O-glycan. Core 2 mucin type O-glycans are synthesized from unsubstituted 
core 1 mucin type O-glycans. A biosynthesis defect in unsubstituted core 1 O-glycans will also 
affect the synthesis of core 2 mucin type O-glycans. Alterations in mucin type O-glycan 
structure have been found in relation to cancer (15). Recently evidence was found for inborn 
errors of metabolism in the biosynthesis of O-glycans.  
Defects were found in mannosylated O-glycan biosynthesis in the Walker–Warburg and muscle-
eye-brain syndromes (7, 8) and in fucosylation of both N- and O-glycans in CDGIIc (9, 10). As 
yet there is no evidence for inborn errors in the biosynthesis of mucin type O-glycans.  
In this study we tested two patients with a firmly established but as yet unidentified N-glycan 
biosynthesis defect. We found an abnormal plasma transferrin isoform distribution in both 
patients on several occasions. These patients have a so-called type-II pattern with asialo-, 
monosialo-, and disialotransferrin isoforms overrepresented. This pattern predicts a defect in the 
Golgi part of N-glycan biosynthesis. Both also have an abnormal TBG isoform distribution. 
Because the primary defect in these patients has not been identified, both were diagnosed as 
CDG type IIx. In this study patient A showed a normal apoC-III isoform profile, whereas patient 
B showed a hypoglycosylation profile (Figure 4, lanes 1 and 2). From this we can conclude that 
the underlying defect causing the disease will be different in the two patients. Because apoC-III 
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is not N-glycosylated, it may be concluded that in patient B the O-glycan biosynthesis of the 
core 1 mucin type O-glycan is disturbed as well. After CDG-IIc this is the second inherited 
disease affecting the biosynthesis of both N- and O-glycans. It may be the first example of a 
patient with an inborn error of metabolism affecting the core 1 mucin type O-glycans. The 
primary defect in this patient remains unidentified, but it must be situated in one of the three 
biosynthetic stages indicated in Fig. 1. Gal and N-acetylneuraminic acid (NeuAc) are the only 
sugars implicated in the biosynthesis of both N-glycans and core 1 mucin type O-glycans; 
therefore, it is very likely that the genetic defect in patient B is situated in one of the three 
biosynthetic stages of one Gal or NeuAc.  
Many of the transferases involved in O-glycan biosynthesis are potentially N-glycosylated 
themselves (25). It is therefore an option that O-glycan biosynthesis would be secondarily 
affected in patients with a primary defect in N-glycan biosynthesis. However, the apoC-III 
profiles of patients with defined primary defects in N-glycan biosynthesis (CDG-Ia-, -Ib, -Ic, -Ie, 
-If, -IIa, and -IId) were all fully normal. It is therefore highly unlikely that the O-glycan 
abnormality in patient B is secondary to a defect in N-glycan biosynthesis.  
Patient A had a normal apoC-III isoform profile and an abnormal transferrin isoform profile. As 
a consequence, it is unlikely that the primary defect in this patient is situated in the biosynthesis, 
activation, or transport to the Golgi of Gal or NeuAc. It seems more likely that the defect in this 
patient is situated in the pathways for the N-glycan specific sugars Man, Glc, or GlcNAc. In 
addition, it may implicate the transferases that transfer Gal or NeuAc to the N-glycan because 
these enzymes are thought to be N-glycan specific. Our data suggest that apoC-III isoform 
testing may be a helpful step in the elucidation of the primary defect for the relatively large 
cohort of CDG type Ix and IIx cases present in the Euroglycan database that serves as a register 
for CDG patients (26). A preliminary study on this group showed that 12 of 25 cases had an 
abnormal apoC-III isoform profile in addition to their abnormal transferrin isoform distribution.  
In this study we also tested diseases and conditions leading to secondary N-glycan 
abnormalities. Among these are galactosemia, alcohol abuse, and HUS. A patient with classic 
galactosemia attributable to deficiency of galactose-1-phosphate uridyltransferase showed a 
normal apoC-III isofocusing profile before dietary treatment. The defect leads to the 
accumulation of galactose 1-phosphate. Transferrin hypoglycosylation in these patients may be 
attributable to direct inhibition of galactosyltransferase activity by the accumulated galactose 1-
phosphate or to an effect on the formation of UDP-galactose, the donorsubstrate in the reaction 
(27 ). Core 1 mucin type O-glycan biosynthesis also requires the availability of UDP-galactose 
in the Golgi. Because the apoC-III O-glycan could be normally synthesized, our data suggest 
that the abnormal N-glycans of plasma transferrin probably are not attributable to decreased 
availability of UDP-galactose. The β-1,4-galactosyltransferase (EC 2.4.1.38) involved in N-
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glycosylation differs from the β-1,3-galactosyltransferase (EC 2.4.1.122) involved in O-glycan 
biosynthesis of apoCIII (28 ). Our findings suggest that galactose 1-phosphate inhibits α-1,4-
galactosyltransferase but not β-1,3-galactosyltransferase in galactosemic patients.  
Secondary transferrin hypoglycosylation has been observed in HUS (29 ) and in chronic alcohol 
abuse (30, 31). Plasma apoC-III was hypoglycosylated in the acute phase of S. pneumoniae-
associated HUS in two patients. S. pneumoniae excretes neuraminidase, which catalyzes the 
hydrolysis of α2–3-, α2–6-, and α2–8-linked NeuAc residues from glycoproteins and 
oligosaccharides. The presence of neuraminidase activity in the plasma of patients with S. 
pneumoniae-associated HUS explains the abnormal isoform pattern of N-glycosylated proteins 
in the acute phase of the disease (29). The high percentage of apoC-III0 in plasma can be 
explained as a loss of sialic acid residues from the termini of apoC-III isoforms as a result of the 
action of circulating neuraminidase.  
Plasma samples from 12 patients with chronic alcohol abuse showed a normal apoC-III 
isofocusing profile. It is widely accepted that chronic ethanol consumption leads to 
hypoglycosylated plasma transferrin. The mechanism behind this N-glycan abnormality is still 
not well understood. Flahaut et al. (32) showed that the abnormal transferrin isofocusing profile 
is the result of the loss of an entire N-linked oligosaccharide and of an alteration in terminal 
sialylation. It has been suggested that ethanol intake alters the biosynthesis and/or transfer of the 
dolichol-oligosaccharide intermediates, leading to loss of the entire N-linked oligosaccharide. 
Alteration of terminal sialylation is suggested to be the result of decreased activity of 
sialyltransferase in the Golgi. Conversely, it has been suggested that ethanol consumption 
enhances the activity of sialidase, which can remove the terminal sialic acid residues from 
glycans. Because sialyltransferases involved in O- and N-glycosylation are specific, our data 
show that this latter hypothesis is less likely.  
It is quite likely that the negative change in pI in the protein found in a healthy volunteer was 
caused by a heterozygous polymorphism of apoC-III. Three polymorphisms have been described 
for apoC-III (33, 34). The observed charge heterogeneity could also result from causes such as 
phosphorylation, acetylation, and sulfation of the protein. The presence of such pI changes may 
hamper the interpretation of apoC-III isoform profiles. However, incubation with neuraminidase 
followed by isofocusing is an easy test to show that the abnormal profile in such cases derives 
from a variation in the protein part of the molecule and is not caused by an O-glycan 
abnormality.  
Further investigations on the biosynthesis of O-glycans are of great importance. O-glycan 
biosynthesis is very complex, with many different end products. It is very likely that further 
work in this field will solve the molecular basis of various human diseases or syndromes.  
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Abstract  
Congenital cutis laxa is a genetically heterogeneous condition presenting with loose and 
redundant skin folds, decreased elasticity of the skin, connective tissue involvement and a 
highly variable spectrum of associated features. The most common forms are inherited in an 
autosomal recessive or dominant fashion. Fibulin 5 and elastin mutations were detected in a 
limited number of patients, but in most cases the etiology is not known. Based on a previous 
observation of an abnormal transferrin isoelectric focusing pattern in a patient with cutis laxa 
indicating a N-glycosylation defect, we performed a screening for disorders of protein 
glycosylation in unrelated children with cutis laxa syndrome, including a recently developed test 
for defective O-glycosylation. Here, we describe five patients from consanguineous marriages 
with a cutis laxa syndrome with skeletal and joint involvement, developmental delay and 
neurological findings.  Three of these five children have an inborn error of glycan biosynthesis 
affecting the synthesis of both N-linked and O-linked glycans. Two patients had normal 
glycosylation patterns. All known causes of secondary glycosylation disorders were excluded in 
the children. No mutations were found in the FBLN5 gene. In conclusion, we have identified a 
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new combined glycosylation defect with a distinct clinical phenotype. Our results suggest that a 
combined defect of glycosylation might be a causative factor in congenital cutis laxa. This is the 
first report where abnormal N- and O-linked glycosylation is implicated in the etiology of cutis 
laxa syndrome.  
 
Introduction 
Cutis laxa syndrome is a rare, genetically heterogeneous condition1-4 presenting in the early 
months of life with loose and redundant skin folds mostly on the trunk and the extremities, and 
decreased elasticity of the skin.1,5,6 A highly variable spectrum of associated features7-11 has been 
reported. The skin histology characteristically demonstrates abnormal elastic fiber structure with 
a significantly decreased amount of elastin.5,6,12  The most common forms are inherited in an 
autosomal recessive or dominant fashion. (MIM 219200, 219100, MIM 123700, MIM 150240). 
Two distinct clinical types of autosomal recessive cutis laxa (ARCL) have been described in 
detail.  In ARCL type I (MIM 219100), congenital cutis laxa presents with a generalized 
disorder of the elastic tissue with diagphragmatic or other hernias, diverticula of the 
gastrointestinal or urinary tract and infantile emphysema.  The disease is often fatal within the 
first year. In this severe form, missense mutations have been detected in the fibulin-5 gene.1,3 
The phenotypic features observed in a fibulin-5 knockout mouse model are similar to those of 
the human ARCL type I.12  In patients with ARCL type II (MIM 219200), the cutis laxa is 
combined with widely patent anterior fontanel, a variety of malformations, retarded growth and 
abnormal development.7,8,11,13,14 Central nervous system anomalies and ophthalmologic findings 
are rare findings in ARCL type II.9,10  So far, the genetic etiology of ARCL type II is not known. 
Congenital defects of glycosylation (CDG) are a group of phenotypically diverse, multi-
systemic disorders caused by various enzyme defects of the N-glycan synthesis. The generally 
used screening method for CDG is transferrin isoelectric focusing (TIEF).15 In some of these 
patients, the underlying enzyme defect is not yet known.  During a systemic screening program 
for CDG in patients with multisystem disorders without a known etiology, we observed an 
abnormal TIEF patter, indicating an N-glycosylation defect (classified as CDG type Iix) in a 
patient with cutis laxa.  Based on this observation, we performed a metabolic evaluation for 
disorders of protein glycosylation (including N-glycan and 0-linked glycan biosynthesis) in 
further unrelated patients with cutis laxa and developmental delay. 
Apolipoprotein C-III (ApoC-III) isoelectric focusing (IEF) has recently been described as a new 
screening method for ‘core 1 mucin type O-glycans’.16   Defects of the O-glycan biosynthesis 
may also lead to clinically very distinct disorders.  Muscle-eye-brain disease and Walker-
Warburg syndrome17 have been identified as O-mannosylation disorders.  The progeriod type of 
Ehlers Danlos18 and multiple exostoses syndrome19 are due to biosynthesis defects in O-xylosyl-
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proteoglycans.  The gene underlying familial tumoral calcinosis encodes a glycosyltransferase 
responsible for initiating mucin-type O-glycosylation.20  
Here, we present three patients with a cutis laxa syndrome associated with skeletal and joint 
involvement, muscle hypotonia and developmental delay. Some of these patients had epilepsy 
and congenital brain malformations as well. Three out of the five children were found to have a 
defect affecting the biosynthesis of both the N- and the O-linked glycans.  
 
Case Reports  
The clinical and laboratory findings of five patients with cutis laxa syndrome are summarized in 
table 1. Here, we describe in detail the phenotype of the three patients (patients 1 – 3) with an 
inborn error of glycosylation.  
 
Table 1: Clinical features and laboratory findings in five patients with cutis laxa 
Clinical features∗ Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Consanguinity + + + + + 
Cutis laxa + ++ + + + 
Microcephaly ++ + + + - 
Large fontanel ++ ++ + - - 
Dysmorphic features + + + + + 
Motor developmental delay/hypotonia + ++ + + + 
Mental retardation + + + + + 
Seizures - ++ + - + 
Intracranial malformation - ++ + ++ - 
Congenital joint anomaly (deformation) + + + - - 
Hypermobile joints + + + + + 
Skeletal anomalies + + + - - 
Eye anomalies (strabismus, myopia) + + ++ + + 
Urogenital anomalies + - + - - 
Characteristic skin histology for cutis 
laxa 
+ + + + + 
Abnormal result of TIEF screening + + + - - 
Abnormal results of ApoC III screening + + + - - 
Fibulin 5 mutation - - - NA NA 
 
 (∗None of the patients had growth retardation, cardiac anomalies, lung emphysema, liver disease, endocrine  
or coagulation anomalies.) 
 +: feature is present  -: feature is absent  ++: feature is present in a pronounced form NA: not analyzed 
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Figure 1:      Family tree of the trhee patients (patients 1-3) with a combined glycosylation disorder 
 
Patient 1:  Patient 1 (Figure 1a) was born as the second child of healthy parents of Turkish 
origin, who were first cousins. The third offspring had nonimmune fetal hydrops and died at the 
20th week of the pregnancy. Our patient presented at term with a birthweight of 2730g (-2SD), a 
birth length of 47 cm (-2SD), microcephaly (HC: 31.0cm, -3.0SD), large fontanel (5.5x7 cm), 
brachycephaly, flat face, midfacial hypoplasia, anteverted nares, long phyltrum, neonatal teeth 
(left incisor), down-slanting palpebral fissures, strabismus, blue sclera, generalized cutis laxa 
and single umbilical artery. Additionally, hyperflexible joints, muscle hypotonia, 
cryptorchidism, and swallowing difficulties were reported. Cranial and abdominal ultrasound, 
EEG and a cranial MRI were normal. VEP and BAEP were both abnormal showing decreased 
conduction velocities. A skeletal survey showed luxated hypoplastic femur heads with hip 
dysplasia. Chromosome analysis, Hb, Htc, MCV, MCH, MCHC, cell counts, serum creatinine, 
BUN, uric acid, electrolytes, calcium, phosphurus, ALP, ASAT, ALAT, γGT, LDH, CK, 
cholesterol, TG, serum proteins, immunoglobulins, lactic acid, glucose, blood gas (ASTRUP), 
coagulation studies (APT, APTT, factor VII, VIII, IX, X, XI, XII, Protein C and S), alpha1-
antitrypsin, endocrine evaluation (TSH, free T4, throxine binding globulin (TBG), ACTH, GH, 
cortisol), markers for a possible infection and initial metabolic studies (serum amino-acid 
profile, acyl-carnitine profile, homocysteine, studies on cholesterol synthesis, phytanic acid, 
lysosomal enzymes, urine organic acid pattern, urine amino acids, purines/pyrimidines) were all 
normal. The skin histology showed a normal epidermis, homogeneous staining of the collagen 
bundles, with somewhat shorter collagen fibers, and the elastic fiber staining detected a 
rarefaction of elastic fibers, which were severely fragmented.  The electronmicroscopy showed a 
decreased elastic material.  Intact elastic fibers could not be observed. The fontanel was closed 
at the age of three years (length:101cm, + 1SD; weight: 18kg, OSD; HC: 46.5 cm, -2.5SD). At 
the age of 10 years, the patient (Figure 2a) had a normal growth with microcephaly (length: 
Patient 3 Patient 1 Patient 2 
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146cm, + 1SD; weight: 31kg, -1SD; HC: 49cm, -2.5SD). He wore hearing aids, showed a 
developmental delay (IQ 69) and followed special education.  He had mild hypotonia and a 
minimal hyperlaxity of the joints (the hip luxation was successfully operated). He showed a 
gradual improvement of the skin disease.  He continued to have a very dry skin but at ten years 
the cutis laxa was localized only in the abdominal region (Figure 2d).  
Patient 2: Patient 2 (Figure 1b) was born premature at 36 weeks of gestation as the first child of 
healthy parents of European origin, who were second cousins. She presented with a birth weight 
of 2250g (-2SD), length of 44cm (2-SD), microcephaly (HC: 29cm, -2.5SD), large fontanel (5 x 
6cm) brachycephaly, flat face, midfacial hypoplasia, anteverted nares, long philtrum, down-
slanting palpebral fissures, strabismus, a generalized severe cutis laxa, dry skin, sparse hair, pes 
adductus, hyperflexible joints, muscle hypotonia and feeding difficulties. Abdominal ultrasound 
and echocardiography were normal. From the age of five months (Figure 3a) she received 
anticonvulsive medication due to a West syndrome and abnormal EEG. A cranial MRI at the 
age of 2,5 years showed bilateral pachygyria (Figure 4a). VEP and BAEP were normal. A 
skeletal survey showed a large, open fontanel, narrow pelvis and generalized osteopenia. She 
had recurrent urinary infections and a gastro-esophageal reflux. Chromosome analysis and blood 
and urine analysis including initial metabolic analysis (see Patient 1) were all normal. The skin 
histology showed a normal epidermis, increased subcutaneous fat and homogeneous staining of 
the collagen bundles; the Weigert elastic fiber technique detected a rarefaction of elastic fibers, 
which were short and fragmented.  Intact leastic fibers could not be observed. The Western 
blotting for collagens and procollaens was normal. Electronmicroscopy showed decreased 
elastic material. 
The patient had no significant feeding problems at the age of 3 years (Figure 3c) and showed a 
normal growth with a microcephaly (HC: 45.5cm, -2.5SD). Her fontanel was closed at the age 
of 2.5 years. At the age of 7.5 years our patient (Figures 2b and 3d) was severely retarded, but 
able to communicate and very social. Her growth was age appropriate (length: 122.5cm, -1SD; 
weight: 22.5kg, -1SD) with a microcephaly (HC: 47, -2.5SD) and psycho-motor developmental 
delay (IQ 52).  She walked clumsy but without help. She had a significant improvement of the 
cutis laxa with a mostly abdominal localization (Figure 3b-d), a very dry skin, and gluteal fat-
pads (Figure 2e). 
Patient 3: Patient 3 (Figure 1c) was born as the first, child of healthy parents of Turkish origin, 
who were first cousins. The patient presented at term with a birth weight of 3605g (+1SD), 
length of 53cm (+1SD), microcephaly (31.5, -2.5SD), large fontanel (4.5x5 cm), flat face, 
midfacial hypoplasia, anteverted nares, down-slanting palpebral fissures, strabismus, 
generalized cutis laxa, club feet, bilateral clinodactyly of the IVth fingers, hyperflexible joints 
and muscle hypotonia. She had recurrent urinary tract infections. A mild bilateral 
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hydronephrosis was found by an abdominal ultrasound.  Further studies detected bilateral pyelo-
urethral stenosis. The echocardiography was normal. From as early as the second day of life she 
suffered from tonic clonic seizures, the EEG was abnormal and she was started on 
anticonvulsive therapy. A cranial MRI showed a partial, bilateral fronto-temporal pachygyria 
(Figure 4b). She was diagnosed with a myopia of 5.5 dioptries. VEP showed decreased 
conduction velocities. BAEP was normal. A skeletal survey showed a large, open fontanel and 
hypoplastic iliac wings and acetabulae. Chromosome analysis and blood and urine analysis 
including initial metabolic analysis (see Patient 1) were all normal.  The skin histology showed 
a slight hyperkeratosis; the Gleason staining detected shorter and thin collagen fibers and the 
elastic fibers were short, scattered and severely fragmented. Electronmicroscopy showed a 
severe decrease in the amount of elastic fibers.  The fibers present were all abnormal in 
structure. The patient at the age of 3 years had no feeding problems, showed a normal growth 
and microcephaly (length: 98cm, + 0.5SD; weight: 16kg, + 1SD; HC: 46.0cm, - 2SD).  Her 
fontanel was closed at the age of 2 years.  She had a developmental delay and speech delay; she 
started to walk at 15 months of age, but could not speak till the age of 22 months and she had 
muscle hypotonia, significant hyperlaxity of the joints and cutis laxa.  At the age of 4 years 
(Figure 2c), she still had generalized cutis laxa (Figure 2f), hyperelastic joints, hypotonia and a 
developmental delay (IQ 59). 
Patient 4: The clinical phenotype of patient 4 (see Table 1) has been described in detail earlier.9  
Patient 5: Patient 5 had a mild intrauterine growth retardation, severe congenital generalized 
cutis laxa with joint hyperlaxity, psychomotor retardation, hypotonia, epilepsy, transient feeding 
problems and normal gowth after the first year of life. He had no microcephaly or brain 
malformations (see Table 1). 
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Figure 2:      Patient 1: facial features with down-slanting palpebral fissures, midfacial hypoplasia, long filtrum (a) and mild 
abdominal cutis laxa (d) at the age of 10 years.  Patient 2: characteristic facial features with high forehead, down-
slanging palpebral fissures, midfacial hypoplasia (b)         
and gluteal fat-pads (e) at the age of  seven years.   
   Patient 3: facial features with down-slanting palpebral fissures, midfacial hypoplasia and facial cutis laxa at the    
  age of 3 years (c), and cutis laxa on the extremities at the age of 3.5 years (f). 
 
 
 
                                              
Figure 3:      Evolving phenotype in patient 2 showing an improvement of the skin symptoms at the age of 5 months (a),  
 18 months (b), 3.5 years (c) and 7 years (d) 
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Figure 4:     Cranial MRI picture of patient 2 with bilateral pachygyria (a) and patient 3 with mild partial fronto-temporal  
                    pachygyria in the sagittal and vertical view (b). 
 
Methods  
 
Patient selection 
Metabolic screening for inborn errors of protein glycosylation was performed in five patients 
with cutis laxa syndrome, consecutively diagnosed in the neonatal period. These unrelated 
patients were all born from consanguineous marriages. The clinical features are summarized in 
Table 1. 
 
Sample preparation for isoelectric focusing of apoC-III, transferrin and 
TBG  
After centrifugation for cell separation, plasma and/or serum samples were stored without delay 
at –80°C until analysis. Samples used for IEF of apolipoprotein C-III (apoC-III) were diluted 
10-fold with saline. Samples used for TIEF were saturated with a 10 mM ferric citrate and 0.5 
mM sodium hydrogen carbonate solution (2:1) in a ratio of 10:3 for 30 minutes. This saturated 
plasma sample is diluted 5 times with water. 
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IEF of apoC-III 
ApoC-III is a mucin type core I O-glycosylated plasma protein. In control samples equal 
amounts of disialo and monosialo isoforms are present with only a very small amount of asialo-
apoC-III. 
IEF of apoC-III was carried out as described by Wopereis et al .16 Plasma was separated on a 
hydrated dry IEF gel (pH 3.5 – 5.0 and 8M urea) on a Phastsystem. After IEF, a Western blot 
was performed. The apoC-III isoforms were specified by adding rabbit anti-human apoC-III 
antibody and visualized by electrochemiluminescence. The relative amounts of apoC-III 
isoforms were determined using densitometry. 
 
IEF of transferrin 
Transferrin is an N-glycosylated protein. Multiple isoforms occur in plasma, with the tetrasialo 
isoform being the most abundant. Transferrin isofocusing is used as a screening method for the 
detection of abnormally high amount of asialo, monosialo disialo and trisialo isoforms in N-
glycan biosynthesis defects. 
TIEF was carried out essentially as described.21 Iron-saturated plasma or serum was separated 
on a hydrated immobiline gel (pH 4-7) on a Ultraphore system (Amersham Pharmacia Biotech). 
After IEF, the isoforms were visualized by adding rabbit anti human transferrin antibodies 
(Dako, Glostrup, Denmark) and stained with Coomassie blue. The relative amounts of isoforms 
were scanned using an Image master Labscan, Ver. 3.00 (Amersham Pharmacia Biotech) and 
quantified using Image master 1D gel analysis, Ver. 4.10, software (Amersham Pharmacia 
Biotech).  
 
IEF of TBG 
Pure plasma was applied to a Phastgel pH 4-6.5 (Amersham Pharmacia Biotech) and analyzed 
using the Phastsystem. After addition of rabbit TBG antibody (Dako), the TBG pattern was 
detected by silver staining. 
 
Mutation analysis of FBLN5 
Genomic DNA was isolated from cultured dermal fibroblasts of patients 1 and 2 and from 
leukocytes of patient 3. Mutation analysis of the FBLN5 gene was performed as described by 
Loeys et al .3 
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Results  
 
Transferrin and TBG isofocusing 
Plasma samples of patients 1 - 3 showed reproducibly an abnormal isofocusing pattern with a 
decrease of the tetrasialotransferrin isoforms but increase of hypoglycosylated transferrin 
isoforms (tri-, di- and monosialilated isoform) (Figure 5a). TBG isoforms were also abnormal, 
confirming a generalized defect in N-glycosylation (data not shown).  All known causes of 
secondary glycosylation disorders wre excluded in the three children.  These three patients were 
classified as having an unidentified CDG type II suggesting a defect in glycan biosynthesis in 
the Golgi.  
The IEF patterns in patients 4 and 5 were repeatedly normal. 
 
ApoC-III isofocusing 
Plasma and/or serum samples of patients 1 – 3 showed an abnormal isofocusing profile for 
apoC-III (Figure 5b) in duplicate over a period of a year. All three patients had increased levels 
of apoC-III1, decreased apoC-III2 and normal apoC-III0. (patient 1: apoC-III1: 73%, controls: 33-
67%; apoC-III2 16%, apoC-III0: 11%, controls: 0-12%;  patient 2: apoC-III1: 76%, controls: 33-
67%; apoC-III2: 14%, controls: 27-60%; apoC-III0: 10%, controls: 0-12%; patient 3: apoC-III1: 
86%, controls: 33-67%; apoC-III2: 8%, controls: 27-60%; apoC-III0: 6%, controls: 0-12%).The 
apo C-III IEF patterns in patients 4 and 5 were normal.  
 
Mutation analysis of FBLN5 
No mutations were performed in the FBLN5 gene in the cutis laxa patients with abnormal 
glycosylation profiles. 
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Figure 5:  IEF results: Abnormal transferrin pattern with decreased tetra-sialotransferrin and increased hypoglycosylated tri-, 
 di- and monosialilated transferrin isoforms (a) and abnormal apoC-III pattern with increased levels of apoC-III1, 
 decreased levels of  apoC-III2 and normal apoC-III0 in patients 1 - 3 (b). 
Discussion 
We performed a metabolic evaluation for glycosylation disorders in five unrelated patients with 
cutis laxa syndrome. We found three patients out of the five with the clinical presentation of 
cutis laxa syndrome and developmental delay who were diagnosed with an inborn error of 
metabolism affecting N- and O-glycan synthesis. All known causes of secondary CDG forms 
were excluded by appropriate measures.   
The patients with the combined glycosylation defect presented with a phenotype similar to that 
of ARCL type II (generalized cutis laxa, mental retardation, microcephaly, late closure of the 
fontanel, joint laxity). However, some features, like the bilateral urethral-pelvic stenosis and 
vesico-urethral reflux in patient 3 support the presence of urethral-wall involvement, which is 
more characteristic for ARCL type I.  
The presence of seizures, found in two of these three patients with glycan abnormalities and in 
one with normal IEF patterns, is not characteristic in cutis laxa syndrome, but common in CDG  
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syndrome.15 Structural abnormalities of the brain occur frequently in CDGS as well. The finding 
of pachygyria as in patient 2 and 3 is a rare observation in cutis laxa patients. However, 
pachygyria have been reported in children with O-glycan biosynthesis defects16 supporting the 
importance of glycosylation in normal brain development. 
There was obvious difference observed in the severity of the cutis laxa at birth (with the most 
severe phenotype in patient 2), but all of the children showed a significant improvement of the 
skin symptoms at an older age. Based on some of the phenotypical overlap observed in these 
children with a glycosylation defect and in patients with known fibulin mutations, our findings 
further support the presence of genetic heterogeneity in cutis laxa syndrome. 
Cutis laxa syndrome is a congenital disorder with major structural and functional defects of the 
elastic fiber system. Elastin is a nonglycosylated extracellular matrix (ECM) protein found in 
vasculature, lung, skin and connective tissue. Crosslinked elastin can be found in association 
with several microfibril-associated glycoproteins like fibrillin-1, fibrillin-2, fibronectin or 
fibulin-1 and fibulin-5 suggesting that these proteins contribute to elastic fiber assembly, 
structure and function.22-24 In the ECM, the final structure and adequate function of collagen and 
elastin fibers are dependent on the perfect function and anchoring of these essential matrix 
glycoprotein molecules. 
Fibulins are widely expressed secretory glycoproteins with a complex structure including N- and 
0-glycosylated sites and are present in the basement membranes and the stroma of most 
tissues.12,24-26 Their have been implicated in organogenesis and vasculogenesis.22,25 In fibuline 
knockout mice, fragmented elastin can be detected in different tissues without an increase of 
elastase activity, indicating a defective development of elastic fibres, similar to that in cutis laxa 
syndromes.12   In some patients with ARCL type I and in a large family with a dominant form of 
cutis laxa, mutations have been detected in the fibulin 5 gene.1-3 
An inborn error of metabolism leading to a combined defect of N- and O-glycosylation might 
alter the structure and therefore the function of several ECM glycoproteins, like fibulin 5. This 
may cause developmental defects already in the early embryonic period and lead to abnormal 
structure and malfunction of different tissues and organs. In the three patients described here 
with a cutis laxa syndrome, the combined N- and O-linked glycosylation defect might explain 
the presence of the characteristic phenotype without a fibulin 5 gene-mutation, and the presence 
of features overlapping with other syndromes with N- or O-glycosylation defects.  However, in 
the absence of an evident enzyme deficiency, the primary defect remains speculative.27 
Recently Wu et al 28 described patients with a lethal form of CDG syndrome and a defect in the 
COG7 subunit of the COG complex (conserved oligomeric Golgi complex).  Disruption of this 
complex caused by COG7 deficiency leads to abnormal localization of enzymes and transporters 
resulting in severe hypoglycosylation of glycoproteins.  The defect also affects both N- and O-
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glycosylation.  These patients had a multisystem disease with neurological involvement, and 
wrinkled skin. The partial phenotypic overlap with the three cutis laxa cases further delineates 
the importance of 0-linked protein glycosylation in the normal skin structure and brain 
development.  The sub-units of COG complex and other proteins, associated with the 
cytoplasmic surface of the Golgi apparatus, and involved in intracellular trafficking, are among 
the candidate proteins for the primary defect in our cutis laxa patients.   
Our findings support the presence of a new cutis laxa syndrome, based on an inborn error of 
glycan biosynthesis.  We suggest that all patients with cutis laxa syndrome, especially with 
microcephaly, late closure of the fontanels and associated features of the central nervous system, 
should be screened for glycosylation defections. 
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Chapter 7 
Congenital Disorders of Glycosylation:                               
Remarks and Future Directions 
Defects in glycosylation are becoming increasingly associated with a range of human diseases. 
In some cases, the disease is caused by glycosylation defects as in CDG, whereas in others, the 
aberrant glycosylation may be a consequence of a disease.  
The challenges for researchers in the field of glycosylation defects are manifold and areas for 
future activity will be focused on, I. the development of new screening techniques, II. 
identification of new gene defects, III. extended studies for increasing the understanding of the 
pathomechanisms and IV. the development of treatment options.  
 
I.  Development of new screening techniques 
For many years, isoelectric focusing of transferrin has been the gold standard as a screening test 
for CDG patients. Different additional methods have been used to determine the N-
glycosylation of transferrin, such as capillary zone electrophoresis, (Carchon, Chevigne et al. 
2004), HPLC (Helander, Bergstrom et al. 2004) or SELDI-TOF-MS after immunocapture on 
protein chip arrays (Mills et al, 2006). IEF has been / and is a very helpful tool, as it is a robust 
method, needing only a small sample volume and is comparably very cheap. But IEF is labour-
intensive and time- consuming and not suitable for automation. Not all CDG subtypes can be 
detected with this test (Volker, De Praeter et al. 2002) and cases have been missed (Fletcher, 
Matthijs et al. 2000).  
Moreover, the test will obviously only identify patients with abnormal glycosylation of an N-
glycoprotein – and, therefore, already O-glycosylation defects will not be picked up. For the 
time being, only one screening test for O-glycosylation defects by IEF has been described, using 
apolipoprotein CIII (apoCIII) as the marker molecule (Wopereis, Morava et al. 2005). ApoCIII 
is a core 1-O-glycoprotein and, therefore, this test can only detect core 1 defects of the mucin 
type O-glycosylation pathway. However, with a combination of IEF and sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) CDG-IIx patients could be further 
subdivided into six biochemical subgroups. This drastically narrowed down the candidate genes 
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for the definition of new CDG defects (Wopereis et al, 2005). This screening test will and 
should be applied to a much broader patient population to help to unravel further inborn errors 
in O-glycan synthesis. As mucin type O- glycans are abundant in the gastrointestinal, 
tracheobronchial and reproductive tract and O-glycans play an important role in the formation 
of the ABO blood group antigens and, during immune responses, patients presenting with 
unexplained symptoms related to these systems should be primarily investigated. So far, only 
one disorder with a genetic defect in the biosynthesis of mucin type O-glycans has been 
described: mutations in N-acetylgalactosaminyltransferase 3 (GALTN3) cause familial tumoral 
calcinosis (FTC) (Topaz, Shurman et al. 2004).  
In the future, it will be advisable to set up a cocktail of glycoproteins to be investigated in 
parallel, covering different N-glycoproteins derived from different tissues and including 
representatives of the variable O-glycan structures. High throughput and robust methods are 
needed and abnormal glycosylation should be investigated by changes of charge and mass. 
Special attention in setting up new tests should be given to the fact that glycosylation is a very 
dynamic process and might be tissue-specific. 
For all CDG patients, once identified, the final diagnosis has to be confirmed by measuring 
enzyme activities and subsequent mutation studies. As the superfamily of CDG is growing 
continuously, automatisation of mutational screening should be set up to look for mutations in 
known genes, especially in CDG types, where enzyme assays are particularly difficult or not 
available: a DHPLC platform profiling as a sensitive, rapid and efficient service for defective 
glycosylation genes has already been evaluated (Schollen, Martens et al. 2002) ( Schollen et al, 
2005).   
 
II.  Identification of new gene defects 
 
The human genome contains of as little as 20,000 to 25,000 protein coding genes and 2-3% of 
its transcripts are probably devoted to the synthesis and recognition of glycans (Varki and Marth 
1995) (International Human Genome Sequencing). This underlines the importance of 
glycosylation in man, which has also received dramatic support from the recent elucidation of 
the biochemical and genetic causes of several subtypes of congenital disorders of glycosylation 
(CDG).  Most of the CDG type I genes have been identified, based on protein homology with 
yeast enzymes. The correct functional activity has been proven by direct enzyme analysis or 
complementation assays in yeast or human deficient cell lines (Aebi and Hennet 2001). The 
existence of homologues, such as for PMM (Heykants, Schollen et al. 2001) however can 
complicate matters. Moreover, there are enzymes involved in the glycosylation pathway without 
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an existing yeast homologue: the flippase MPDU1 for example could only be identified in 
studies of CHO cell studies, deficient in the utilisation of dol-P-Man (Lec35) (Schenk 2001).  
 
The implementation of highly sensitive and rapid mass spectrometric screening strategies for 
glycan profiling, is revealing valuable insights into the disease. Performing detailed glycan 
analysis has proven to be a very successful strategy to provide a basis for diagnosis, 
investigating the cause of aberrant glycosylation, identifying potential candidate genes, and 
bringing a deeper insight into the pathogenesis (Mills, Mills et al. 2001; Mills, Mills et al. 
2003), (Butler, Quelhas et al. 2003) (M. Butler et al 2003). Glycoproteomics of N-glycosylation 
has been applied to various CDG patients’ samples using modern mass-spectrometry 
instruments, obtaining information on mass, sequences and linkage positions of N-glycans 
(Mills et al, 2006), (Sagi, Kienz et al. 2005). It will be a superior strategy, not only as a 
screening test for CDG, but in the identification of strong candidate genes.  
 
III.  Extended studies for increasing the understanding of the pathomechanisms 
 
Glycobiology deals with the nature and role of carbohydrates in biological events. The last 
decade has witnessed an exponential interest in the association of oligosaccharides with disease 
mechanisms. It is obvious, that any disruption of the glycosylation machinery will affect the 
biological function of various glycoproteins. The clinical consequences have been extensively 
reported in the field of primary glycosylation diseases such as CDG, characterised as generalised 
glycosylation defects. Although more than 700 patients will have been identified so far, there is 
still a huge lack in the understanding of the underlying pathogenesis of the variable signs and 
symptoms. For example, hypergonadotropic hypogonadism has been reported in CDG-Ia 
females. It is still not known if the hormonal deficiency is due to underglycosylation of 
releasing hormones, peripheral hormones, possible dysglycosylation of hormone receptors or 
even other factors. Interestingly, female patients with galactosaemia – a secondary glycosylation 
defect – show similar hormonal deficiency (Leslie 2003). It is very interesting to learn, that 
supplementation with rFSH in a woman with classical galactosaemia and ovarian failure 
resulted in a pregnancy (Menezo, Lescaille et al. 2004).  Future work, therefore, should 
characterise the glycosylation pattern of factors in that feedback pathway.    
Additional important insights arose from the work on other secondary glycosylation defects: in 
rheumatoid arthritis it could be shown, that differential expression of galactosyltransferase 
isoforms results in a profound change in the galactosylation of immunglobulin G, integrally 
associated with the inflammation process. It has been hypothesised, that there is a disruption of 
the regulatory mechanism controlling the galactosylation activity (Alavi et al, 2005). It seems, 
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therefore, important to characterise the secondary changes of glycosylation patterns of signal 
transduction molecules, the mediators in inflammatory processes etc. This work could 
eventually identify disease-specific markers that could possibly be used to monitor disease 
progression as well. Comparable studies will be important for patients with primary 
glycosylation defects with the aim of identifying specific biomarkers.   
For one new CDG family branch, the muscular dystrophies due to O-glycanopathies, there is 
already a much better understanding of the pathogenesis: a disruption of the dystroglycan 
complex interactions with the extracellular matrix partners, gives rise to both,  progressive 
muscle degeneration and abnormal neuronal migration in the brain (Muntoni 2004). Only very 
recently, the metabolic defect was identified revealing the basis of this disease group as in 
defective O-glycosylation. Dystroglyconopathies are a very interesting example for tissue- 
specific glycosylation abnormalities and profiling tissue specific glycosylation patterns of target 
glycoproteins will enable us to identify new diseases and will increase our understanding of the 
pathogenesis of signs and symptoms in patients affected by N- and/or O-glycosylation defects. 
 
Very exciting new techniques are under development to define simultaneously the tissue-
specific expression of hundreds of different genes involved in the glycosylation pathway: arrays 
to generate glycogene-expression profiles in different tissues are on their way. In a murine 
model, it has been shown, that the biosynthetic enzymes in these pathways are ubiquitously 
expressed, whereas glycosyltransferases elaborating terminal structures are expressed in a highly 
tissue specific manner. These analyses will provide exciting insights into the extent of 
transcriptional regulation of glycosylation (Comelli, Amado et al. 2002). 
 
Animal models for CDG defects will be of great value, even though, they may show phenotypic 
changes that differ from the human clinical presentation. They will be of tremendous 
importance as, hopefully, disease progression can be analysed. So far, only very few mouse 
models of CDG subtypes have been generated. Ablation of the gene for several glycosylation 
enzymes has been shown to be lethal, as for CDG Ia (Korner C, personal communication) and Ib 
(DeRossi 2005). The CDG IIa mouse model (Mgat2-null mice), deficient in GlcNAcT-II 
enzyme activity and complex N-glycan synthesis, presents with severe gastrointestinal, 
haematologic and osteogenic abnormalities. All mutant mice died in early post-natal 
development. However, crossing the Mgat2 mutation into a distinct genetic background resulted 
in a low frequency of survivors exhibiting additional and novel disease signs of CDG-IIa. Pre-
natal defects appear in a significant number of embryos, and likely reflect a limited window of 
time in which a future therapeutic approach might effectively operate (Wang, Schachter et al. 
2002).  
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IV.  Development of treatment options 
 
Up to now, treatment is only available for very few patients with CDG: patients with CDG-Ib 
treated with oral mannose have shown significant improvement (Niehues, Hasilik et al. 1998) 
which emphasises the importance of recognising these patients early. In patients with a GDP-
fucose transporter defect, fucose improved the fucosylation of glycoproteins and reduced 
recurrent infections (Marquardt, Luhn et al. 1999).  
Two interesting avenues for a possible treatment option for CDG Ia have very recently been 
described: Mutations in phosphomannomutase (PMM2) cause CDG-Ia by reducing the activity 
of PMM, which converts mannose (Man)-6-P to Man-1-P before formation of GDP-Man. These 
patients have reduced Man-1-P and GDP-Man levels. Oral or intravenous mannose treatment 
has been shown to be unsuccessful in CDG Ia, as there is insufficient uptake into the cells. The 
first treatment option to be further explored is to treat patients with metformin: metformin 
stimulates D-mannose transport (MSMT) and increases a mannose uptake by 1.8-fold in 
fibroblasts of CDG-Ia patients (Shang and Lehrman 2004). However, the effect on patients still 
has to be shown.  
The more direct approach is currently being explored by the group of Freeze et al: to replenish 
the intracellular Man-1-P pools in CDG-Ia cells, two hydrophobic, membrane-permeable 
acylated versions of Man-1-P were synthesised and their ability to normalize LLO size and N-
glycosylation in CDG-Ia fibroblasts was determined. Both compounds normalised truncated 
LLO with different efficiency. Moreover, supplementation to CDG Ie cells also corrected 
impaired LLO biosynthesis and partially corrected LLO in cells from an ALG12 
mannosyltransferase-deficient patient (CDG-Ig). However glycosylation in cells from an ALG3-
deficient patient (CDG-Id) and from an MPDU1-deficient patient (CDG-If) could not be 
corrected (DeRossi et al, 2005). These results validate the general concept of using pro-Man-1-P 
substrates as potential therapeutics for CDG-I patients and need to be further explored.  
Experiences in diseases with secondary abnormal glycosylation patterns might be important to 
evaluate: altered terminal glycosylation (increased fucosylation and decreased sialylation) of the 
cystic fibrosis transmembrane conductance regulator (CFTR) is a biochemical hallmark of 
cystic fibrosis and expression of wtCFTR in CF airway epithelial cells modulated the abnormal 
glycosylation pathway of the cells (Scanlin and Glick 2000). It had been concluded, that most 
probably the compartmentalisation of glycosyltransferases in the Golgi-apparatus is affected by 
CFTR (Rhim, Stoykova et al. 2004). Pseudomonas aeruginosa is the major pathogen in CF and 
it has been shown, that PA-IIL, a P. aeruginosa lectin “docks” to terminal alpha 1,3 fucose 
containing carbohydrate motifs on CF airway epithelial cells, which might explain the high 
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incidence of P. aeruginosa infections in cells presenting the CF glycophenotype (Rhim 2004). 
“Glycomimetic blockade” therapy will have to be proven to be an effective, targeted therapy. 
Hyperfucosylation has also been shown in CDG type I and in secondary glycosylation defects, 
such as galactosaemia (Mills, Mills et al. 2001), (Callewaert, Schollen et al. 2003). Both patient 
groups, especially when they are young, seem to be especially prone to develop overwhelming 
illnesses, bacterial infections, pleural and pericardial effusions and ascites. If hyperfucosylation 
in CDG and galactosaemia causes the susceptibility for these life-threatening illnesses, 
pharmacologically reduction of fucosylation or glycomimetic blockade could be a future 
effective and targeted therapy in CDG.   
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CDG overview for parents 
The congenital disorders of glycosylation (CDG), formerly called the carbohydrate deficient 
glycoprotein syndromes, are a large family of inherited disorders that affect the glycosylation of 
protein. Glycosylation is a process whereby human cells build up, stepwise, long sugar chains 
called glycans that are then attached to a protein.  The glycans, together with the proteins, are 
called glycoproteins.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Have a look at the picture: imagine you have a factory and the end product is a sugar tree that 
has been built up stepwise on the production line.  Only when the structures are normally 
completed can they be transferred to the van (stands for the protein).  If anybody in the factory 
is not working properly, the process will be stopped and the end product is an incomplete 
building block, which cannot be properly transferred to the protein or will only be transferred in 
very small quantities.   
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More than 100 enzymatic steps (the factory worker, operating each step in the production line in 
our picture) are involved in the glycosylation pathway. Inborn errors of this pathway are called 
congenital disorder of glycosylation (CDG).  
 
Glycoproteins have many important functions in the human body and might act as hormones, 
enzymes or receptors and they are required for normal growth. Essentially, glycoproteins are 
important for the function of all tissues in the human body.   
In patients with CDG one of these many glycosylation enzymes in the pathway is deficient and 
so far 19 different types of CDG have been identified. All these diseases have in common that a 
poorly formed glycoprotein with incorrect sugar chains attached can no longer function in the 
proper way.    
 
 
 
 
 
 
 
 
This causes problems in many different systems, such as muscle, skin, bones, nerves and central 
nervous system. Professor Jaeken, a Paediatrician from Leuven in Belgium, first described two 
children with CDG syndrome about 25 years ago.  They belong actually to the most common 
group of CDG, which is CDG-Ia.  The two children presented with what we could call the 
classical features of CDG-Ia, that is, inverted nipples and peculiar fat pads, difficulty in putting 
on weight (failure to thrive) and part of their brain was too small (cerebellar hypoplasia).   
 
How do we find children who are affected?  Professor Jaeken set up a very powerful screening 
method for CDG with the Belgian group in 1994.  This used transferrin, which we have in a 
substantial amount in our blood.  Transferrin is, in fact, a glycoprotein with two glycan trees 
attached to the protein and the terminal sugar of these branched glycans is sialic acid.  
 
 
 
 
 
 Normal  
 
Defective  
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    Normal   CDG-I  CDG-I CDG-II 
 
 
The most abundant band we get in a normal patient is the “4” band.  In CDG patients that band 
might be reduced and additional bands such as the “3” or “2” band can be seen. The beauty of 
the screening test is that it can detect whether the glycans of the CDG patient are not made up 
correctly. The answer we get back from this test is, therefore, whether there is insufficient 
glycosylation, and it makes it even possible to distinguish two different CDG types, which we 
call CDG Type I (disorders in the early glycosylation pathway) and CDG Type 2 (defects in the 
late glycosylation pathway).  Once the isoelectric focusing test is abnormal, further tests are 
required to identify the precise enzymatic defect.   
 
This screening test (isoelectric focusing of transferrin) is very powerful.  However, we know 
about some pitfalls, and some parents unfortunately have encountered this problem.  First of all, 
we do know from work by my colleague, Professor Clayton, that you can get false negative 
results if the test is performed too early in childhood.  Up to six weeks of age one can get false 
negative reports.  Secondly, other metabolic diseases, which might influence the building up of 
sugar trees, can give an abnormal isoelectric focusing pattern as well, such as galactosaemia, and 
it is very important for the clinicians to rule out these secondary effects before they can tell the 
parents “we think your child has a CDG disorder”.  The clinician then will need further samples 
from the child and might need to take more blood and a skin biopsy. The reason for that is, that 
we need to find the precise problem in the patient’s glycosylation pathway. This is what CDG is 
all about.  So, with the additional samples, we hope to identify exactly where the stop at the 
production line is and can name the specific enzyme deficiency and therefore the CDG subtype. 
This is even more important, as it not only enables us to name exactly the diagnosis for the 
4 
2 
0 
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patient, but also we might be able to offer prenatal diagnosis for future pregnancies in these 
families. CDG is a recessive inherited disease, which means, there is a 1:4 risk for the families 
having another affected baby. 
 
Once we have established the diagnosis, the next question asked by parents is usually, “what is 
going to happen to my child”?  As mentioned before, CDG-Ia is the most common subtype we 
diagnose and we know about 700 patients worldwide.  It is important to mention, that even in 
this one subtype of CDG, patients can present quite differently and may be more or less severely 
affected.  Gathering as much information as possible about the known CDG-Ia patients, we have 
learnt over the years: CDG-Ia has a huge variation in clinical presentation. So, in the following, 
I can only talk about the “classical” CDG-Ia child and families with these children have taught 
us that there might be surprisingly different outcomes.   
In general, we should talk about three different age groups. Although we do know adult patients 
with CDG-Ia, we have more experience with what happens to the young ones. It is important to 
go through the different age groups because CDG patients have different problems.  The 
classical symptom for CDG-Ia newborns and toddlers is that they are quite floppy and it is 
difficult for them to put on weight, so that a lot of the children are helped by tube-feeding.  
Some of them show early abnormal eye movements and a squint, which might correct itself with 
time.  
When the children become a little bit older, they are prone to become suddenly quite sick and 
can quickly get critically ill. This can happen when suffering from normal children’s diseases, 
such as chicken pox or other infections. Quite often, we cannot even explain why they run into 
such problems and, very unfortunately, I have to say we still lose our young CDG-Ia patients to 
these overwhelming illnesses.   
When CDG-Ia children become older, it becomes more and more apparent that they have some 
problems with their neurological development and most of them present with mental retardation 
but to a differing degree.  A lot of CDG-Ia patients have problems with their speech: however, 
their understanding is much better than their expressive language. Therefore, we have started to 
use speech computers for some of the patients with very good success.   
 
Although communication is difficult, the children are able to have very good social contact, 
have very charming personalities and have a strong will. They have very good memory and put 
much energy into learning new things. Some of the children might develop convulsions and 
suffer from stroke-like episodes. Fortunately, once they get older things seem to stabilise and 
acute illnesses become less frequent. Because the children are classically born with a small 
cerebellum, which is important to coordinate their body movements, it is difficult for the CDG-
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Ia children to learn to stand up and walk and some children are, at least for a prolonged period, 
wheelchair bound.  Years ago we said that CDG-Ia children would not learn to walk and it is 
wonderful that we have been proven wrong by some of our families. This has actually also been 
seen in the twins that Professor Jaeken described back in 1978, who have now grown up.  They 
have moderate mental retardation and they live together with their parents. They go to work 
every day, coming back in the evening; they have problems with moving around and are in a 
wheelchair when they are outside, but they can, with help, move around inside their house 
themselves. Other adult patients, like German twins at the age of 34 years, have developed some 
eye problems called retinitis pigmentosa and they need glasses for light protection. Another 
peculiar observation is, that especially the CDG girls hardly develop any pubertal signs and 
might not develop their breasts and pubic hair.  The underlying problem is an incorrect 
regulation of the hormones, which we call hypergonadatrophic hypogonadism and the older 
CDG children need appropriate treatment.   
 
It can be a challenge to identify the milder CDG Type Ia cases and patients might only be 
picked up because doctors specifically thought about CDG, as in the following case; a little girl 
presented to the hospital with some level of floppiness (muscular hypotonia) and squint 
(strabismus) and came for an eye operation.  Because she had some abnormal clotting factors 
(which are also glycoproteins), CDG was considered and the diagnosis of CDG-Ia was 
established.  This child, goes to a normal school and only needs some minor additional help.  
Sometimes we pick up very mild cases only because there is somebody else in the family who is 
much more affected, as in a little Spanish girl, who was the cousin of a boy with severe 
psychomotor delay and epilepsy and again clotting problems.  She, herself, had only a minor 
problem with walking, but in her skin tests it was proven that she suffered from CDG-Ia as well.  
So you can see we have marked variability in the severity of CDG Ia and we have observed that 
as well in other CDG subtypes.   
 
As mentioned above, isoelectric focusing is only a screening test and more and more children 
with an abnormal result turned out not to suffer from CDG-Ia, but from another enzymatic 
defect.  Until now 13 different enzymes have been identified to lead to a CDG Type I pattern on 
isoelectric focusing being listed alphabetically (CDG-Ia-Il). And for the CDG type II, we have 6 
family members (CDG-IIa –IIf).  Whenever we identify a new enzyme defect then it comes onto 
the list and is given the next letter in the alphabet.   
 
 174
Having identified so many new diseases presenting with many different problems, it makes it 
even more difficult for us doctors to say, “CDG can be recognised by ….” And I will try to 
explain why it is so difficult for us: 
Firstly there are now 19 different diseases and in some of these patients we see similar problems 
to those with CDG-Ia.  Children with CDG may have any or all of the clinical symptoms, such 
as floppiness (hypotonia), delayed motor development, disturbances of co-ordination and 
balance, failure to thrive, liver problems (hepatic dysfunction), hypothyroidism (under-
functioning of the thyroid), hypoglycaemia (low blood sugars), seizures, changes of the eyes 
(retinitis pigmentosa), progressive bone problems (scoliosis) and/or nerve damage (peripheral 
neuropathy) or even very different signs and symptoms, that we have not linked so far to any 
CDG patient.  This is the reason why it is impossible to diagnose CDG only on a clinical basis. 
As an example, to show you how difficult it can be, here is the story of the detection of CDG-Ic 
patients: 
In 1998 I met several patients in The Netherlands with psychomotor retardation, hypotonia and 
seizures and we knew that they had an abnormal isoelectric focusing pattern.  However, CDG-Ia 
had been excluded by measuring the disease-specific enzyme. Furthermore, there were slight 
differences to CDG-Ia cases, as these children had no inverted nipples, no fat pads and the MRI 
of the brain was completely normal.  At that point we were sure, that although they resembled 
CDG-Ia, it was a new disease group.  The way we solved the problem was that scientists in 
Zurich were persuaded by Professor Jaeken to investigate the skin biopsies of our patients.  He 
had heard colleagues talking at a congress and they actually knew all about the steps in yeast 
that are needed for building up glycoproteins and which are very comparable to those that occur 
in man.  Glycosylation is present in all kinds of organisms, including bacteria, yeast, plants and 
mammalian systems.  After convincing the experts on yeast to work on human material, they 
revealed the underlying enzymatic problems in the children and, actually, this approach has 
helped to identify many more CDG Type I subtypes later on.  The trick is to compare the glycan 
structures that have been built up insufficiently by the CDG patients, with those patterns they 
obtained from different yeast mutants (genetically altered yeasts), with known enzyme defects 
in the glycosylation pathway.   
 
So the question remains “which patient has to be tested for glycosylation defects” and the 
answer probably should be “whenever there is a patient with unexplained psychomotor 
retardation and who has, additionally, any other organ problems” isoelectric focusing of 
transferrin should be performed. CDG should at least be on the differential diagnosis list in any 
patients with yet unexplained symptoms. It can also be helpful to look into factors involving in 
clotting of the patients, as most of the CDG patients present with low protein C & S and 
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decreased Factor VIII and XI, which can be helpful additional biochemical markers. The 
diagnostic approach in any child must start with listing the patient’s symptoms and problems, 
and also by looking at the family’s and patient’s history.  Then, isoelectric focusing should be 
performed. It is important to say, that some patients with CDG will not show an abnormal 
pattern in the screening test. In very difficult cases a discussion between clinicians and the 
experts in the field might be helpful in deciding what to do.  
 
The message to doctors is “to think big”.  CDG also stands for Charles de Gaulle airport in Paris 
and it might be as difficult to find your plane, as it is to find the diagnosis of CDG for the 
affected children. Over the last years, as more and more clinicians have CDG in their mind 
(some of them becoming real Glycomaniacs) many more patients have been diagnosed and new 
CDG diseases have been identified.   
 
Most importantly, we do not only want to diagnose patients, but we also obviously want to treat 
them.  Very unfortunately, so far, we only have a treatment for one CDG subtype: CDG-Ib 
presents with a very different clinical picture than CDG-Ia. The children mainly suffer from loss 
of protein from intestine (protein-losing enteropathy). The treatment has a very beneficial effect 
on the biochemistry and clinical problems of the children: supplementing CDG-Ib children with 
mannose has definitely helped these children.  The reason why it works in this condition is that 
there is another enzyme in the body that compensates for the missing one in these patients. Very 
unfortunately, mannose supplementation has not helped either the most common CDG-Ia 
patients or any other subtype in the CDG super family.   
 
Future research activity is concentrating on getting a better understanding of the diseases and 
finding better diagnostic tools. A major goal is to develop treatment options as, so far, for the 
vast majority of CDG cases, only supportive therapy is available. Researchers, clinicians, 
biochemists, geneticists and others are working closely together and in Europe we have an 
established network called Euroglycanet.  This coordinating action was started in Leuven, 
Belgium in November 1999 under the name of Euroglycan, which later on became 
Euroglycanet. London is one of the 5 core centres (London, Leuven, Barcelona, Nijmegen, 
Paris) and we are linked to another 24 participating research centres.  National referral centres 
have been established to support existing centres.  They also recruit, accept and despatch patient 
samples.  Euroglycanet brings together families and patients, referring clinicians and referral 
centres, reference centres, research and private partners.  It holds a database, has a web site and 
organises education, training and meetings.  It ensures that, by carousel testing, expert 
diagnostic workup will be done on all the different samples.  Over 400 patients have been 
 176
included in the database, roughly about two-thirds with a known defect, of which the majority 
are CDG-Ia patients. 
It is very important that we raise awareness for congenital disorders of glycosylation and 
publicity has been achieved through parents and the public by various websites, for example, the 
Euroglycanet Network – www.euroglycanet.org.  Educational sessions such as the CLIMB 
conferences, and parents’ meetings are another important means of raising awareness.  Highly 
specialised doctors and researchers in CDG and metabolic diseases carry on giving talks on 
CDG and will give lectures at FOCUS courses attended by interested colleagues. One course is 
run in collaboration with the Orphan Europe Academy, giving ‘hands-on’ training. Two 
FOCUS courses on glycosylation defects have already been held in Catania, Italy in 2003 and 
Athens, Greece in 2005. 
 
CDG can affect children in any country and CDG has been diagnosed all over the world. 
Parents’ association have pooled important information that can be found on the following web 
pages:  HTTP://www.cdg.dk (Denmark CDG Society, HTTP://www.cdg-syndrome.de (German 
Glycokids CDG, HTTP://www.cdgs.info (Sweden CDG Society), HTTP://www.cdgs.com 
(CDG Family Network USA) and the Euroglycanet website.   
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Summary 
Glycosylation is the most complex type of biomolecule modification occurring in living 
organisms. Because it is ubiquitous, glycosylation affects many biological processes and has a 
huge impact upon various organ functions. In Congenital disorders of glycosylation (CDG), 
glycosylation of glycoconjugates is disrupted and leads to various clinical problems in affected 
patients. Since the first children were described by Prof. Jaeken in 1980 (Jaeken, 
Vanderschueren-Lodeweyckx et al. 1980), setting up the powerful screening test, by isoelectric 
focusing of transferrin (TIEF) (Jaeken, van Eijk et al. 1984) and using the yeast genetic system 
as a tool to characterize specific types of CDG, had had a major impact on the discovery of 
various new CDG subtypes (Aebi and Hennet 2001).   
 
CDG: an introduction (Chapter 1)  
Chapter 1 introduces the broad variety of congenital disorders of glycosylation characterized so 
far, and their clinical presentation, biochemical and molecular hallmarks are discussed.  
Whereas in the beginning of the CDG era, only N-glycosylation defects were confined to CDG, 
new CDG family members such as O-glycosylation (Muntoni, Brockington et al. 2002) and 
combined N- and O-glycosylation defects have been included recently and are described.  
 
 
The classical CDG: CDG-Ia (Chapter 2) 
It took 15 years after the first clinical description of a CDG-Ia patient to reveal the underlying 
biochemical basis of this most commonly diagnosed CDG type: the activity of 
phosphomannomutase (PMM) was shown to be decreased in CDG-Ia, often referred as the 
“classical” CDG (Van Schaftingen and Jaeken 1995). It took another two years to detect the 
PMM2 gene, using a yeast-cloning strategy (Matthijs, Schollen et al. 1997). There are two 
human PMMs, encoded by two paralogue genes, PMM1 and PMM2, with slightly different 
substrate specificity (Schollen, Pardon et al. 1998). The protein is relatively conserved, and 
there is 92% homology between the human and mouse gene (Heykants, Schollen et al. 2001). 
Only mutations in PMM2, located on chromosome 16p13 have been identified so far in CDG-Ia 
patients, (Matthijs, Schollen et al. 1997). Worldwide, more than 500 patients have been reported 
and there is a huge clinical variability (de Lonlay, Seta et al. 2001).  A plethora of mutations 
have been described and their effect on the activity on the PMM2 enzyme has been studied 
(Pirard, Matthijs et al. 1999). Genotype-phenotype analysis is hampered by the wide variety of 
clinical presentations and the PMM2 mutational spectrum, as discussed in this chapter. 
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However, patients carrying R141H/V231M showed high morbidity and lethality. C241S is 
particularly frequent in milder phenotypes and overexpression studies of this mutant showed 
only 50% decrease of the enzyme activity level. No clear correlation has been found between 
enzymatic residual activity and clinical severity, but it was observed, that enzyme activity was 
severely decreased in compound heterozygotes for R141H/F119L, showing a severe clinical 
phenotype.  These two mutations are the most frequently observed in mutant alleles. Another 
contributing factor for the restricted genotype-phenotype correlation might be the influence of 
modifier genes. We studied the possible influence of a glucosyltransferase (Alg6) polymorphism 
on the clinical severity of CDG-Ia patients. The F304S, with an allele frequency of 0.28 in the 
normal population is clearly a polymorphic variant. In the genotypic homogenous population of 
F119L/R141H, 63% (14/22) with a severe phenotype were heterozygous for the F304S variant 
(Westphal, Kjaergaard et al. 2002). The synergistic effect of two (partially) deficient enzymes in 
the same pathway, PMM2 and ALG6, might aggravate the N-glycosylation deficiency with a 
negative effect on the patients’ clinical outcome.  
In the majority of patients, the enzyme activity of PMM has been measured in fibroblasts. By 
pooling data on enzyme levels obtained in fibroblasts and lymphocytes in patients with 
genetically proven CDG-Ia, it became obvious that intermediate PMM activity levels in 
fibroblasts may mask the diagnosis of CDG, whereas enzyme levels obtained in lymphocytes 
can clearly distinguish between affected, heterozygous and normal population. In this study, a 
family with three affected children was identified. Whereas intermediate PMM levels were 
measured in fibroblasts, only measuring PMM activity in lymphocytes and subsequent 
sequencing of the PMM gene, could confirm the diagnosis of CDG-Ia in the three individuals 
(Drouin-Garraud, Belgrand et al. 2001).  
 
Abnormal transfer of hypoglycosylated glycoproteins (Chapter 3) 
Correct glycosylation of secreted glycoproteins is essential for their trafficking (Marquardt and 
Helenius 1992), (Beccari, Mancuso et al. 2000). In this electron-microscopical study on liver 
tissue and fibroblast cultures on 19 CDG patients of different subtypes (CDG-Ia,b,c,e,f,CDG-IIa 
and CDG-x), we could show unusual lysosomal inclusions in the cytoplasma of nearly all 
hepatocytes of CDG-I patients. These findings suggest that the targeting to the secretory 
pathway and its sorting of glycoproteins is disturbed, leading to accumulation and storage of 
misfolded heterogenous material. This explains elevated levels of lysosomal enzymes in plasma 
of CDG patients (Barone, Carchon et al. 1998). Very recently, we could show that the activity 
of aspartylglucosaminidase (AGA) is an additional indicator of CDG. The high levels of this 
lysosomal hydrolase probably reflect the increased catabolism of abnormally glycosylated 
glycoproteins (Jackson, Clayton et al.2005). 
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From yeast to man: identification of CDG-Ic (Chapter 4)  
CDG-Ic, due to Dolichol-P-Glc: Man9GlcNAc2-P-dolichol glucosyltransferase deficiency was 
the first enzymatic defect being identified in the second compartment of the glycosylation 
pathway, the Endoplasmatic Reticulum. It has also been the first CDG defect elucidated with the 
help of the yeast approach: the oligosaccharide structures accumulating in these patients 
(Man9GlcNAc2-PP-Dol) were compared with the pattern of different mutant yeast strains. This 
oligosaccharide pattern is observed in alg6 yeast mutants and subsequent genetic analysis 
documented mutations in the human analogue, the ALG6 gene. We found a high frequency of 
homozygosity for the A333V mutation, which was thought to reflect a founder effect, as all 
eight patients were of Dutch origin. In the second study we identified another seven patients and 
again, found A333V to be the most frequent disease allele (11/14). In the meantime, additional 
patients have been diagnosed and it is of note that the clinical spectrum, which initially was 
thought to be quite mild, broadened and life threatening protein-losing enteropathy and neonatal 
severe intractable diarrhoea has been observed. The mutations in these patients were 
A333V/S308R and R18Q/A333V respectively (Westphal, Xiao et al. 2003), (Mention, Michaud 
et al. 2001).  
 
Abnormal glycosylation in brain (Chapter 5) 
From the beginning of the CDG screening, analyses were focused on underglycosylation of 
serum proteins. We were interested to study the glycosylation pattern of glycoproteins derived 
from brain tissue for various reasons. Showing the disturbed glycosylation profile in serum and, 
in parallel, in CSF glycoproteins proved that the glycosylation defect affects different organ 
systems. The majority of CDG patients present with neurological symptoms and psychomotor 
retardation and it was hypothesised, that abnormal glycosylation in the brain therefore may well 
contribute to these clinical symptoms and that tissue specific, such as brain specific - 
glycosylation defects could exist. By establishing an N-glycosylation screen in CSF by 
isoelectric focusing of ß-trace protein (ß-TP), we could show that all nine CDG patients had 
abnormal ß-TP isoforms, which proves, that the glycosylation deficiency affects the synthesis of 
brain derived glycoproteins. By screening CSF samples of 500 patients with neurological 
impairment of unknown cause we identified a patient with isolated hypoglycosylation of ß-trace 
protein, while IEF of different serum proteins had been normal. Unfortunately further 
investigations were limited, as the patient died. 
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From N- to O-glycosylation (Chapter 6) 
Chapter 6 bridges N- and O-glycosylation defects. We have developed a new screening method, 
and could prove, that IEF of Apolipoprotein CIII (ApoCIII) is a rapid, reliable and simple 
screening assay for the detection of core-1 O-glycosylation defects. Patients primarily included 
in this study were CDG-x patients, in whom an abnormal IEF of transferrin, proving an N-
glycosylation defect was previously shown, and the known defects of the N-glycosylation 
pathway had been excluded. Combining both IEF of transferrin and ApoCIII led to the 
identification of a new clinical entity:  three patients with a combined N- and O-glycosylation 
defect presented with cutis laxa and developmental delay. The underlying defect has yet to be 
established. Detailed biochemical hallmarks of these patients have been characterised and 
published and could narrow down the possible gene candidates (Wopereis, Morava et al. 2005). 
In the meantime it was shown, that a combination of IEF of transferrin and ApoCIII in 
combination with SDS-PAGE of ApoCIII could distinguish biochemical subgroups in CDG-IIx 
patients. This again, drastically narrows down the options for the primary defect in each 
subgroup and will be helpful in defining new CDG II defects (Wopereis, Morava et al. 2005). 
 
Future perspectives (Chapter 7) 
Research on defects in the glycosylation pathway is a rapidly emerging field. Since the first 
patient description back in 1980, new techniques have facilitated patients’ identification and 
helped to characterise numerous new defects. However, there still is a considerable lack of 
understanding of the underlying pathomechanism of CDG. Intensive research work is ongoing 
and a broad spectrum of specialists including biochemists, glycobiologists, geneticists, 
clinicians and others need to combine their expertise to get a better insight in this fascinating 
field. With the better understanding, new therapeutic options will hopefully be discovered.  
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Samenvatting 
 
Glycosylering is het meest complexe modificatie type van biomoleculen dat in levende 
organismen plaatsvindt. Omdat het alom tegenwoordig is, beïnvloedt glycosylering vele 
biologische processen en heeft een enorme impact op verschillende orgaanfuncties. In 
congenitale defecten van de glycosylering (CDG), is de glycosylering van glycoconjugaten 
gestoord en dit leidt tot verschillende klinische problemen in de aangedane patiënten. Vanaf de 
eerste beschrijving van kinderen met CDG door Prof. Jaeken in 1980 (Jaeken, Vanderschueren-
Lodeweyckx et al. 1980), heeft het implementeren van een sterke screenings test zoals de 
isoelectrische focusering van transferrine (Jaeken, van Eijck, et al. 1984) en het gebruik van het 
gist genetisch systeem als methode om de verschillende types van CDG te karakteriseren, een 
grote impact gehad in de ontdekking van een aantal CDG subtypes (Aebi en Hennet 2001). 
 
CDG: introductie (hoofdstuk 1) 
Hoofdstuk 1 introduceert de brede variëteit aan congenitale defecten in de glycosylering die tot 
op heden bekend is evenals de klinische presentatie, de biochemie en de moleculaire biologie. 
Terwijl eerst alleen de N-glycosylerings defecten bekend waren, zijn er inmiddels defecten in de 
O-glycosylering- (Muntoni, Brockington et al. 2002) en gecombineerde defecten in de N- en O-
glycosylering gerapporteerd. 
 
De klassieke CDG: CDG-1A (hoofdstuk 2) 
Pas 15 jaar nadat de eerste klinische presentatie van een patiënt met CDG type-1a werd 
beschreven, is het onderliggende biochemische defect van het meest gediagnosticeerde CDG 
type opgehelderd: de activiteit van de phosphomannomutase (PMM) werd verlaagd gevonden in 
CDG type 1a, vaak gerefereerd als de ”klassieke” CDG (Van Schaftingen en Jaeken 1995). Er 
waren twee extra jaren nodig om het PMM2-gen te identificeren, gebruik makend van de gist 
kloon strategie (Matthijs, Schollen et al. 1997). Er zijn twee humane PMM’s, die gecodeerd 
worden door twee paraloge genen, PMM1 en PMM2, met een subtiel verschil in substraat 
specificiteit (Schollen, Pardon et al. 1988). Het eiwit is relatief goed geconserveerd en er is 92% 
homologie tussen het humane en het muis gen (Heykants, Schollen et al. 2001). Alleen mutaties 
in PMM2, gelokaliseerd op chromosoom 16p13, zijn tot nu toe geïdentificeerd bij patiënten met 
CDG type 1a (Mathijs, Schollen et al. 1997). Wereldwijd zijn er meer dan 500 patiënten 
gerapporteerd en er is een gigantische klinische variabiliteit (de Lonlay, Seta et al. 2001). Een 
plethora aan mutaties is beschreven en hun effect op de activiteit van het PMM2 enzym is 
bestudeerd (Pirard, Matthijs et al. 1999). Genotype-fenotype analyse wordt bemoeilijkt door de 
veelzijdigheid aan klinische presentaties en het PMM2 mutatie spectrum als bediscussieerd in 
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dit hoofdstuk. Desalniettemin, patiënten met genotype R141H/V231M hebben een hoge 
morbiditeit en lethaliteit.. Het C241S genotype komt het meest voor in milde fenotypes en 
overexpressie studies van deze mutant laten een 50% verlaging van de enzymactiviteit zien. Er 
is geen duidelijke correlatie gevonden tussen residuele enzymactiviteit en ernst van het klinisch 
beeld, echter de enzymactiviteit is ernstig verlaagd in compound heterozygoten voor 
R141H/F119L, met een ernstig klinisch fenotype. Deze twee mutaties worden het vaakst gezien 
in de mutante allelen. Een andere factor die kan bijdragen aan de beperkte genotype-fenotype 
correlatie zijn de modifier genen. We hebben de mogelijke invloed van een glucosyltransferase 
(Alg6) polymorfisme op de klinische ernst van CDG type 1a patiënten bestudeerd. De F304S, 
met een allel frequentie van 0.28 in de normale populatie, is een duidelijke polymorfisme 
variant. In de genotypisch homogene populatie van F119L/R14H, waren 63% (14/22) van de 
patienten met een ernstig phenotype heterozygoot voor de F304S variant (Westphal, Kjaergaard 
et al. 2002). Het synergistisch effect van twee (partieel) deficiënte enzymen in dezelfde 
pathway, PMM2 en Alg6, zou de N-glycosylering deficiëntie kunnen verergeren en zou een 
negatief effect op de klinische uitkomst van patiënten kunnen hebben.  
Bij de meerderheid van de patiënten is de enzymactiviteit van PMM gemeten in fibroblasten. 
Door data van enzymactiviteiten in fibroblasten en in lymfocyten te poolen in patiënten met 
genetisch bevestigd CDG type-Ia, werd duidelijk dat intermediaire PMM activiteit niveaus in 
fibroblasten de diagnose van CDG in de weg staan, terwijl enzymactiviteiten niveaus afkomstig 
uit lymfocyten beter het verschil kunnen aangeven tussen aangedane patiënten, heterozygoten en 
de normale polupatie. In deze studie is een familie met 3 aangedane kinderen geïdentificeerd. 
Terwijl intermediare PMM niveaus werden gemeten in fibroblasten, was het mogelijk om de 
diagnose CDG type-Ia te bevestigen in de drie individuen, door het meten van PMM activiteit in 
lymfocyten en het sequencen van het PMM gen (Drouin-Garraud, Belgrand et al. 2001). 
 
Abnormale overdracht van hypogeglycosyleerde glycoproteïnen (hoofdstuk 3). 
Correcte glycosylering van gesecreteerde glycoproteïnen is essentieel voor de trafficking 
(Marquardt and Helenius. 1992), (Beccari en Mancuso et al. 2000). In deze electronen- 
microscopische studie van leverweefsel en fibroblasten kweken bij negentien CDG patiënten 
met verschillende subtypes (CDG-1a, b, c, e, f, CDG-2a en CDG-x), konden we abnormale 
lysosomale inclusies aantonen in het cytoplasma van bijna alle hepatocyten van CDG-1 
patiënten. Deze bevindingen suggereren dat de targetting naar de secretoire pathway en de 
verdeling van glycoproteïnen verstoord zijn, wat leidt tot accumulatie van slecht gevouwen 
heterogeen materiaal. Dit verklaart de gevonden hogere concentraties van lysosomale enzymen 
in plasma van CDG-patiënten (Barone, Carchon, et al. 1998). Zeer recent, hebben we kunnen 
aantonen dat de activiteit van aspartylglucosaminidase (AGA) een additionele indicator van 
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CDG is. De hoge concentraties van dit lysosomale hydrolase weerspiegelen waarschijnlijk het 
verhoogde catabolisme van abnormaal geglycosyleerde glycoproteïnen (Jackson, Clayton, et al. 
2005). 
 
Van gist tot mens: identificatie van CDG-Ic (hoofdstuk 4) 
CDG-Ic veroorzaakt door Dolichol-P-Glc: Man9GlcNAc-2-P-dolichol glucosyltransferase 
deficiëntie was het eerste enzymatische defect dat werd geïndentificeerd in het tweede 
compartiment van de glycosylering pathway, het endoplasmatische reticulum. Het is ook het 
eerste CDG defect dat is geïdentificeerd met behulp van de gist benadering: de oligosaccharide 
structuren die accumuleren in deze patiënten (Man9GlcNAc-2-P-Dol) werden vergeleken met de 
profielen van verschillende mutante gist stammen. Dit lipid-linked oligosaccharide patroon 
wordt gezien in alg6 gist mutanten, waarna genetische analyse, mutaties in de humane analoog, 
het ALG6 gen aantoonde. We hebben een hoge frequentie van homozygotie voor de A333V 
mutatie gevonden, welke mogelijk een founder effect reflecteert, omdat alle 8 patiënten 
Nederlandse patiënten waren. In de tweede studie hebben we zeven andere patiënten 
geïdentificeerd en ook hier was de A333V de meest frequente ziekte allel (11/14). Inmiddels 
zijn er additionele patiënten gediagnosticeerd en het klinische spectrum, waarvan in het begin 
werd gedacht dat het mild was, is erg uitgebreid en zelfs levens bedreigende proteïn-losing 
enteropathy en ernstige neonatale niet-behandelbare diarree zijn gerapporteerd. De mutaties bij 
deze patiënten waren respectievelijk A333V/S308R en R18Q/A333V (Westphal, Xiao, et al. 
2003), (Mention, Michaud, et al. 2001). 
 
Abnormale glycosylering in de hersenen (hoofdstuk 5). 
Vanaf het begin van de CDG screening werden de analyses gericht op hypoglycosylering van 
serum eiwitten. We waren geïnteresseerd in het bestuderen van het glycosylerings profiel van 
glycoproteïnen afkomstig van hersenweefsel om verschillende redenen: het vinden van een 
abnormaal glycosylering profiel in serum en tegelijkertijd in liquor glycoproteïnen bevestigt dat 
het glycosylerings defect verschillende orgaansystemen beïnvloedt; de meerderheid van CDG 
patiënten presenteren zich met neurologische symptomen en psychomotore retardatie en 
abnormale glycosylering in de hersenen zou derhalve kunnen bijdragen aan de klinische 
symptomen: weefsel specificiteit zoals hersen specifieke – glycosylerings defecten zijn 
theoretisch mogelijk. Door een N-glycosylering screening in liquor door isoelectric focusering 
van β-trace eiwit (β-TP) op te zetten hebben we kunnen aantonen dat alle negen CDG patiënten 
abnormale β-TP isovormen hadden, hetgeen bevestigt dat de glycosylerings deficiëntie ook de 
synthese van uit de hersenen afkomstige glycoproteïnen aantast. Bij screening van 500 liquor 
monsters van patiënten met neurologische problemen van onbekende etiologie hebben we éen 
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patiënt geïdentificeerd met een geïsoleerd hypoglycosylerings defect van β-trace eiwit terwijl de 
isoelectrische focusering van verschillende serum eiwitten normaal was. Het is helaas bij deze 
patiënt niet mogelijk geweest verder onderzoek te verrichten, omdat de patiënt is overleden.  
 
Van N- tot O-glycosylering (hoofdstuk 6) 
Hoofdstuk zes beschrijft de brug tussen N- en O-glycosyleringsdefecten. We hebben een nieuwe 
screeningsmethode ontwikkeld en zijn in staat geweest om aan te tonen dat isoelectric 
focussering (IEF) van Apolipoproteïne CIII (ApoCIII) een snelle, goede en simpele screening is 
voor de opsporing van core-I O-glycosylerings defecten. Voornamelijk CDG-x patiënten werden 
geïncludeerd in deze studie, met een abnormale IEF van transferrine, zodat er sprake was van 
een N-glycosylerings defect. De bekende defecten in de N-glycosylering pathway waren 
uitgesloten. De combinatie van beide, IEF van transferrine en ApoCIII heeft geleid tot de 
identificatie van een nieuwe klinische entiteit: drie patiënten met een gecombineerde N- en O-
glycosylerings defect die presenteerden zich met cutis laxa en ontwikkelingsachterstand. Het 
onderliggende defect moet nog opgehelderd worden. Gedetailleerde biochemische kenmerken 
van deze patiënten hebben ons in staat gesteld om de mogelijk kandidaat genen te beperken 
(Wopereis, Morava et al. 2005). 
Inmiddels is duidelijk geworden dat met behulp van een combinatie van IEF van transferrine en 
ApoCIII en SDS-PAGE van ApoCIII mogelijk is om biochemische subgroepen in CDG-IIx 
patiënten te maken. Dit versmalt drastisch de opties voor een primair defect in iedere subgroep 
en zal behulpzaam zijn om nieuwe CDG-II defecten te definiëren (Wopereis, Morava et al. 
2005). 
 
Toekomst perspectiven (hoofdstuk 7) 
Onderzoek van defecten in de glycosylerings pathway is een zich snel ontwikkelend gebied. 
Sinds de beschrijving van de eerste patiënt in 1980 hebben nieuwe technieken het mogelijk 
gemaakt om de identificatie van patiënten en de karakterisering van vele nieuwe defecten te 
realiseren. Desalniettemin zijn er nog vele vragen over de onderliggende pathofysiologische 
mechanismen in CDG. Intensief wetenschappelijk onderzoek is gaande en een breed spectrum 
aan specialisten, o.a. biochemici, glycobiologen, genetici, clinici erfelijke metabole ziekten en 
anderen moeten hun expertise bundelen om een beter inzicht in dit fascinerend veld te krijgen. 
Met een betere kennis kunnen waarschijnlijk nieuwe therapeutische opties gevonden worden.  
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